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Abstract  
Recent evidence supports inflammation and immunological  modification as being important 
for age related macular degeneration (AMD). Immune respo nse gene polymorphisms could 
explain both the role of inflammation and genetic pred isposition reported in AMD. We 
therefore  explored  immunogenetic  pathways  in  AMD  by  testi ng  several  interlinked 
hypotheses. These included, analysing HLA genotypes which ma y genetically predispose 
AMD patients towards immune mediated AMD responses, me asuring serum biomarkers 
like C reactive protein and soluble intercellular ad hesion molecule 1 along with studying 
functional polymorphisms in these and other related genes (Co mplement factor H, cytokines 
like Interleukins and VEGF). Also, mutation screening  of candidate genes coding Bruch's 
membrane  proteins  which  may  have  functional  implicatio ns  in  AMD  was  undertaken 
(LOXL1  gene, PEDF and CRYAA  gene Polymorphisms). Resul ts from the HLA study 
showed  that  individuals  harbouring  the  HLA  Cw*0701  all ele  had  an  increased  risk  of 
developing AMD with localization of HLA class I and DR  antigens in the choriocapillaris 
and  drusen,  respectively.  These  novel  HLA AMD  associatio ns  were  reproducible  in  a 
cohort  of  AMD  cases  and  controls  from  Michigan.  Furth er  analysis  of  KIR  genotypes 
(which are ligands for HLA) showed that, HLA C*0701  allele in combination with the 
inhibitory KIR AA haplotype was strongly associated wit h AMD status. Our CRP results 
confirmed previous associations with AMD. The interleuk in IL8 251A/T variant showed a 
pro inflammatory association in AMD while the ICAM1 1 2959G/A variant appears to raise 
ICAM1 levels especially in cigarette smokers and could  predict AMD development. The 
strong association of the CFH Y402H coding polymorphis m with AMD was confirmed in 
our UK cohort, while no association could be found betw een CRP levels and the CFH 
Y402H polymorphism in AMD.  CFH Y402H association was  significantly strongest in the 
predominantly  classic  CNV  group  both  for  CC  and  CT  gen otypes.  Visual  outcomes 
following PDT was significantly poorer in the CFH geno type groups; 50% of CC cases 
(n=13) and 45% of the CT cases (n=12) lost 15 or more ETDRS  letters. Mutation screening 
of the LOXL1 gene responsible for basement membrane in tegrity and elastinogenesis, and 
testing for promoter region SNP's in PEDF and CRYAA g enes did not yield significant 
results. These null findings need to be confirmed by stud ying other population cohorts and 
also  perhaps  by  LD  based  studies.  In  summary,  this  rese arch  has  provided  important 
evidence for our hypothesis of g enetic predisposition to inflammation as being import ant in 
a significant proportion of AMD cases.      
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CHAPTER ONE: INTRODUCTION AND STUDY AIMS   
An introduction to age related macular degeneration ( AMD), the current known pathways 
for disease aetiology, available treatment options, an d the main aims of this research study 
are briefly summarised in this chapter. 
 
 
Figure  1.  Gross  and  microscopic  anatomy  of  the  macula  in  the  retina  (modified  from 
Forrester JV, Macrophages eyed in macular degeneration , Nat Med. 2003 Nov; 9(11):1390 
7). 
 
1. 1   ANATOMY OF THE MACULA 
The macula is the central portion of the retina at t he back of the eye responsible for the fine 
and detailed vision of the human eye. Beneath the reti na are retinal pigment epithelial cells 
(RPE), and below that is the choroid containing a bed of tiny blood  vessels that help to bring 
oxygen  and  nutrients  to  the  eye  and  remove  waste  produc ts that are  generated through 
normal cellular metabolism (fig.1).  
 
1. 2    AGE RELATED MACULAR DEGENERATION (AMD)  
Macular  degeneration  is  a  degenerative  retinal  disease  that  causes  progressive  loss  of 
function  of  the  portion  of  the  eye  responsible  for  cen tral  vision.  While  some  forms  of 
macular degeneration result from monogenetic hereditary  diseases, most cases occurring in 
patients aged 50 or older are known as age related macula r degeneration (AMD).    
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1.2.1   AMD DISEASE EPIDEMIOLOGY 
AMD  is  a  major  health  problem.  It  accounts  for  approxim ately  50%  of  all  cases  of 
registered blindness in the western world. It affects up to 30% o f the population over the age 
of 75 and as the population ages its overall prevalen ce will continue to rise 
2 . Although not 
life threatening, AMD has been judged on the basis of  a spectrum of measures of patient 
disability to be the third most disabling disease in t he US population after diabetes and 
cancer
1 . Because central vision makes detailed vision poss ible, macular degeneration may 
significantly diminish quality of life and the ability  to function independently in individuals 
who suffer from this disease. As the disease progresse s patients lose their ability to read and 
write, watch television or even recognise people’s face s. As expected, this interferes with 
work, hobbies, mobility, communication, and social in teraction. It also leads to an increased 
risk of falls with hip fractures and   social isolation
2 . Choroidal neovascularisation (CNV) is 
responsible for the majority of cases of severe central  visual loss, often sudden in onset with 
devastating psychological and practical consequences. Unfo rtunately current treatments are 
rarely sight saving. Therefore new insights into the dis ease with emphasis on defining an ‘at 
risk’ population are necessary so that specific preventiv e and disease modification measures 
may be applied. In this context research to identify  the basic pathological processes which 
lead to this disease is paramount to develop more effec tive treatment strategies.  
 
1.2.2   AMD CLASSIFICATION AND DISEASE PHENOTYPES 
The characteristic ophthalmoscopic lesions of AMD are  drusen with areas of increased or 
irregular pigmentation at the level of the retinal pigm ent epithelium (RPE). If these are the 
only  lesions  present,  the  condition  is  best  referre d  to  as  early  age  related  maculopathy 
(ARM), reserving the terms late ARM or AMD to describ e more advanced changes which 
are likely to be associated with visual impairment. The  classification and grading of ARM    
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and AMD has been complicated by the large variation i n location, size, number, and types 
of  lesion  that  may  occur.  Over  the  years,  many  definitions   have  been  used  in 
epidemiological studies making comparisons difficult.  This problem was simplified to some 
extent by the International Age related Maculopathy Epidem iological Study Group which 
proposed  a  classification  and  grading  system  for  ARM  and  AMD  based  on  detailed 
assessment of colour fundus photographs
3 .  
   
AMD can take two forms, d ry AMD ; also referred to as geographic atrophy (GA) or non 
exudative AMD (seen in 90% cases) and wet AMD; also k nown as neovascular, exudative 
or disciform AMD (seen in 10% cases). The dry form i s  characterised by thinning of the 
macular retina with/without drusen, while the wet form  is characterised by the growth of 
abnormal  new  blood  vessels  from  the  choroid  beneath  t he  retina.  These  new  vessels 
( choroidal neovascularisation – CNV)  can leak fluid and blood causing scarring, which can 
threaten  vision.  Using  fluorescein  angiography  these  ves sels  have  been  classified  into 
‘classic’ if they can be seen clearly and ‘occult’ if  they cannot (figs. 2 and 3). If the picture 
is mixed they would be then classed as either ‘minimally classi c’ or ‘predominantly classic’. 
Wet  macular  degeneration  usually  occurs  in  people  who  alr eady  have  dry  macular 
degeneration and this variety of macular degeneration  progresses more quickly with severe 
visual loss.  
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Figure 2. Patient with classic CNV.  
A   Fundus appearance. B   Fluorescein angiography appea rance showing central leakage 
from  CNV  (arrow).  C     Corresponding  Optical  Coherence   Tomography  (OCT)  scan 
showing sub retinal and intra retinal fluid from CNV. 
 
 
Figure  3.  F luorescein  angiographic   appearances  of  Classic  (A)  and Occult (B) types of 
CNV. 
 
C  
B   A  
A   B     
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1.2.3   DRUSEN IN AMD 
Drusen are extracellular deposits that accumulate bet ween the basal lamina of the retinal 
pigmented epithelium (RPE) and the inner collagenous l ayer of Bruch's membrane in the 
human eye. They are typically associated with advancing age an d are commonly observed in 
AMD. 'Drusen' has been derived from the German word for  node or geode, and were first 
described by F.C. Donders in 1854. He described "reflec tive spheres" surrounded by rings 
of hyperpigmentation after studying the eyes of a 70  year old woman. Müller confirmed 
Donders'  description  of  the  frequent  presence  of  hyper pigmentation  around  the  rims  of 
drusen, and suggested that they may be due to the displa cement of RPE cells away from the 
apices of drusen, this is now commonly accepted.  
   
The presence of large, soft, and/or numerous macular  drusen is a strong risk factor for the 
development  of  both  Dry  and  Wet  AMD
4 .  In  addition  to macular drusen, extramacular 
drusen also appear to be a significant risk factor for  the development of AMD. Pauleikhoff 
et al demonstrated that the size, number, and extent of  confluency of drusen are important 
determinants for the risk of developing AMD
5 . The presence of soft, large and/or confluent 
drusen  is  correlated  to  the  occurrence  of  choroidal  neova scularization,  a  clinically 
devastating manifestation of AMD. The risk of developing ne ovascular complications in 
patients with bilateral drusen has been estimated at 3  4% per year. A previous report from 
the  Macular  Photocoagulation  Study  Group  shows  a  relati ve  risk of 2.1 for developing 
choroidal neovascularization in eyes possessing five or  more drusen, and a risk of 1.5 in 
eyes with one or more large drusen 
6 . 
 
1.2.4   ORIGIN AND STRUCTURE OF DRUSEN 
Ultrastructural studies suggest that drusen constituents  are derived from the RPE 
7 . Many 
components  of  drusen  have  been  identified  which  provide  cr ucial  information  towards    
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understanding the aetiology of AMD. Wolter and Falls ma de the observation in two human 
donor eyes that drusen stain with oil red O, indicat ing the presence of neutral lipids in at 
least some drusen
8 . Farkas et al performed a many experiments in which drusen co mposition 
was  analyzed  by  enzymatic  digestion,  organic  extracti on,  and  histochemical  staining 
methods in order to provide information on drusen asso ciated molecules
9 . They concluded 
that  drusen  are  comprised  of  sialomucins  (glycoprotei ns  with  O glycosidically  linked 
oligosaccharides), cerebrosides and/or gangliosides. 
   
In an immunohistochemical study, Newsome et al
10  described labeling of soft drusen with 
antibodies  directed  against  fibronectin,  and  both  har d  and  soft  drusen  with  antibodies 
directed  against  IgG  and  IgM.  In  more  recent  studies,   a  weak  reaction  of  drusen  with 
antibodies directed against beta amyloid
11  and complement factors (C1q, C3c, C3d, and C4) 
was observed
12 . More intense labelling with antibodies directed agai nst ubiquitin, TIMP 3, 
and advanced glycation end products have been reported.  Hageman et al have identified a 
number  of  drusen associated  carbohydrate  moieties,  spec ifically  binding  sites  for 
Concanavalin A, LFA, WGA, and RCA I 
13 . They also reported vitronectin to be a major 
constituent of hard and soft drusen.  
 
1.2.5   AMD RISK FACTORS 
 AMD is a “complex disease.” This means an interplay  between genetic and environmental 
risk  factors  result  in  it’s  development
14 .  The  relative  significance  of  environmental  and 
genetic  risk  will  vary  between  individual  patients  with  s ome  having  a  mainly  genetic 
aetiology and others mostly environmental. In this con text, smoking is the most consistently 
identified and easily modifiable environmental risk  factor. In others, genetic predisposition 
is the main reason they develop AMD. An early age of  onset and family history, in the    
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absence of smoking, suggest a strongly genetic cause for  AMD. In some patients it is likely 
they  have  a  weak  genetic  risk  of  AMD  but  this  tips  t he balance to developing disease 
because they also smoke. In others who have never smoked i t is more likely they have a 
major genetic risk independent of environment. 
 
1.2.6   GENETIC FACTORS IN AMD  
The aetiology for this blinding disease still remains el usive. However, a number of studies 
have implicated both genetic and environmental facto rs in AMD aetiology. In addition to 
age, the evidence for heredity in AMD is compelling and  nearly 20% of AMD patients have 
been shown to have a positive family history
15;16 .  
       
Until recently the search for AMD genes has been frus tratingly slow. This is because AMD 
is difficult to study genetically because of its lat e age of onset and the consequent lack of 
large families available for study. This limits appli cation of the most successful method of 
gene discovery called “positional cloning.” This metho d requires three generation families 
to  be  available  for  study.  Genes  are  then  identified  by   association  of  affected  family 
members with genetic markers which segregate with di sease and can be traced through the 
family. Finding such segregation of marker and phenotype  then positions a disease to a 
specific chromosomal location. Candidate genes can the n be screened within the region and 
the disease gene identified or “cloned.” 
       
Despite these limitations multiple studies have  conf irmed that AMD is inherited. These 
studies include twin studies where a higher prevalence o f AMD is seen among monozygotic 
twins as compared to their spouses and first degree r elative
17 , population based segregation 
analyses
18 ,  familial  aggregation  studies,  gene  variation  associa tion  studies,  studies    
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identifying AMD chromosomal loci by linkage
19  and more recently by actual AMD genes 
identified through studies of related dominant macular  dystrophies
20 27 .  
    
Twin studies have demonstrated a high concordance of AMD  in monozygotic twins 
3; 4 . The 
Rotterdam Eye Study suggested that a genetic (as oppos ed to environmental) cause was 
responsible in 76 % of subjects with a family histor y of AMD 
6 .  In one large family with 
AMD, a genetic locus has actually been identified by conve ntional genetic mapping 
7 . Thus 
it  is  clear  that  either  a  single  gene  or  several  gene s  may  cause  age  related  macular 
degeneration. Klein et al reported 8 of 9 monozygotic (M Z) twins concordant for AMD
28 . 
Meyers et al reported 100% concordance in 25 MZ twins co mpared to 42% concordance in 
12 dizygotic (DZ) twins
29 . Gottfredsdottir et al found 90% concordance in 50 MZ twi ns 
which was significantly higher than for twin/spouse pair s
30 . Further evidence of a genetic 
predisposition to ARM was provided by Piguet et al who c ompared the characteristics of 
drusen in spouses and siblings of AMD patients and foun d a marked concordance between 
sibs  but  not  with  spouses
31 .  Smith  et  al  confirmed  in  a  questionnaire study that  family 
history is a risk factor, obtaining an odds ratio of 4. 2
32 . Two studies from the United States 
have investigated the frequency of AMD in siblings of i ndex cases and controls. Hyman et 
al found 29/146 (20%) of the siblings of index cases were  affected, compared to 12/152 
(8%) of the siblings of controls, giving an odds rati o of 2.9 
33 . In the study by Seddon et al 
the corresponding figures were 35/98 (36%) for cases and  15/112 (13%) for controls, giving 
an odds ratio of 2.7 
34 . In a similar case control study from Belfast, fundus photog raphs were 
obtained  in  half  of  the  siblings  but  diagnosis  in  the  rest  relied  on  reports  from 
ophthalmologists or opticians: 20/81 (25%) siblings of  index cases were affected but only 
1/78 (1%) siblings of controls, giving a relative risk of  19 
35 . Klaver et al studied fundus 
photographs of first degree relatives of 87 index cases  with late AMD and 135 controls and    
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obtained  a  relative  risk  of  4.2 
17 .  There  was  evidence  that  relatives  of  cases  expressed 
features  of  ARM  at  a  younger  age  suggesting  that  genetic   susceptibility  may  play  an 
important role in  determining the onset of disease.  All studies cited here had moderate 
sample  size  with  some  having  methodological  shortcoming s.  Despite  this,  when  taken 
together there is considerable proof for a genetic com ponent in AMD although uncertainty 
exists about the magnitude and nature of this genetic ef fect and whether it varies with the 
type of AMD or with the age of disease onset.  
Studies  of  inherited  retinal  disorders  such  as  retini tis  pigmentosa  have  revealed  how 
genetically heterogeneous seemingly specific retinal pheno types are. The number of cloned 
retinal genes has increased exponentially over the last  twenty years and updated reports of 
this can be viewed at the Retnet website (fig.4). We now  know that monogenetic retinal 
diseases involve functional sequence variations in numero us genes, sometimes singly and 
sometimes in combination e.g. digenic retinitis pigmento sa.
36  
 
Figure 4. Mapped and Cloned Retinal disease genes (1980 to  2006)  
(http://www.sph.uth.tmc.edu/Retnet/home.htm) 
 
An initial strategy to identify AMD genes was to use pos itional cloning to identify genes 
that cause early onset inherited macular diseases. The  hope being that these genes would 
also be mutated in AMD. Positional cloning is easier in  such early onset macular disease 
because more family generations are available. Many domin ant macular dystrophy genes    
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have been identified (table 1. and website   
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM). Ho wever none has 
convincingly been demonstrated to be involved in a clinical ly significant fraction of 
AMD
21;23;24;27 . The hereditary macular disease that is clinically  most similar to “typical” 
AMD is Malattia Leventinese (Doyne’s honeycomb retinal  dystrophy). This is caused by a 
single mutation (Arg345Trp) in the fibulin 3 gene (also k nown as EFEMP1)
37 . The 
discovery that fibulin 3 was mutated in a juvenile form  of macular degeneration, made the 
fibulin gene family potential candidate genes for AMD (ta ble 2). In a recent analysis of the 
fibulin group of genes in 402 patients with AMD and 429 ag e matched controls 7 different 
missense mutations were identified in the fibulin 5 gene
38 . These sequence changes were 
seen in 1.7% of patients, but none were found in the contro l individuals (P = 0.006). Fibulin 
5 which is essential for elastinogenesis therefore appe ars important in the development of 
AMD. 
   
Genes other than those associated with hereditary retina l dystrophies can also be candidate 
genes for AMD (table 2). Klaver et al
39  have reported that the ApoE  ε 4 allele is associated 
with a reduced risk of AMD (odds ratio 0.43) and the  ε 2 allele with a slightly increased risk 
(odds  ratio  1.5).  ApoE  is  an  important  receptor  for  c holesterol  and  lipid  clearance  and 
transport. In a large AMD family with 10 affected mem bers, Schultz et al
40   have identified 
that fibulin 6 (hemicentin 1) is mutated in a single  family with AMD but not in simplex 
cases. Other genes which have been evaluated recently w ith some positive findings include 
cystatin  C  (CST3)
41 ,  superoxide  dismutase  (SOD)
42   toll like  receptor  4  (TLR4)
43   and 
angiotensin converting enzyme (ACE) where the ACE Alu+/+ ge notype was protective
44 . 
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Finally, as in other complex diseases, the additional e ffect exerted by multiple gene variants 
by  their  interaction  with  environmental  factors  cannot  be  discounted.  Environmental 
components  such  as  smoking  therefore  could  trigger  the   development  of  AMD  in 
genetically  predisposed  individuals.  There  is  also  in creasing  evidence  that  low  grade 
inflammation is important in AMD, for example; raised  serum C Reactive Protein levels 
have been associated with AMD in one retrospective study
45 .  
                       
Progress is being made in the molecular mechanisms of  AMD. In the last year there has 
been an exciting discovery in the molecular genetics of  AMD. Four groups have recently 
reported the association of a common coding polymorphis m (Y402H) present in the CFH 
(complement factor H) complement regulation gene in  nearly 50% cases of AMD. If a 
patient  carries  one  or  two  copies  of  this  mutant  ge ne  the  risk  of  developing  AMD  is 
increased by over 2.4 to 7.4 fold
46 48 . These studies now suggest that in up to 50 % of case s 
genetic variation in a regulator of the alternative comple ment pathway, when combined with 
a triggering event, such as infection, may result in a m ajor proportion of AMD cases.  
               
This  intriguing  result  has  renewed  interest  in  the  com plement  pathway.  Complement 
activation  can  arise  through  the  classical,  lectin,  o r  alternative  pathways
49 .  All  three 
pathways lead to the generation of a C3 convertase enz yme and subsequent activation of the 
immune response, terminal pathway pore like membrane a ttack complex (C5b 9) formation 
then leads to cell lysis. CFH is an essential inhib itor of the alternative complement pathway 
preventing uncontrolled complement activation. The Y402H  polymorphism is particularly 
interesting since it is located within the cluster of  positively charged amino acids implicated 
in the binding of heparin, CRP and M proteins and various  microbes
49  (figure 2). CHF 
through its direct binding to CRP is known to reduce  the deposition of C5b 9 complexes.    
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Several  components  of  the  complement  cascade  and  oth er  terminal  components  of  the 
complement pathway along with other markers of inflamm ation have been shown to be 
deposited  in  drusen  and  the  choroid  of  eyes  with  AMD
50 .  Abnormal  regulation  of  the 
alternative pathway of complement activation by CFH s eems to be consistent with these 
observations.  Thus  alteration  of  the  binding  propert ies  of  CHF  may  have  functional 
implications for AMD. CFH  represents the first major susceptibility gene for this comple x 
disorder which is now directing research to the role of inflammati on and innate immunity in 
the aetiology of AMD. We are now closer to our  goal of being able to genetically screen 
individuals even at an early age to assess their genet ic predisposition for developing AMD; 
so that effective interventions can be planned optima lly even before the disease develops.  
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1.2.7   INFLAMMATORY FACTORS AND AMD 
Inflammation is associated with AMD. However until re cently it has not been clear whether 
this was a secondary phenomenon or part of the primary di sease process. Circumstantial 
evidence  has  included  the  presence  of  inflammatory  prote ins  in  drusen,  these  include 
complement regulatory proteins such as vitronectin
51 . In addition, drusen contain several 
acute phase  reactants,  immunoglobulins,  activated  comp lement,  and  proteins  that  are 
involved
 in the induction or activation of the immune response
52 .  
   
Histological studies dating back to the 1970’s have implic ated inflammatory cells including 
macrophages
53 , multinucleate giant cells
54 , fibroblasts and mast cells in the breakdown of 
Bruch’s  membrane  associated  with  AMD
55 .    Macrophages
  are  observed  in  the  choroid 
adjacent  to  drusen.  These
  cells  have  been  implicated  in  the  development  of  choroidal  
neovascularisation 
55 57 , but might also contribute to drusen accretion,
  directly or indirectly, 
by  synthesizing  and  secreting  drusen associated
  molecules  such  as  complement  C5, 
apolipoprotein E, Factor X,
 and prothrombin
51 . Both soft and hard drusen also exhibit intense 
HLA DR
  immunoreactivity.  Chronic  inflammatory  cellular  componen ts  have  also  been 
demonstrated in early, intermediate and late AMD 
58 . This suggests that a low grade chronic 
inflammatory  response  focused  at  the  level  of  Bruch’s   membrane  is  involved  in  the 
pathogenesis of AMD. Recently, an animal model with  the chemokine, cc motif, receptor 2 
knockout mouse (CCR2)  /   has been shown to have an  AMD phenotype with drusen and 
choroidal neovascularisation 
59 . All these suggest that these inflammatory changes are  causal 
rather than an epi phenomenon. Auto antibodies, indicati ve of autoimmune disease, have 
also 
  been  detected  in  the  sera  of  some  AMD  patients 
60,61 .  In  addition,  a  serological 
association has recently been reported between Chlamydi a pneumoniae infection and AMD  
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62 . A unifying hypothesis to explain both the genetic i nheritance of AMD and the role of 
inflammation in AMD would be that AMD is, at least in  part, an immune mediated disease. 
1.2.8   BIOMARKERS IN AMD 
Following  the  renewed  interest  in  inflammation  and  imm unological  modification  in  the 
pathogenesis of AMD, many research groups are current ly involved in identifying potential 
inflammatory  biomarkers  like  CRP,  ICAM1,  interleukin s  and  VEGF  which  could  be 
important  for  AMD  progression.  The  importance  of  identif ying  these  in  AMD  lies  in 
providing new insights into its basic pathogenesis and  to help define an ‘at risk’ population 
for preventive measures to become applicable. This is  particularly true, as there has been a 
recent paradigm shift in the understanding of atheroscl erosis and heart disease which may be 
relevant to AMD. Atherosclerosis, like AMD, is a comp lex prevalent disease of the elderly 
sharing many environmental risk factors. Raised CRP l evels have been demonstrated to be 
significantly associated with atherosclerosis, even in t he presence of low cholesterol levels
63  
and have been shown to be an independent predictor of t he risk of first time heart disease or 
stroke.  Treatment  of  atherosclerosis  and  coronary  hear t  disease  has  benefited  from  this 
insight as it has been shown that aspirin and statins  are most effective in reducing the risk of 
heart attacks in patients with elevated CRP levels.  Indeed patients taking statins have been 
shown to have lower rates of AMD
64 , possibly due to an anti inflammatory effect. 
 
Auto antibodies  indicative of autoimmune disease, hav e
  been detected in the sera of some 
AMD patients 
60 . A retrospective study which was ancillary to the Age  Related Eye Disease 
Study (AREDS) has reported that elevated CRP could be a  possible independent risk factor 
in AMD development
45 , while a  recent report by the same author showed tha t higher levels 
of systemic inflammatory markers (CRP and Interleuki n 6) were independently associated 
with progression of AMD in a prospective study
65 . During the course of my research, we  
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found a similar association of elevated serum CRP l evels with AMD in a UK case control 
cohort
66 . CRP may thus be a useful biomarker to predict those  patients who will develop 
severe AMD.  
1.2.9   AMD PATHOGENESIS  
While the exact cause of AMD is not known, the disease  process begins when the transport 
of  nutrients  and  waste  products  via  the  RPE  begins  t o  slow  down,  leading  to  the 
accumulation of waste products. Small deposits of these  waste products, known as drusen, 
can be observed even before macular degeneration begins. The  presence of drusen does not 
always indicate that visual loss will occur, but a po rtion of individuals with drusen will 
progress to either the dry or wet form of AMD. Some of  the new vessels may also grow up 
into the retina, creating blind spots. A scar forms once the bleed ing has stopped, and this scar 
may create a large blind spot in central vision. 
   
Despite much research, the primary pathological proce sses remain poorly understood and 
this delays the development of rational therapies. In  the normal eye throughout life there is a 
regular turnover of the photoreceptor outer segments  which contain the photosensitive visual 
pigments. Material shed from the outer segments is  engulfed and digested by the RPE and 
ultimately  cleared  by  the  capillaries  of  the  choroid.  The  RPE  is  separated  from  the 
choriocapillaris by a multilayered structure called B ruch membrane. It is known that this 
membrane  thickens  with  age  and  that  in  the  early  sta ges  of  ARM/AMD  there  is  focal 
accumulation of extracellular eosinophilic material  between the basement membrane of the 
RPE and inner collagenous zone of Bruch membrane, wh ich contributes to the development 
of drusen, one of the characteristic clinical features  of early ARM 
67 . It is likely that this 
material is derived from the debris being continually di scharged from the RPE. In addition 
there are degenerative changes evident in the RPE and ch oriocapillaris 
67 . It is not known  
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why material accumulates in Bruch membrane, why some  patients are more susceptible than 
others and what determines the subsequent progression  to GA, detachment of the RPE or 
CNV. It has been suggested that genetic and other factors predi sposing to the development of 
ARM/AMD might exert their effect by increasing outer s egment turnover, reducing activity 
of RPE degradative enzymes causing free radical damag e to the substrate of degradation, 
modifying the processes of ageing in Bruch membrane such  as the cross linkage of collagen, 
or reducing the clearance of material from Bruch membrane.   
 
1.2.10   PREVENTION STRATEGIES 
The Age Related Eye Disease Study (AREDS) reported s ignificant reduction (25%) in the 
progression of disease from an intermediate stage to adva nced neovascular AMD by the use 
of high dose antioxidant, vitamin, and zinc supplement ation given over 6.3 years. There are 
numerous  alternative  food  supplements  ranging  from  lutein   and  zeaxanthin  to  selenium 
which claim to reduce the risk of progression of AMD.  A t present their efficacy is not well 
established.  
    
There  is  conflicting  evidence  concerning  the  associatio n  between  AMD  and 
hypertension
68;69 ,  raised  cholesterol
70   and  raised  C reactive  protein  (CRP)
45 .  Among  all 
identified potential environmental factors, only age,  diet and smoking are agreed upon by all 
to  increase  the  risk  of  AMD.  People  with  AMD  would  th erefore  benefit  from  lifestyle 
counselling in relation to diet, smoking and other known m odifiable risk factors of CNV 
development.  
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1.2.11   TREATMENT OF AMD 
Argon laser therapy has been traditionally used to c oagulate new vessels in wet macular 
degeneration. However the procedure itself may permanent ly impair vision, especially if the 
vessels are very close to the fovea and recurrence is common.  Laser photocoagulation is only 
effective in cases of classic CNV and is still the t reatment of choice for extrafoveal CNV as 
described by the Macular Photocoagulation Study (MPS)
6 . Classic subfoveal CNV is best 
treated with photodynamic therapy (PDT).  
1.2.12   PHOTODYNAMIC THERAPY (PDT) 
Photodynamic therapy (Visudyne®) is an approved laser  therapy for the treatment of wet 
AMD ( subfoveal CNV) .  PDT for AMD is a two stage process requiring admini stration of 
both verteporfin and nonthermal laser. This is achie ved by a 10 minute intravenous infusion 
of 6mg/kg verteporfin followed by activation 5 minutes  later by a 689nm diode laser for 83 
seconds at 50J/cm2. Lesions up to 5400 mm in greates t linear diameter can be treated. The 
photosensitive verteporfin is selectively taken up by the  rapidly proliferating endothelial cells 
within  the  target  CNV  reaching  its  peak  concentration  a t  15  minutes.  Microvascular 
thrombosis of the CNV is then caused by endothelial d amage from reactive oxygen radicals 
generated by the light activated verteporfin.  
   
Evidence  of  clinical  effectiveness  of  PDT  with  vertepo rfin  comes  from  two  major 
multicentre, randomised controlled clinical trials; the Tr eatment of AMD with Photodynamic 
therapy (TAP)
71;72  and Verteporfin In Photodynamic therapy (VIP)
73  trials which showed 
that vision outcomes were significantly better in tr eated than in untreated eyes throughout a 
two year study period. The TAP trial included 609 patien ts with subfoveal predominantly 
classic CNV having lesions of 5400 mm size, and best corrected v isual acuity between 20/40 
and 20/200. Of those patients treated with verteporfin,  59% of those on verteporfin had lower  
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vision loss compared to 31% of those on placebo (p<0, 001) at 24 months. The VIP study 
analysed a subgroup of patients with subfoveal lesions  composed of occult with no classic 
CNV.  Some  benefits  were  shown  in  reducing  the  risk  of  mo derate  visual  loss  in  the 
verteporfin treated group; especially in those with re cent disease progression (29% in treated 
versus 47% in placebo,  P= 0 .004).  
 
1.2.13   TREATMENT WITH ANTIANGIOGENIC DRUGS  
There is now new evidence
74  that CNV is caused by a low grade inflammation, which can be 
reduced with drug treatment. VEGF (vascular endothelial growt h factor), a key cytokine 
controlling  angiogenesis  and  has  been  implicated  in  neovascularizat ion during AMD
75 . 
The biological actions of VEGF are mediated via two receptors, VE GFR 1 and VEGFR 2. 
Increased expression of VEGF and pigment epithelium derived factor  (PEDF) has been 
found in the maculae of human eyes with AMD and also in surgically r emoved human 
CNV membranes
75 .   
 
Over  the  last  year,  there  has  been  a  rapid  uptake  in  the  use  of  intravitreal  anti VEGF 
therapies for treating choroidal neovascularisation (CN V) in AMD. Of these, Pegaptanib   a 
non immunogenic compound which binds with high affini ty and high specificity to VEGF
76 , 
Bevacizumab  or  Avastin     a  149 kDa  full length  humanize d  antibody  against  VEGF A 
isoforms and Ranibizumab or Lucentis   a recombinant humani zed monoclonal antibody 
fragment directed towards VEGF A isoforms have all been  shown  to be clinically  effective  
both for vision and for reducing macular thickening in  many studies.
77 79   Ranibizumab
80;81  is 
currently the approved first line of therapy for CNV in A MD.  
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1.2.14   GENE THERAPY AND GENE DIRECTED THERAPY  
Gene  discoveries  will  lead  to  more  effective  therapies   for  AMD  by  identifying  specific 
underlying disease mechanisms that may be corrected b y gene therapy or gene directed drug 
therapy. Once the disease gene has been characterized, ge ne functions can be dissected and 
biological processes involved in the normal and pathogenic  states confirmed. The resulting 
information  could be used to  design novel therapies ut ilising gene products, vaccine, or 
genetic material. Gene therapy encompasses many strat egies where genes, gene segments or 
oligonucleotides are transferred directly into diseased RPE  or retinal cells within a patient ( in 
vivo  gene therapy) using viral vectors
82 , or cells may be removed from the patient and the 
genetic material inserted into them  in vitro . Once inside the desired cells, the expressed 
genes help produce a product that the patient lacks.  Currently there is an ongoing human 
AMD gene therapy trial  using pigment epithelium deri ved factor (PEDF)
83 . The gene for 
this potent inhibitor of angiogenesis has been incorpor ated into an adenoviral vector and 
delivered into the eye by intravitreal injections to i nhibit growth of CNV
84 .  
1. 3    STUDY AIMS 
Literature review points to multiple lines of eviden ce which suggest an important role for 
inflammatory  events  in  the  pathogenesis  of  AMD.  In  f act,  among  the  various  factors 
involved in the pathogenesis of AMD, there has been a renewed inte rest in inflammation and 
immunological modification as being important for AMD  progression. Recent Complement 
gene studies have provided more evidence for AMD to b e an immune mediated disease
85 88 . 
Immune  response  gene  polymorphisms  may  therefore  modul ate  susceptibility  to  AMD 
which could explain both the role of inflammation and  genetic predisposition reported in 
AMD. The overall objective of this research was to e xplore the immunogenetic pathways in 
AMD.  This  will  be  achieved  by  testing  novel  interlinke d  immune  hypothesis  and  by  
 
31  
mutation screening of suitable AMD candidate genes. T he study will therefore attempt to 
answer the following questions, 
 
1. Are there specific HLA genotypes which may geneti cally predispose AMD patients to 
become susceptible to immune mediated responses which  cause AMD?  
2. Are  biomarkers  like  CRP  and  soluble  intercellular  adhesion  molecule 1(sICAM 1) 
associated with AMD? And do functional   polymorphisms in CRP, Complement factor H 
and ICAM1 genes influence serum expression levels in AMD ? 
3. Do  expression related  cytokine  polymorphisms  (Inter leukin/VEGF)  result  in  genetic 
susceptibility to AMD? 
4. Could genes encoding Bruch's membrane components be impo rtant for AMD? Candidate 
gene mutation screening will be undertaken by a case cont rol approach for;  
A.   LOXL1 gene 
B.   PEDF gene Polymorphisms 
C.   CRYAA gene Polymorphisms  
D.   TCOF1 2055 del AG mutation 
5. Do  mutations/polymorphisms  in  these  genes  affect  AMD   phenotype  or  outcome  to 
treatments such as with photodynamic therapy? 
6. Are HLA Cw and it’s cognate KIR (killer cell immunoglo bulin like receptor) ligand 
genotypes/haplotypes associated with AMD?    
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CHAPTER TWO: MUTATION DETECTION METHODS   
This chapter summarises the molecular mutation detectio n techniques used in this research. 
 
2.1   SINGLE NUCLEOTIDE POLYMORPHISMS 
In any two unrelated individuals, 99.9% of the DNA sequence  is similar and only 0.1% 
contains genetic variants that influence how people dif fer in their risk of disease. Single 
nucleotide polymorphisms (SNPs) which are pronounced  as ‘snips’ are sites in the genome 
where  DNA  sequences  differ  by  a  single  base.  For  exampl e,  some  people  may  have  a 
chromosome with an A at a particular site where other s have a chromosome with a G. As we 
have two copies of all chromosomes except the sex chro mosomes, for the above SNP a 
person could have the genotype AA, AG, or GG. Each form is f urther called an allele and the 
set  of  alleles  that  a  person  has  is  called  a  genotype.  A  “Haplotype”  refers  to  a  set  of 
associated SNP alleles in a region of the chromosome.  Most chromosome regions have only 
a few common haplotypes (each with a frequency of at  least 5%), which account for most of 
the variation from person to person in a population. 
 
2.2   MUTATIONS 
Both “Mutation” and “polymorphism” refer to a heritab le change in the DNA, they differ 
mainly in allele frequency (Mutation < 1% and Polymor phism > 1% frequency). Mutations 
could be a genome mutation such as a change in chromos ome complement e.g. Down's 
syndrome (trisomy 21), a chromosomal mutation such as  a translocation, or a gene mutation 
involving a number of bases. Gene mutations include base pa ir substitutions, deletions or 
insertions. They may originate through the normal proces s of DNA replication or because of 
mutagens. If they occur in the germline they could be passed  on to offspring.   
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A point mutation in a gene may not confirm it as the  disease causing mutation. The mean 
heterozygosity of human genomic DNA has been estimat ed to be 0.0037. This means that 1 
in 250 to 1 in 300 bases are different between allel ic sequences
89 . This sequence variation is 
lower in conserved gene sequences, but in an average g ene several neutral (non pathogenic) 
variants  are  still  likely  to  be  found;  without  functi onal  testing  it  may  be  impossible  to 
differentiate a neutral from pathological variant. Muta tion detection usually accomplishes 
one of two goals. Firstly, to detect or exclude known  mutations ( spec ifi c  mutation t es ting ) or 
secondly, to scan known genes or exons for  any  mutation ( mutation  sc anning ). There are 
several methods available for detecting mutations in ca ndidate genes. The chosen method 
varies with available resources and the researcher's experie nce and preference. 
 
2.3   MUTATION DETECTION METHODS 
Apart from DNA sequencing mutation detection methods f all into two groups. The first is 
based on the detecting aberrant migration of mutant m olecules during electrophoresis. This 
includes  heteroduplex  analysis,  single strand  conformatio n  polymorphism  analysis  and 
denaturing  gradient  gel  electrophoresis.  These  method s  while  simple  do  not  reveal  the 
position of the mutation and do not have 100% sensitivity
90 . The second group of methods 
relies on cleavage of RNA or DNA molecules prior to  analysis and includes chemical and 
enzymatic mismatch cleavage. Their advantages include  localisation of the mutation and the 
ability to scan DNA up to 1.6 kb in length
90 .  
 
2.3.1   SINGLE-STRAND CONFORMATION POLYMORPHISM ANALYSIS  
The  most  widely  used  mutation  screening  method  is  proba bly  SSCP  (single  strand 
conformational  polymorphism)  a  technically  simple  me thod  with  moderate  sensitivity. 
Single strand Conformation Polymorphism Analysis (SSC P) is based on the principle that  
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single  stranded  DNA  folds  up  and  develops  a  sequence  dep endent  secondary  structure 
(conformers) under non denaturing conditions. The electrophor etic mobility of such DNA on 
non denaturing gels depends not only on its chain lengt h but also on its secondary structure 
which  is  dictated  by  the  DNA  sequence.  DNA  differing  by   as  little  as  a  single  base 
substitution  can  form  different  conformers  and  migrate  differently  on  a  denaturing 
polyacrylamide gel
91 . The precise pattern seen on a gel is very dependent  on conditions used 
and conditions need to be optimised for each exon being assessed . Wild type controls need to 
be run on the gel as well. SSCP is most sensitive f or detecting base substitutions for DNA 
fragments of ≤150 bp. It becomes inefficient for fragme nts greater than 200 bp and does not 
reveal the position  or nature of the mutation
92 . 100 % sensitivity is claimed if SSCP is 
performed  on  short  DNA  segments  using  two  different  el ectrophoretic  conditions
90 .  If 
dideoxy fingerprinting, a modified version of SSCP, i s used, close to 100 % sensitivity is 
claimed with one electrophoretic condition
90 . 
 
2.3.2   DHPLC ANALYSIS 
DHPLC  (Denaturing  High  Performance  Liquid  Chromatography )  identifies  mutations 
without  sequencing.  This  method  can  screen  large  numbe rs  of  crude  PCR  products  for 
mutations and polymorphisms and direct sequencing can be  used to confirm DHPLC results. 
The  main  principle  of  DHPLC  is  "Heteroduplex  formation"   through  hybridization  after 
heating and cooling the PCR products. Thus, mutations  and polymorphisms are detected by 
heteroduplex  formation  between  mismatched  nucleotides  i n  PCR  amplified  DNA.  The 
sequence variation creates a mixed population of hete roduplexes and homoduplexes during 
reannealing of wild type and mutant DNA.   
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The DNA is mixed with an ion pairing agent Triethylammon ium acetate (TEAA), and the 
mix passes through a column (polystyrene divinylbenzene copolym er) which binds the DNA. 
A linear gradient of acetonitrile allows separation of  fragments based on size and/or presence 
of  heteroduplexes.  When  this  mixed  population  is  analyz ed  under  partially  denaturing 
temperatures,  the  heteroduplexes  elute  from  the  column  ear lier  than  the  homoduplexes 
because of their reduced melting temperature. As the fr agments elute, they are UV detected 
(260 nm).  
 
2.3.3   ENZYMATIC CLEAVAGE OF MISMATCHES 
In these techniques, a labelled wild type sequence is  mixed with a test sequence. If the 
sequences  differ,  heteroduplexes  form  which  can  be  cleave d  by  chemical  or  enzymatic 
methods
93 . Cleaved products are detected as short labelled fragme nts on a gel. The chemical 
method although very sensitive involves the use of toxic  chemicals. Two enzymatic methods 
are  used  commonly;  ribonuclease  cleavage  and  enzyme  m ismatch  cleavage  (EMC). 
Enzymatic  techniques  offer  (in  principle)  a  greater  s implicity  of use while retaining the 
advantages of high sensitivity and specificity. Most e nzymatic cleavage methods work on 
heteroduplex molecules, cleaving the helix at the disto rted region caused by the mismatch. 
This  means  that  homozygous  or  hemizygous  mutations  wo uld  not  be  detected  unless  a 
control sample is included to form the mismatched hetero duplex. 
    
 
36  
For mutation scanning, the enzymatic methods currently  available are less widely used than 
physical and chemical alternatives such as SSCP and DG GE. This is because, despite some 
very  encouraging  reports  no  single  enzymatic  method  has   yet been able to match these 
methods  for  simplicity  or  sensitivity.  An  additional   problem  lies  with  high  cost,  or 
availability of some of these mismatch recognition prot eins. 
 
2.4    LABORATORY TECHNIQUES 
2.4.4   DNA EXTRACTION
94   
1. Blood samples (10 ml) were defrosted and mixed for  1 hr on a rotary mixer in the cold 
room. 
2. ELB (Erythrocyte Lysing Buffer)   washes x 3: 
In a 50ml conical tube: Add at least 30ml cold ELB to 1 0ml blood sample, mix and place on 
ice for 15 mins, mixing gently on the shaker (set to s peed 3). Then spin at 1500rpm for 10 
mins at 4◦C (in large centrifuge). Pour supernatant into Virk on. Add another 30ml cold ELB, 
mix and place on ice for 15 mins, mixing gently on the shaker. Ag ain spin at 1500rpm for 10 
mins at 4◦C. Pour off supernatant. Add final 30ml cold  ELB, mix and place on ice for 15 
mins, mixing gently on the shaker. Spin blood tubes at  1500rpm for 10 mins at 4◦C. Pour off 
all supernatant, keeping the tube upright drain the exc ess ELB and blot end of tube on tissue. 
If pellet falls onto the tissue it may be cut out and put  back into the tube. 
3. Overnight Protein Digestion: 
Add 1ml NLB (Nuclear lysis buffer) to all tubes then  pour each pellet into a fresh 15ml 
conical tube, rinse the 50ml tube with a further 2ml a nd discard it. Add 250 l 10% SDS 
(no.5 on pipette) and 150 l 40mg/ml Protease (no.3 on pipette) t o each of the tubes. Mix and 
incubate at 37◦C overnight in the shaker incubator. 
4. Ethanolic Precipitation of DNA:  
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As the DNA will be in a high concentration of salt so lution, it is best to complete this stage 
in  batches  of  10 12  samples  at  a  time.  Allow  the  tubes  to  cool  to  room  temperature 
(approximately 30 minutes). 
Add 1ml saturated NaCL solution, shake tubes vigorous ly for 15 seconds, and then spin at 
4000rpm for 20mins at room temperature. Mark up a new s et of 15ml conical tubes. Using a 
P1000 pipette, take as much as possible (3 4ml) of t he supernatant into the fresh tubes. If the 
last ml of supernatant is not clear, transfer it to a  1.5ml eppendorf tube, label it clearly and 
spin in the microfuge at 14,000rpm for 5mins. Then pour  this into the corresponding 15ml 
tube. Using the 5ml Gilson pipette, add exactly twice  the volume of cold Absolute Ethanol 
(Example: If tube contains 4ml supernatant, add 2x 4 ml a bsolute ethanol), invert the tube 
gently until the DNA precipitates out and forms a fluff y pellet. 
Add 1ml of 70% Ethanol to labelled 1.5ml eppendorfs. Re move the sticky pellet using a 
yellow tip on a 200 l pipette and place it in the corresponding  eppendorf. This may be left in 
the 70% ethanol for several hours. Repeat the wash if th e DNA looks very brown. Pulse spin 
the eppendorfs in microfuge (hold pulse button for 10  15seconds), pour off the ethanol, blot 
the end of the tube and allow the DNA to nearly dry (~15 mins). Add 500 l TE Buffer and 
allow DNA to dissolve overnight at room temperature and t hen transfer to the freezer. 
 
2.4.5   PICOGREEN DNA QUANTIFICATION 
Defrost  DNA samples  and mix gently. Pulse spin sample s to remove DNA from lid, if 
necessary make a 1 in 20 dilution with ddH2O in a 96 w ell PCR plate e.g. 38 l water + 2 l 
sample. Mix well and pulse spin plate. In a flat bottom  welled reaction plate, add 50 l TE 
Buffer to each well + 2 l dilute sample or standards ( Use 5 l of undiluted Picogreen reagent 
for every 1ml of water in the Picogreen mix). Add 50 l  Picogreen mix to each well and  
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incubate for 15 mins in dark to allow the Picogreen to  bind to DNA in the samples. Then 
scan the plate on flourimager as follows, 
1. Carefully insert plate into 3 plate holder and in sert into Flourimager, Use 'tricia pg530'  
template, highlight the area you would like to scan (ex,  B H, 1 5), then press 'scan', choose a 
file name and location to be saved (D drive). Then, sel ect 'Analysis', 'Volume report Set up', 
'Object name' and 'Median' to be ticked, finally click OK.  
2. Auto tracer set up: Threshold 0.1 Region 40x40 Set, U se the autotracer tool to select each 
region of the plate and adjust their position using the pointer. T hen select 'Analysis', 'Volume 
report' and highlight all regions. When closing subseque nt results window, click 'Yes' to 
activate Excel and save or print the results. 
2.4.6   THE POLYMERASE CHAIN REACTION 
Polymerase chain reaction (PCR) is a technique which is  used to amplify the number of 
copies of a defined target segment of DNA from a hete rogeneous DNA source (genomic or 
cDNA  population),  in  order  to  produce  enough  DNA  to  be  a dequately  tested.  Initially 
described  in  the  1980's
95   it  has  now  become  an  indispensable  technique  in  mole cular 
genetics.  The  reaction  requires  the  presence  of  a  buffe red  solution  containing  DNA 
polymerase with the cofactor MgCl2, the four deoxynucl eotide building blocks of DNA 
precursors  (the  deoxynucleoside  triphosphates  dATP,  dCTP,  dGTP  and  dTTP),  selected 
oligonucleotide primers and the DNA source. The PCR mixture pr oceeds through replication 
cycles consisting of three temperature states: 
1.   One to several minutes at 94 96 degrees C, during whic h the DNA is denatured 
into single strands; 
2.   One to several minutes at 50 65 degrees C, during whic h the primers hybridize 
or "anneal" (by way of hydrogen bonds) to their compleme ntary sequences on either 
side of the target sequence;  
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3.   One to several minutes at 72 degrees C, during which the  polymerase binds and 
extends a complementary DNA strand from each primer.  
As amplification proceeds, the DNA sequence between the pr imers doubles after each cycle. 
Following thirty such cycles, a theoretical amplific ation factor of one billion is attained. A 
typical 35 cycle experiment theoretically produces a  2
34  amplification of the original desired 
sequence (plus an insignificant 35 copies of products  with variable 3' ends). In practice this 
means  that  one  can  start  with  nanogram  amounts  of  DNA  and  following  PCR  have  a 
sufficient quantity to visualise the desired product by a convenie nt means such as agarose gel 
electrophoresis. Two important innovations were respon sible for automating PCR. First, a 
heat stable DNA polymerase was isolated from the ba cterium Thermus aquaticus, which 
inhabits  hot  springs.  This  enzyme,  called  the  Taq  polyme rase,  remains  active  despite 
repeated heating during many cycles of amplification. Sec ond, DNA thermal cyclers were 
invented that use a computer to control the repetitive tem perature changes required for PCR.  
 
General PCR amplification conditions used in the study w ere as follows. These conditions 
were varied according to the primers used, but in genera l the following was used: 
Denaturation at94°C for 3 min 
Denaturing 94°C for 1 min   
Annealing  55°C for 1 min   
Extension  72°C for 1 min   
Final extension72°C for 10 min 
 
 
2.4.7   DESIGNING PRIMER OLIGONUCLEOTIDES 
Primers  were  custom  made  using  "Primer  3"  software
96   using  the  following  general 
principles,  
}   30 35 cycles  
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1.   If using genomic DNA, oligonucleotides should be greater th an 20 bases (up to 
24 bases) in length to ensure sequence specificity. It  is extremely unlikely with this 
base length that a second sequence would exist which would be a per fect match to the 
target region.   Primer length is also proportional to annealing efficiency: in  general, 
the  longer  the  primer,  the  more  inefficient  the  annealing.  With  fe wer  templates 
primed at each step, this can result in a significant decrease in amplified produc t. 
2.   Primers should not contain runs of a single base or a  tandem repeat (Poly G or 
Poly C stretches). This avoids matching to known repeti tive DNA sequences (which 
could produce non specific products). The base composition of pri mers should be 
between 45% and 55% GC. Poly A and Poly T stretches are also to be  avoided as 
these will open up stretches of the primer template complex low ering the efficiency 
of amplification. The ideal primer will have a near random mix of  nucleotides, a 
50% GC content and be ~20 bases long. This will put the  T m  in the range of 56°C – 
62°C. 
3.   To reduce primer dimer formation there should be no bas e homology internally 
or at the 3' end of primers. The inclusion of a G or C residue  at the 3' end (GC 
Clamp) helps to ensure correct binding at the 3' end due to the stronger  hydrogen 
bonding of G/C residues.  
4.   The  %GC  content  plus  length  of  the  primers  should  allow  f or  the  melting 
temperature (T m ) of the two primers to be equal.   If primers are mismatched in terms 
of T m , amplification will be less efficient or may not work at all  since the primer 
with the higher T m  will mis prime at lower temperatures and the primer with t he 
lower  T m   may  not  work  at  higher  temperatures.  The  T m   is  the  temperature 
corresponding to the midpoint in the observed transition  of double stranded to single 
stranded  DNA.  The  PCR  annealing  stage  is  usually  most  efficient  if  set  at  a  
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temperature corresponding to the T m   5 
0 C of the chosen primers. The T m  (
0 C) may be 
calculated approximately by the equation: T m  (
0 C) = 2  ×  no. of (A  +  T) bases  +  4  ×  
no. of (G  +  C) bases.   
2.4.8   AGAROSE GEL PREPARATION AND ELECTROPHORESIS 
1.   Mix 10 g of agarose with 500  l of Tris acetate buffer (TA E) 1x. 
2.   Bring to boil until agarose is dissolved. 
3.   Cool gel to 65 
0 C in a water bath. 
4.   Add 25  l of ethidium bromide and mix well.  
5.   Insert combs into the slots on the gel tank and pour the gel slowl y, remove any bubbles on 
the gel. 
6.   Ensure adequate buffer level in the gel tank. Allow the  gel to set for 30 mins before 
loading the samples (samples can be diluted in bromophen ol blue  BPB loading buffer).  
7.   A 100kb DNA ladder is loaded into the end lane as a mar ker. 
8.   Run at 150 Volts (approx 20mins for 250bp sample separ ation) or until products have run 
1/2 of the way down the gel. 
9.   View and document the gel on a UV transilluminator. 
10. The image can be saved to disk as a windows “TIFF”  (tagged image file format file). 
11. The gel may be clear plastic wrapped and stored at 4
0 C for several days. 
   
2.4.9   DIRECT DNA SEQUENCING  
DNA sequencing is the determination of the precise sequence o f nucleotides in a sample of 
DNA. The most popular method for doing this is called the "dideoxy met hod". Automated 
sequencing is used more commonly now, this uses fluore scent labelling where each of the 
four different dNTPs is labelled with a different flu orophore and run in a single lane.  For 
this project, Big Dye® Terminator v1.1.1 Cycle Sequen cing Kit and the ABI P RISM ® 3100 
Genetic  Analyser  were  used.  Samples  to  be  sequenced  wer e  selected  and  a  50 l  PCR  
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reaction carried out for each.  Samples were then elect rophoresed on a 2% Agarose Gel to 
ensure adequate product formation.  These appeared as a  distinct band and corresponding to 
the right size when compared to a 100bp PCR ladder.   
   
The products were then purified using the Qiagen purificati on Kit (Qiagen Ltd, UK) 
following the manufacturer’s protocol.  After purifica tion, a 20 l sequencing reaction (using 
half strength Big Dye) was carried out on the Thermal Cy cler according to protocol.  This 
reaction contains 4 l Big Dye kit, 2 l 5X Buffer (Abgene ), 3.2 l of 1 M primer, 3 – 10ng of 
the purified PCR product and 10.8 l sterile water.  Both fo rward and reverse sequencing 
reactions were performed per sample fragment. A Qiagen  DyeEx 2.0 Spin Kit (Qiagen Ltd, 
UK) was used to remove excess big dye and precipitate the D NA from the sequencing 
reaction.  The products from this were then re suspended  in HiDi Formamide and transferred 
to a 96 well optical plate approved for use in the ABI  P RISM ® 3100 Genetic Analyser. This 
was then set to denature at 94ºC for ten minutes and 4ºC  after that until it is ready to be 
loaded into the sequencer.  The sequencer was loaded accord ing to the settings 
recommended and left to run as long as necessary (~ 45mins fo r 16 samples). Results were 
exported and sequences analysed by visual inspection of the  sequence printout on sequence 
analysing software (BioEdit Version 7.0) and by sequence c omparison using the BLAST 
algorithm from NCBI. Each sample was checked by two obse rvers (SVG and AJL). Any 
deviation between normal and affected or between the sam ple and the published sequence 
was noted. 
 
   
2.4.10   RECRUITMENT OF AMD CASES AND CONTROLS  
The study was approved by the Southampton and Southwest H ants Local Research Ethics 
Committee and was performed in accordance with the revi sed Helsinki declaration of 1983.  
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After informed and written consent, Caucasian subjects  over the age of 55 with a diagnosis 
of AMD were recruited by qualified ophthalmologists from  the ophthalmology clinics of the 
Southampton Eye Unit and research clinics (SG and A JL) on the Island of Guernsey (UK). 
Likewise age matched normal Caucasian controls over ag e 55 were also recruited from the 
same clinics. Patients for the study underwent a detai led, dilated Ophthalmic examination to 
evaluate for the presence or absence of AMD. Fundus pho tographs were recorded using a 
Topcon digital retinal camera (model TRC50IX) at Southa mpton, while a portable camera 
was used in Guernsey. These photographs were graded by  a masked observer into 4 groups 
of increasing disease severity as described in the ARE DS study
97 . AREDS 1 changes were 
considered as normal and these cases were included in t he control group during analysis. 
Each patient provided a 10 ml peripheral blood sample  from which DNA was extracted in 
the laboratory using a rapid salting method as described in  section 2.4.4. 
98   
 CHAPTER THREE : HLA GENE POLYMORPHISMS ARE 
ASSOCIATED WITH AMD  
3.1   INTRODUCTION 
3.1.1   HLA POLYMORPHISMS  
The  Human  Leukocyte  Antigen  (HLA)  gene  complex  is loca ted in the MHC region at 
chromosome 6p21.3. It encodes HLA Class I (A, B, and C ) and Class II (DR, DP and DQ) 
antigens. HLA genes are the most polymorphic within t he human genome, with at least 396 
HLA A, 699 HLA B, 198 HLA C, 494 DRB, 28 DQA1, 66 DQB1 , 23 DPA1 and 119 
DPB1  alleles  currently  recognised.  A  current  listing  of  all  alleles  can  be  electronically 
accessed from the European immunogenetic database 
99 . More than 2000 HLA alleles are 
now known to be encoded by the Class I and II loci. The enc oded polypeptides of these 
alleles  differ  from  each  other  by  one  or  more  amino  a cid  substitutions.  These 
polymorphisms are known to influence the repertoire of pep tides presented by both the HLA 
Class I and Class II antigens. HLA allele frequencies  exhibit ethnic variations, with some 
alleles like DRB1*0401 distributed widely among popula tions while others are exclusive to 
a  particular  ethnic  group  like  the  DRB1*0302  allele  se en  only  in  afrocarribeans.  The 
majority of polymorphism occurs in the exons that enco de the α 1 and α  2 Class I (exons 2 
and 3) and the α  1 and β 1 Class II (exon 2) domains wh ich bind processed peptides and 
present them to T cells 
100 . T cells then recognise the antigen as a peptide bou nd by a 
particular allelic variant of an HLA molecule, but w ill not recognise the same peptide bound 
to other HLA molecules. Most HLA alleles differ fro m one another by multiple amino acid 
substitutions, and these differences are focused on t he peptide binding site and adjacent 
regions that make direct contact with the T cell rece ptor. At least three properties of HLA 
molecules  are  affected  by  HLA  polymorphism:  the  range  o f  peptides  bound;  the 
conformation of the bound peptide; and the direct int eraction of the HLA molecule with the  
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T cell  receptor.  Thus  the  highly  polymorphic  nature  of  th e  HLA system has functional 
consequences, and the  evolutionary selection for the se polymorphisms suggest that it is 
critical in the immune response. 
3.1.2   HLA AND EYE DISEASES  
The phenomenon of “immune privilege” has been described  in the human eye for tissues 
like the cornea, anterior chamber (AC), lens, vitreous  cavity, and the subretinal space. In 
comparison to peripheral blood the eye permits prolonge d survival of foreign tumour and 
tissue allografts in the AC while inducing systemic tol erance to eye derived antigens which 
suppress  the  TH1  immune  response.  Ocular  immune  privile ge  is  attributed  to  multiple 
anatomical,  physiological  and  immunoregulatory  factors ;  these  include  ocular  blood 
barriers, the absence of lymphatic pathways, presence of  soluble immunomodulatory factors 
in aqueous humour and the presence of tolerance promot ing antigen presenting cells 
101 . 
Also ocular tissue cells and fluids express various i mmunomodulatory ligands like CD95L, 
TGF β,  complement  regulatory  proteins,  macrophage  mi gration  inhibitory  factor,  α 
melanocyte stimulating hormone, etc
102 . Another important mechanism attributed to ocular 
immune privilege is an active process of differential  cellular HLA expression (or absence 
thereof) of Class I and Class II molecules in the eye.  In the cornea, Class I antigens are 
highly  expressed  on  the  epithelium  and  keratocytes  bu t  less  so  on  the  endothelium
103 . 
Similarly, Class I antigen expression is low in paren chymal cells of the uvea, the retinal 
pigment epithelium and cells in the neural retina. Norm al retinal expression includes Class I 
and II antigens on microglia 
53 ;
104  and Class I antigens on uveal pigment epithelium an d 
vascular  endothelium 
105   Under  normal  conditions  none  of  these  cells  express  Cla ss  II 
antigens. In contrast, increased HLA Class II immuno reactivity has been observed in the 
human retina affected with age related macular dege neration (AMD) and related to drusen 
formation 
106 . Interestingly, and possibly of clinical importance, t his differential HLA Class  
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II  antigen  expression  is  reduced  with  intravitreal  tr iamcinolone  acetonide 
107 .  This  may 
partly explain the benefit seen with intravitreal triamc inolone acetonide in AMD treatment 
108;108 110 .  
3.1.3   HLA AND AGE RELATED MACULAR DEGENERATION (AMD)  
Human leukocyte antigen (HLA) gene products have been i mplicated in the pathogenesis of 
an  increasing  number  of  eye  diseases,  mainly  inflammato ry  in  nature
111 .  Accumulating 
evidence implicates an immune component to the aetiology  of AMD. Research has shown 
that the retinal pigment epithelium (RPE) is replet e with the ability to synthesize molecules 
involved  in  the  immune  response 
112 .  Also  dendritic  cells,  which  are  potent  antigen 
presenting cells, have been intimately associated with d rusen development along with key 
complement pathways both within drusen and along the RPE  choroid interface. Drusen are 
a constant feature and an important risk factor in al l AMD phenotypes 
12 . HLA DR and 
certain immune related cluster differentiation (CD)  antigens including CD1a, CD83, and 
CD86 have been associated with core domains within dru sen
12 . Previous immunostaining 
and ultrastructural studies have confirmed that these cores a re derived from cell processes of 
choroidal dendritic cells that breach the Bruch’s membr ane
12 .  
   
A unifying hypothesis is that immune response gene polymorphisms  modulate susceptibility 
to  AMD.  This  could  explain  both  the  role  of  inflammat ion  and  genetic  predisposition 
reported  in  AMD.    In  this  context,  human  leukocyte  ant igen  (HLA)  polymorphisms, 
encoded within the major histocompatibility complex (MHC)  are of particular interest. In 
other  eye  diseases,  such  as  Birdshot  chorioretinopathy   specific  HLA  genotypes  are  a 
significant risk factor for the development of the disease.  In this part of my study therefore, I 
evaluated whether specific HLA genotypes are also a ri sk factor for the development of  
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AMD  and  in  addition  whether  HLA  class  I  antigens  are  differentially  expressed in the 
elderly human eye. 
 
3.2   METHODS 
This  part  of  the  study  was  approved  by  the  Southampton  and  Southwest  Hants  Local 
Research  Ethics  Committee  (approval  no.  347/02/t)  an d  followed  the  tenets  of  the 
Declaration of Helsinki.  
3.2.1   PATIENTS AND CONTROLS  
After informed and written consent, Caucasian subjects  over the age of 55 with a diagnosis 
of AMD and normal Caucasian controls over age 55 wer e recruited from ophthalmology 
clinics at the Southampton General Hospital. Patients  for the study underwent a detailed 
ophthalmic  examination  and  fundus  photographs  were  recor ded  using  a  Topcon  digital 
retinal camera (model TRC50IX). These photographs were gr aded by a masked observer 
into  4  groups  of  increasing  disease  severity  as  descri bed in the  AREDS study
113 . Each 
patient provided a peripheral blood sample from which DN A was extracted using methods 
described in section 2.4.4. 
114   
 
3.2.2   HLA GENOTYPING BY PCR-SSP 
Genotyping was performed in two stages, initially for  principal allele groups in a cohort of 
100  AMD  cases  and  92  controls,  and  then  alleles/allele   groups  which  showed  a  trend 
towards significance ( P  < 0.1) on initial typing were genotyped in the next 98  cases and 102 
controls from the same cohort. HLA class I A, B and Cw  and class II DRB1 and DQB1 
genotyping for principal allele groups was performed by P CR SSP (section 2.3.1) 
115,116 . 
PCR  amplification  was  performed  using  panels  of  primer s  specific  to  92  HLA  Class  I 
A,B,Cw and 30 class II DRB1 and DQB1 allele groups,  plus primers specific for the HLA  
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DRB3, 4 and  5 genes. Primer sequences were derived both from t he literature
117 120  and also 
in  house  using  published  HLA DRB  allele  sequences.  Pri mers  were  combined  into  24 
separate PCR reaction mixes to detect 21 HLA A alleles o r allele groups, 48 reactions for 46 
HLA B alleles or allele groups and 23 reactions for 23  HLA Cw alleles. Similarly, primers 
were combined into 23 reaction mixes for DRB typing, dete cting 22 HLA DRB1 alleles or 
allele groups plus the presence of the HLA DRB3, DRB4  or DRB5 genes (encoding the 
DR52,  53  and  51  sub types,  respectively).  Eight  primer   mixes  for  DQB  typing  were 
employed,  detecting  8  HLA DQB1  alleles  or  allele  groups .  Each  PCR  reaction  mix 
contained separate allele or allele group specific P CR primers, combined with an ‘internal 
control’ PCR primer pair to test for successful PCR a mplification. Pre tested PCR reaction 
mixes were aliquoted into 96 well plates (for single s ample HLA A, B, Cw typing or 3 
arrays/plate for HLA DRB1/DQB1 genotyping). The total  volume of each PCR reaction 
was 10  l. The reaction mix for each primer pair was:  1  l 10x buffer (200 mM NH 4 SO 4, 
750 mM Tris HCL pH 9.0, 0.1% Tween 20 (Advanced Biote chnologies Ltd, London), 1  l 
dNTP mix (2mM), 0.6  l MgCl 2  (25 mM), 0.05  l Taq polymerase (5 u/ l), 0.5  l DN A 
template. Each PCR mix contained 5´  and 3´  allele or  allele group specific PCR primers at 
a final concentration of 0.5  M. Each reaction mix also  contained a second primer pair (at a 
final concentration of 0.05  M) which amplified a 429 b ase pair fragment of the human 
growth hormone gene and functioned as an internal positive  control for each PCR reaction. 
PCR products were visualized by  running the entire  rea ction mix on a 2% agarose gel 
(Sigma, Dorset), prestained with ethidium bromide (Sig ma, 0.5mg/ml gel), at 100 V for 20 
minutes, in 1 x TAE buffer. Gels were photographed under  ultraviolet transillumination and 
images  interpreted  by  two  independent  observers  (SVG  an d  WMH).  Genotyping  was 
validated  by  random repeat typing in 10% of  cases  and  cont rols, for each of the HLA  
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genotypes which showed a significant association with AMD  in the study. PCR conditions 
used were: 
1.   96° for 1:00 
2.   96° for 0:15 
3.   65° for 0:50          steps 2 to 4 x 10 cycles 
4.   72° for 0:40 
5.   96° for 0:10 
6.   60° for 0:50           steps 5 to 7 x 20 cycles 
7.   72° for 0:40  
8.   End / 4° forever 
 
3.2.3   HLA CLASS I IMMUNOHISTOCHEMISTRY  
Immunohistochemistry was done in collaboration with Pr of. Rob Mullins who obtained four 
donor human eyes, ranging in age from 76 to 100 years o f age, from the Iowa Lions Eye 
bank (Iowa City, IA, USA). Cryostat sections contai ning the retinal pigment epithelium 
(RPE), choroid, and sclera, were obtained from a sa gittal wedge spanning from the ora 
serrata to the fovea embedded in optimal cutting tempe rature compound (Ted Pella, Inc; 
Redding, CA) without fixation.  The neural retina was i ncluded in one specimen.  Frozen 
sections were incubated with a monoclonal antibody dire cted against a shared epitope on 
expressed HLA class I A, B, and C molecules (clone W6/ 32HL; Chemicon, Temecula, CA, 
USA) at a concentration of 2 g/mL.  In some experiment s, the same sections were also 
incubated  with  antibodies  directed  against  von  Willeb rand  factor  (Chemicon)  at  a 
concentration  of  5 g/mL,  in  order  to  visualize  the  chor oidal  vasculature.  
Immunohistochemical labeling was performed as describe d previously
121  using Alexa 488 
and Alexa 546 conjugated secondary antibodies (Molecula r Probes, Eugene, OR).  Negative 
controls included omission of primary antibody and c omparison with antibodies directed 
against irrelevant antigens.  In order to compare the  labeling of MHC class I and class II 
antigens  in  drusen,  adjacent  unfixed  cryostat  sectio ns  were  labeled  with  monoclonal 
antibody W6/32HL and with a monoclonal antibody directed  against MHC class II proteins  
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HLA DP/DQ/DR (Dako, clone CR3/43).  Digital photomicrog raphs were collected using an 
Olympus BX41 microscope with fluorescence attachment and a  SPOT RT digital camera.  
 
3.2.4   STATISTICAL METHODS AND ANALYSIS 
Power calculations were performed utilizing the Epi I nfo statistical package (Revision 2, 
2003) provided by the Center for Disease Control and Prevent ion (CDC). These calculations 
were  based  upon  the  number  of  cases  and  controls  to  be  g enotyped  and  the  known 
frequency  of  specific  HLA  alleles.  Allelic  distribut ions  for  each  locus  were  tested  for 
conformity  to  Hardy Weinberg  equilibrium.  This  was  a chieved  using  PyPop  statistical 
software
122  from the International Histocompatibility Working Group  (IHWG) based on a 
methodology described by Guo and Thompson
123 . Alleles at each loci were said to be in 
Hardy Weinberg equilibrium if the observed homozygote  and heterozygote frequencies did 
not differ significantly (p>0.05) from expected freque ncies. PyPop was also utilized for 
linkage disequilibrium (LD) analysis and haplotype estim ation where complete data were 
available. 
3.2.5   TWO-LOCUS STRATIFICATION ANALYSIS 
Genotype  frequencies  after  first  and  second  stage  typ ing  were  compared  in  cases  and 
controls by 2x2 contingency tables and two tailed  P  values calculated using Fisher’s exact 
test. Adjustment for multiple comparisons was made a fter second stage typing using the 
Bonferroni  method  i.e.  P  values  for  each  comparison  less  than  or  equal  to  0.05  were 
multiplied by the total number of study comparisons (ni ne in the full study group). Alleles 
showing significant positive or negative associations w ere then compared for all two locus 
combinations using methodology for HLA association studies  as described by Svejgaard et 
al
124 , involving stratification of each allele against t he other in order to determine whether 
the HLA associations were independent of each other or  reflective of linkage disequilibrium  
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(LD) between the HLA loci concerned. The basic data fo r the analyses were 2x4 tables, 
giving the frequencies of the four phenotypic combination s from patients and controls for 
the  two  alleles  being  compared.  These  data  were  analyze d  as  2x2  tables  involving 
stratification of one of the two factors against the other. Two  tailed  P  values were calculated 
using Fisher’s exact test for all of these analyses. Wh en looking at two locus associations 
with AMD,  P   values were corrected by a multiple of the number of  alleles tested for at the 
two loci involved i.e. 1 for HLA B, 3 for Cw, 2 for D RB1 and 3 for DQB1. The level of 
statistical significance was set at  P  < 0.05 and  P c  < 0.05 after application of the Bonferroni 
correction. Odds Ratios were estimated using the approximation  of Woolf to avoid problems 
when critical entries were zero. Logistic regression a nalysis was carried out for each of the 
significant HLA alleles using data on age, sex, body mass  index (BMI) and smoking status 
as covariables in the regression model. This was done  between all the AREDS groups and 
with the control group. All statistical analyses were  performed using the SPSS statistical 
software package version 12.0.  
3.3   RESULTS 
3.3.1   HLA GENOTYPING  
Baseline  demographics  of  the  unrelated  caucasian  cohor t  recruited  from  a  single  clinic 
population (198 cases with AMD and 194 normal controls) are d escribed in table 3. AREDS 
grading data from fundus photographs were available for  174 (87%) of the 200 AMD cases 
(table 4). Alleles were distributed in accordance wit h Hardy Weinberg equilibrium for all 
loci tested. The results from genotyping repeats per formed in 10% of cases and controls 
were found to be 100% concordant with those obtained during  initial genotyping. In total, 
genotyping data for 92 HLA class I A, B and Cw and 30  class II DRB1 and DQB1 principal 
allele groups were available for analysis after the fi rst stage of genotyping. Nine alleles 
revealed a trend towards significance on initial typin g, based on uncorrected  P  values  <  0.1  
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i.e., B*4001 ( P= 0.001), Cw*0302 ( P= 0.099), Cw*0701 ( P= 0.011), Cw*0702 ( P= 0.035), 
DRB1*1301  ( P= 0.0006),  DRB1*11  ( P= 0.035),  DQB1*0301  ( P= 0.056),  DQB1*0302 
( P= 0.019) and DQB1*0303 ( P= 0.034). These alleles were then genotyped in the next 9 8 
cases and 102 controls. The allele frequencies for the  above antigens in the control group 
were  similar  to  those  previously  reported  for  Caucasian   UK  populations
125 127 .  HLA 
genotype frequencies for both class I and class II alle les in the AMD group ( n =200) were 
compared with those in the normal controls ( n =192). Data analysis demonstrated a positive 
association with class I Cw*0701 ( P =0.003) and class II DQB1*0303 ( P =0.023) alleles, 
while a negative association was found with HLA class I  alleles B*4001 ( P =0.004) and 
HLA class II alleles DRB1*1301 ( P =0.0005) and DQB1*0302 ( P =0.013) (table 3). After 
correcting for multiple comparisons, the positive asso ciation of Cw*0701 ( P c =0.027) and 
the  negative  associations  of  B*4001  ( P c =0.036)  and  DRB1*1301  ( P c =0.004)  remained 
significant.  
Two   locus  stratification  of  alleles  showed  that  B*4001   was negatively  associated with 
AMD in DRB1*1301 negative (test 4) but not in the DRB 1*1301 positive subjects (test 3) 
(tables 6 8). Likewise DRB1*1301 was associated with A MD in B*4001 negative but not 
positive individuals (test 6). Tests 9 and 10 did no t demonstrate any association ( i. e .,  LD) 
between B*4001 and DRB1*1301 in either patients or contro ls. The results for comparisons 
between  DRB1*1301  vs.  DQB1*0302,  B*4001  vs.  DQB1*0302  and  Cw*0701  vs. 
DQB1*0303  were  similar  (table  8).  DRB1*1301  and  DQB1*030 2  demonstrated  strong 
apparent negative LD in the control population (test  10). An elevated odds ratio (OR) of 
5.82 was observed only in individuals carrying both Cw *0701 and DQB1*0303 positively 
associated alleles (test 8) but was not significant  after a Bonferroni correction ( P =0.025, 
P c =0.23).  Similarly individuals expressing both  B*4001 an d DQB1*0302 alleles had a 
reduced odds ratio of 0.1 ( P =0.023,  P c = 0.07,   OR=0.10, CI 0.01 to 0.84), while a smaller  
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effect  was  seen  when  both  B*4001  and  DRB1*1301  were  a nalyzed  in  combination 
( P =0.045,  P c =0.09,   OR=0.21, CI 0.04 to 1.04).  However in each case these effects we re not 
significant after correction for multiple comparisons. 
   
These significant HLA associations were further confir med by logistic regression analysis. 
Correcting for sex, age, BMI, current smoker or previous  smoker status again produced 
significant  HLA  associations  for  alleles  B*4001  ( P= 0.001),  Cw*0701  ( P= 0.02)  and 
DRB1*1301 ( P= 0.0001) (tables 9  11). This regression model was also  applied for two 
locus HLA analysis using frequencies from all possible  pair wise combinations of the 5 
significant alleles found in the study. In total, t en possible pair wise combinations were 
tested. None of these alleles were found to influence  or predict the second allele in the 
combination, thus excluding confounding LD between the alle les.  
Further categorization was possible in 174 subjects i n the AMD group, who were divided 
into 4 groups of increasing AMD severity using AREDS cr iteria. No significant difference 
was  found  in  comparison  of  the  4  AREDS  groups  and  al leles  B*4001,  Cw*0701, 
DRB1*1301,  DQB1*0302  or  DQB1*0303  alleles.  A  multivari ate  logistic  regression 
analysis for these 5 alleles in relation to age, sex,  BMI and smoking status as covariables 
was performed between AREDS group IV compared to AREDS  group I. The only positive 
association was with current smokers. Smoking increased  the risk of developing advanced 
AMD 4 fold. This was seen irrespective of the allele t ested ( P =0.019 to 0.017, OR=4.55 to 
4.79). No significant associations were found between  the same covariables in the other 
AREDS groups or compared with the control group.  
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Figure 5. Gel run photograph for HLA Class II Genotyping in  an AMD patient. 
 
Table 3. Basic demographic characteristics of the HLA study  population. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  AMD CASES   CONTROLS 
Age 
         Mean  
     n = 198 (% ) 
     76.26 
  n = 194 (% )      
   71.57            
         Range       55   95     55   91 
         SD       7.36     9.43 
Sex 
          Female 
          Male 
     n= 198 (%) 
    119 (60.1)       
     81 (39.9) 
   n=194 (%) 
   116 (59.8) 
    76 (41.2) 
BMI 
          Mean 
          SD 
     n=137 
     26.73 
     4.75 
    n=173 
     27.19 
     5.13 
Smoking status 
          Current smokers 
          Past smokers 
          Non smokers 
     n=198(%) 
     28(14.1) 
     97(50.0) 
     75(37.9) 
     n=194(%) 
     24 (12.3) 
     93(47.9) 
     77(39.8) 
Internal Control Band 
Allele Specific Band  
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Table 4. AREDS sub grouping of cases according to the severity of 
AMD in affected eye/s.  
  AREDS                         Phenotypic Characteristic s of AMD   
  Grading                        (changes seen in worst  affected eye)  
AMD Cases   
 n = 174 (%)  
 
  Grade I      non  extensive small drusen or no drusen in fellow eye (normal) 
   
 02 (1.2) 
 
  Grade II     extensive small or  ≥ 1 intermediate size drusen, pigment changes 
   
 71 (40.8) 
    
  Grade III     ≥ 1 large drusen 63  diameter or Geographic Atrophy < 1/8 D D 
  
39 (22.4) 
 
  Grade IV  GA  ≥ 1/8 DD or Neovascular AMD ( RPE detachments and CNV)  
  
62 (35.6) 
 
 
Table 5. HLA   A, B, Cw, DRB1 and DQB1 genotype frequency (%) tables for AMD c ases 
and normal controls, first table after first stage genotyping and second table  after final stage 
genotyping. 
 
  HLA              AMD Group   Control Group    P  value
†       Odds                  95% CI 
Allele                 n =100(%)          n =94(%)        Significant*    Ratio
‡  
B*4001     4(4)                   18(19.1)       0.001 1*      0.176    0.058 to 0.542 
Cw*0302     14(14)                22(23.4)       0.09 99      0.533   0.254 to 1.116 
Cw*0701     46(46)                26(27.6)       0.01 13*      2.228   1.224 to 4.056 
Cw*0702            20(22)               32(34.0)           0.0348*           0.484           0.253 to 0 .928 
DRB1*1301       02(2)                 15(15.9)            0.0006*          0.107            0.024 to 0. 484 
DRB1*11           22(22)               10(10.6)            0.0353*          2.369            1.055 to 5 .319 
DQB1*0301       46(46)               30(31.9)            0.0557            1.817           1.012 to 3.2 64 
DQB1*0302       12(12)               25(26.6)            0.0108*          0.376           0.177 to 0.80 2 
DQB1*0303       10(10)               02(2.1)              0.0339*          5.111           1.089 to 23. 988 
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Table 6 (cont) 
HLA 
allele 
AMD cases 
 n =198 (%) 
Controls    
n =194(%) 
P  value
†   P c  value
§   Odds  
Ratio
‡  
95% CI 
B*4001  16 (8.0)  35 (18.0)  0.004*  0.036*  0.39  0.21 to 0 .75 
Cw*0302  30 (15.0)  27 (13.9)  0.776    1.09  0.62 to 1.91 
Cw*0701  84 (42.0)  54 (28.1)  0.003*  0.027*  1.91  1.25 t o 2.91 
Cw*0702  43 (21.5)  55 (27.8)  0.161    0.71  0.45 to 1.13 
DRB1*1301  14 (7.0)  37 (19.7)  0.0005*  0.004*  0.32  0.16  to 0.61 
DRB1*11  32 (16.5)  25 (12.9)  0.323    1.34  0.76 to 2.34 
DQB1*0301  73 (36.5)  69 (35.05)  0.834    1.06  0.70 to 1.69  
DQB1*0302  27 (13.5)  46 (23.7)  0.013*  0.117  0.50  0.30 t o 0.86 
DQB1*0303  22 (11.5)  9 (4.6)  0.023*  0.207  2.57  1.15 to  5.73 
† Two sided  P  values using Fisher's exact test (*Significant values) ;  P c   indicates  P  values 
after application of Bonferroni correction factor (n=9 ). 
‡ Odds Ratio using the approximation 
of Woolf. 
 
Tables  7a/6b.  Showing  construct  of  basic  data  which  was u tilised for  2x2 stratification 
analysis  
 
Table 6a. 
HLA  ‘A’ 
allele 
HLA  ‘B’ 
allele 
AMD 
cases(n) 
Controls(n) 
           +           +            X1           Y1 
           +                     X2        Y2 
                       +         X3        Y3 
                                 X4        Y4 
 
Table 6b. 
Test   Values 
     a 
for  
    b 
2x2tables  
    c 
 
   d 
Allele frequencies tested with interpretation for 
each test 
1  X1+X2      X3+X4  Y1+Y2  Y3+Y4   A+ vs. A , individual ‘A’ association tested 
2  X1+X3  X2+X4  Y1+Y3  Y2+Y4   B+ vs. B , individual ‘B’ association tested 
3  X1  X3  Y1  Y3  A+ vs. B+, association of ‘A’ independent  of ‘B’ 
4  X2  X4  Y2  Y4  A+ vs. B+, association of ‘A’ independent  of ‘B’ 
5  X1  X2  Y1  Y2  B+ vs. A+, association of ‘B’ independent o f ‘A’ 
6  X3  X4  Y3  Y4  B+ vs. A+, association of ‘B’ independent o f ‘A’ 
7  X2  X3  Y2  Y3  Difference between ‘A’ and ‘B’ association s tested 
8  X1  X4  Y1  Y4  Combined association of ‘A’ and ‘B’ tested 
9  X1  X2  X3  X4  LD tested between ‘A’ and ‘B’ in AMD case s  
10  Y1  Y2  Y3  Y4  LD tested between ‘A’ and ‘B’ in control s 
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Table 8. Frequencies for individual significant alleles (basic da ta) used 
in the 2x2 stratification analysis. 
B*4001      DRB1*1301     DQB1*0302     Cw*0701     DQB1*0303  AMD patients 
 (n=198) 
Controls  
(n=194) 
+ve  +ve          2    7 
+ve   ve          14    28 
 ve  +ve          12    30 
 ve   ve          172    129 
  +ve  +ve        0    0 
  +ve   ve        14    37 
   ve  +ve        27    46 
   ve   ve        159    111 
+ve    +ve        1    7 
+ve     ve        15    28 
 ve    +ve        26    39 
 ve     ve        158    120 
      +ve  +ve    9    2 
      +ve   ve    75    52 
       ve  +ve    14    7 
       ve   ve    102    132 
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3.3.2   HLA CLASS I IMMUNOHISTOCHEMISTRY 
Immunohistochemical detection of HLA class I  antigen s was performed on four human 
donor eyes without remarkable pathology, using a pan HLA c lass I monoclonal antibody.  
The  most  notable  labeling  was  observed  in  endothelial  cells,  particularly  in  the 
choriocapillaris  but  also  in  large  vessels  of  the  choro id  (Figure  6A).  This pattern  was 
different from that of von Willebrand factor which was  detected in capillaries but showed 
much stronger labeling in large veins and arteries of the o uter choroid (Figure 6B).  Labeling 
of  large  retinal  vessels  was  also  apparent  with  relat ively  little  localization  to  retinal 
capillaries.  Occasional RPE cells showed minor labeling  along the basal aspect (data not 
shown).  Vessels in the sclera as well as a population  of scleral cells with an elongated 
morphology were immunoreactive.  In contrast to MHC clas s II antigens
128 , drusen present 
in these specimen did not exhibit strong immunoreactivit y for HLA class I (Figure 6. C, D). 
 
A           B
C                                                       D  
RPE
CC
RPE
CC
*
*
*
*
RPE
RPE
CC
CC
 
Figure 6. Immunolabeling of the RPE and choroid. 
Monoclonal antibody directed against HLA class I antigens (A) and  polyclonal antibodies 
directed against von Willebrand factor (B) on the same section. The  fluorescence of the 
RPE is due to lipofuscin autofluorescence. The endothelial cells wi th the most notable  
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HLA labeling are cells of the choriocapillaris (CC, arrows),  although other vessels are 
also weakly positive (asterisks).  In contrast, robust labeling of  large vessels is noted with 
antibodies directed against von Willebrand factor (B, asterisks). Im munolocalization of 
HLA class I (C) and class II (D) molecules in eyes with dr usen reveals that, unlike MHC 
class II antigens, MHC class I antigens are not detectable  as major components of drusen 
or other subRPE deposits. Drusen borders are indicated by the dashed line. 
 
3.4   DISCUSSION  
The importance of defining associations between HLA ant igens and AMD lies in providing 
new  insights  into  its  basic  pathogenesis  and  to  help  de fine  an  ‘at  risk’  population  for 
preventive measures to become applicable. This is part icularly true, since the overwhelming 
majority of HLA gene polymorphisms result in functional  amino acid substitutions in the 
expressed HLA molecules, thereby modulating the immun e response to a vast range of 
antigens,  with  inter individual  differences  in  immu ne  responses  to  complex  or  simple 
antigens
129 . Due to the critical role of HLA in regulating the  immune response, combined 
with  its  extensive  polymorphism,  it  is  perhaps  unsurpris ing  that  many  HLA  gene 
polymorphisms have been linked to susceptibility in a  large number of immunologically 
mediated diseases including the retina and uvea of the  eye, the skin, gut, endocrine and joint 
systems
130 .  
   
Association  studies  for  a  disease  like  AMD  which  has   multiple  etiological  factors  are 
difficult and require a robust study design and execut ion. In our study, several steps have 
been taken to avoid confounding variables.  These inclu de ethnically matched cases and 
controls of similar ages, with both groups having been screened  for AMD; appropriate study 
sample sizes and the application of stringent statisti cal methods to detect the strength of our 
associations.  
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Due to the extreme polymorphic nature of the HLA region , sampling variation between 
cases and  controls can  easily lead to both false po sitive and false negative associations. 
Accordingly, application of a Bonferroni correction fa ctor for the number of allelic subtypes 
tested is recommended and was applied in this study. A tw o step genotyping procedure was 
followed. This permitted a realistic Bonferroni correc tion for a small group of candidate 
alleles, rather than an over conservative correction fo r all possible HLA alleles, which may 
cause even true positive associations to be discarded.   The two stage method of genotyping 
used in our study has been modified from a previously  reported similar study 
131  where 
candidate  alleles  were  identified  initially  by  compa ring  frequencies  in  patient  versus 
population controls.  These short listed candidate all eles were then genotyped and compared 
between the two groups. This approach reduces the number  of multiple comparisons made 
after the second stage and helps minimize the type I e rror rate. In addition, DNA based 
typing was utilized, which has a better allelic resol ution and accuracy as compared with 
serological HLA typing.   
   
Finally, LD occurs frequently between alleles of diffe rent HLA loci, whereby an allele from 
one locus often occurs more frequently in combination wit h an allele of a second locus than 
is expected from their individual allele frequencies. This can  complicate studies of HLA and 
disease  predisposition.  In  cases  where  alleles  of  more   than  one  locus  show  positive  or 
negative  associations  with  disease,  it  is  therefore  im portant  to  determine  whether  such 
associations are independent or reflect LD between the  alleles concerned.  Methods such as 
the two locus stratification analysis described
132  and the use of relevant genomic software 
such  as  PyPoP  therefore  assume  importance  in  excluding   LD  and  were  applied  in  the 
present investigation. PyPoP also enables haplotype e stimation. Such haplotype estimation 
was attempted in our study, but this was not possible  for the whole study group since full  
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genotyping data were available only in the first half  of cases and controls. However, we did 
obtain haplotype estimates for 2 and 3 locus combinati ons for the first 100 cases and 92 
controls where complete genotype data was available. Ea ch 2 locus haplotype estimation 
revealed between 85 to 161 haplotypes, and their corre sponding frequencies were too small 
for any meaningful analysis between the groups (data not sh own). 
   
After  controlling  for  known  AMD  risk  factors  (smoking,  age   and  BMI)  by  logistic 
regression  analysis  alleles  B*4001,  DRB1*1301  and  Cw*0 701  remained  significantly 
associated  with  AMD.  Allele  Cw*0701  increased  suscept ibility  to  AMD  while  HLA 
B*4001 and DRB1*1301 decreased susceptibility to AMD. Two  locus stratification and 
logistic  regression  analysis  indicated  that  these  asso ciations  were  independent  and  not 
reflective  of  LD  between  alleles.  For  example,  two lo cus  stratification  and  logistic 
regression analysis demonstrated that the negative associ ation of HLA B*4001 with AMD 
was  observed  in  DRB1*1301  negative  (but  not  positive)  individuals  and  the  negative 
association  of  DRB1*1301  with  AMD  was  seen  in  B*4001 nega tive (but not positive) 
individuals  (table  6).  The  apparent  negative  LD  found  be tween  DRB1*1301  and 
DQB1*0302 in our control but not AMD subjects is most  probably a reflection of well 
described  strong  LD  between  DRB1*1301  and  DQB1*06  alleles  in  Caucasian  UK 
populations
133;134 . After Bonferroni correction alleles DQB1*0302 and DQB1* 0303 were 
not significantly associated with AMD. However as th eir uncorrected p values were < 0.05 
these alleles would still merit further investigation i n an independent/larger study group.   
   
The mean age of our control population was slightly lower co mpared to our cases (mean age 
71.57 vs. 76.26). Therefore some of our controls may subsequen tly develop AMD. However 
if so, the HLA associations described would be an und erestimate. HLA associations with  
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AMD may therefore be stronger than we describe. In additi on, controlling for age during 
regression analysis did not alter the described HLA  associations. This study had 80% power 
to detect significant differences in allele frequenci es between cases and controls at an alpha 
level of 0.05. For example, for an allele occurring at  a frequency of 10% in the control 
population, detectable odds ratios are 2.3 for a predisp osing allele and 0.5 for a protective 
allele with 95% confidence. We may therefore have not d etected smaller HLA associations 
with this sample size. 
   
This  study  broadens  the  role  of  HLA  associations  in  opht halmic  disease.  Previous  eye 
associations  have  all  been  in  uveitic  diseases  i.e.  HLA  B27  is  strongly  associated  with 
anterior uveitis
135;136 . HLA A29 confers an increased risk of birdshot chorio retinopathy up 
to 224 times higher than for non carriers
137;138 . Sympathetic ophthalmia is associated with 
HLA B1*04 and intermediate uveitis with HLA DRB1*03
139;140 . Our statistical correction 
for multiple comparisons is at least as conservative,  and in some cases more conservative, 
than that used in these accepted HLA associations with uvei tic eye disease. 
   
More  than  one  HLA  locus  may  be  involved  with  disease  p redisposition.  This  is  not 
uncommon and has been described for other diseases, inc luding celiac disease
141  and insulin 
dependent diabetes mellitus. HLA  DQA1 and DQB1 alle les have been associated with the 
former, while in the latter case, a number of predisp osing and protecting alleles and allele 
combinations have been identified
142 . Based on our findings, multi allelic HLA associatio ns 
may also be important in AMD. 
   
Logistic regression analysis was performed to evaluate  relationships between the five HLA 
alleles initially associated with AMD (table 9) and t heir effect on disease severity. Smoking  
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in  association  with  the  HLA  alleles  conferred  a  fou r  fold  increased  risk  of  developing 
advanced AMD (AREDS group IV) (table 10). Further in vestigation of these five HLA 
alleles in a larger study would be useful in determi ning the amount of risk contributed by 
these alleles towards advanced AMD and possibly CNV. Pre viously, significant associations 
have been reported between HLA DRB1*15 ( P c =0.000001) and DQB1*06 ( P c =0.00001) 
alleles and the development of CNV in presumed ocular  histoplasmosis syndrome
143 . These 
findings, along with the data from the current study, sup port the notion that certain HLA 
alleles are associated with CNV in various retinal disea ses. 
   
The localization of HLA class I antigens to choroida l endothelial cells is consistent with 
previous  studies  using  tissues  with  longer  post mortem  ti mes
144 .  It  is  interesting  that 
choriocapillary endothelial cells exhibit more robust e xpression than the endothelium of 
larger  vessels,  as  visualized  by  the  von  Willebrand  fa ctor  dual  labeling  experiments.  
Endothelial cells in some tissues express HLA antigens con stitutively and cultured choroidal 
endothelial cells increase their expression of HLA cla ss I antigens following exposure to 
certain cytokines
145 . Whether these antigens are up regulated in endothe lial cells or other 
ocular cell types in eyes with AMD remains to be determ ined, but this is an intriguing area 
of future study. It is also interesting that the expr ession patterns differ between HLA I and 
HLA II antigens in the choroid and in sub RPE deposit s, suggesting possible differences in 
how these molecules may confer risk in macular disease .  Notably, drusen contain MHC 
class II antigens but do not appear to contain MHC cl ass I proteins.  The high level of 
expression of HLA class I antigens by choriocapillary en dothelial cells could potentially 
place the choriocapillaris at risk for T cell mediate d attack in AMD and other inflammatory 
diseases. 
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The underlying mechanisms by which HLA genes determine  susceptibility to various ocular 
diseases has not been fully elucidated yet and it sho uld be stressed that an HLA association 
determined by a case control study does not necessaril y implicate HLA polymorphism in 
causality, but may reflect LD with causal polymorphism s in other genes, for example, LD 
between  HLA A*03  and  causal  polymorphisms  in  the  HFE  g ene  which  determine 
susceptibility to hereditary hemochromatosis
146 . While we cannot exclude LD with non 
HLA polymorphisms as causal in AMD, a number of lines  of evidence, both indirect and 
direct, suggest a direct role for HLA in the disease pr ocess.   
   
Firstly,  HLA A29  transgenic  mice  have  been  shown  to  devel op  a histologically  similar 
disease to birdshot chorioretinopathy in humans, confir ming the functional role of the HLA 
A29 molecule in the pathogenesis of this condition
147 . Thus, certain HLA alleles are known 
to promote the development of other inflammatory ocular  diseases. Secondly, and more 
importantly,  accumulating  evidence  implicates  an  immun e  as  well  as  genetic  and 
environmental components in the aetiology of AMD. Research  shows that the RPE is replete 
with the ability to synthesize molecules involved in  the immune response
148 . Also dendritic 
cells, which are potent antigen presenting cells, have be en intimately associated with drusen 
development along with key complement pathways both w ithin drusen and along the RPE 
choroid interface. Drusen are a constant feature and  an important risk factor in all AMD 
phenotypes, seen even in sub clinical AMD phenotypes a s typical small drusen
12 .  HLA DR 
and certain immune related cluster differentiation ( CD) antigens have been associated with 
core  domains  within  drusen
12 .  Immunohistochemical  and  ultrastructural  studies  have 
suggested that these cores are derived from cell proce sses of choroidal antigen presenting 
cells that breach the Bruch’s membrane
12 . Accordingly, the HLA associations found here 
suggest a potential direct role for HLA molecules in the cell ular immune mediated processes  
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directed against specific local antigens or newly crea ted antigens particularly during drusen 
and AMD evolution.  
   
Thirdly, another mechanism which might indicate a dir ect role for HLA polymorphism in 
determining susceptibility to AMD is “molecular mimi cry,” where antigenic cross reactions 
occur between HLA antigens and extraneous trigger antige ns possibly from an invading 
organism. The latter itself may not induce a strong i mmune response, but instead induce a 
localized autoimmune reaction responsible for the associ ated pathology. Interestingly, anti 
Chlamydia pneumoniae antibodies have been found to be el evated in patients with AMD, 
suggesting an association of this pathogen with AMD
62 . The pathogenesis for this could be 
similar  to  that  reported  in  acute  anterior  uveitis  (A AU)  where  potential  Gram negative 
bacterial  antigens  have  been  shown  to  alter  the  immun e  response  of  resident  antigen 
presenting HLA DR(+) dendritic cells in the uvea
149 . Our findings reinforce the possible 
autoimmune  nature  of  AMD  as  being  a  disordered  respons e  to  inflammation  or 
superantigens.  
   
It is well established in genetic epidemiology research t hat it is important to evaluate any 
initial associations in at least one separate cohort . For this purpose DNA samples were 
obtained from a cohort of 576 AMD cases and 288 control s from Michigan, USA (courtesy 
of Prof. Anand Swaroop), these have now been genotyped  and results summarised below. 
Following on from this hypothesis generating study, furth er larger HLA AMD association 
studies  are  needed  in  other  populations  to  confirm  thes e  novel  HLA  associations.    In 
addition, these studies where possible should be compl emented by functional studies to 
determine the contribution of these genes to the develop ment of AMD. Dissecting the role 
of HLA and immune pathways in AMD may ultimately lea d to opportunities to modulate  
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these pathways by precise pharmacological means and th us improve the visual outcome in 
this devastating disease. 
 
3.5   HLA REPLICATION STUDY IN MICHIGAN COHORT 
HLA genotyping for the 3 significant alleles found in  the UK cohort was carried out in the 
Michigan cohort using the same methodology as previously de scribed above. Frequencies 
for the three tested HLA alleles in the Michigan AM D group ( n =576) were compared with 
those  in  their  normal  controls  ( n =288).  Data  analysis  demonstrated  a  similar  trend  as 
reported previously
150  in the UK cohort (table 12). The positive AMD associa tion with class 
I HLA Cw*0701 allele ( P =0.016, OR=1.81), the negative AMD associations found wi th 
HLA class I allele B*4001 ( P =0.044, OR=0.67) and class II allele DRB1*1301 ( P =0.006, 
OR=0.60) were all found to be significant. After corre cting for multiple comparisons, the 
positive association of Cw*0701 ( P c =0.048) and the negative association of DRB1*1301 
( P c =0.018) remained significant while the B*4001 ( P c =0.132) did not reach significance. 
The lower HLA Cw*0701 frequencies seen in the Michigan normal contro ls as compared 
to  the  normal  UK  controls  seem  to  mirror  reported  population  difference s  in  allelic 
distributions (US populations vs. Western Europe, 0.13 and 0.17 respectively)
151 . 
  
Table 12. HLA   B*4001, Cw*0701 and DRB1*1301 genotype  frequencies in AMD cases 
and normal controls of the Michigan cohort. 
HLA 
allele 
AMD Group 
 n =576  
Control Group 
 n =288  
P  value
†   P c  
value
§  
Odds  
Ratio
‡  
95% CI 
Cw*0701  78 (0.14)  23 (0.08)  0.016*  0.048*  1.81  1.11 2 .94 
B*4001  71 (0.13)  50 (0.18)  0.044*  0.132  0.67  0.45 0.99 
DRB1*1301   85 (0.15)  64 (0.22)  0.006*  0.018*  0.60  0.42 0.87 
 
† Two sided  P  values using chi squared test (*Significant values);  P c  indicates  P  values after 
application of Bonferroni correction factor (n=3). 
‡ Odds Ratio using the approximation of 
Woolf.  
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In this study we have been able to replicate to a majo r extent the previously reported HLA   
AMD associations in a different population cohort. Alt hough the AMD risk (nearly 2 fold) 
conferred by the presence of the C*0701 allele seems to be simi lar in both Southampton and 
Michigan AMD cohorts (odds  ratios of  1.92  and 1.81  res pectively), the strength of the 
HLA Cw*0701 association with AMD in the US cohort seem s to be lower than that seen in 
the  UK  cohort.  One  possible  explanation  for  this  could  be   the  lower  Cw*0701  allele 
frequencies seen in the Michigan cohort due to report ed population differences in allelic 
distributions  (US  vs.  Western  Europe,  0.13  and  0.17  r espectively)
152   .  It  is  also  well 
recognized that the first report describing an associati on between a gene and a disease often 
overestimates the fraction of  disease caused by muta tion in the gene in question.
153  This 
emphasizes the need for replication studies such as ours to assess the HLA ef fect in further 
AMD populations. 
 
In summary, the novel HLA AMD associations found in this  study were reproducible to a 
major extent in a different population cohort. It is theref ore logical that these HLA 
associations could predictably play an important role in  AMD among most western 
populations. Larger HLA AMD studies in different ethni c populations are needed to further 
confirm these novel HLA AMD associations.       CHAPTER FOUR: C-REACTIVE PROTEIN, ICAM-1, 
INTERLEUKIN, VEGF AND COMPLEMENT FACTOR H GENE 
VARIANTS IN AMD.  
4.1   INTRODUCTION 
Currently, both  genetic  and environmental risk factor s are known to be associated with 
AMD 
154;155 .  Genetic  associations  include  sequence  changes  in  the  Apo E,  fibulin  5, 
complement factor H, toll like receptor 4 and HLA genes  
150;156 162 . In addition elevated 
serum C reactive protein and smoking have been associat ed with AMD 
45;163 . 
   
There are now multiple lines of evidence suggesting an  important role for inflammatory 
events in the pathogenesis of AMD. Histologically, drus en, which are extra cellular deposits 
seen  in  the  retina  in  patients  with  AMD,  contain  protei ns  which  modulate  the  body's 
response  to  inflammation.  These  proteins  include  vitro nectin,  complement  and 
immunoglobulins
164 . Auto retinal antibodies have
  been detected in the sera of some AMD 
patients
165   and  a  serological  association  has  also  been  reported   between  Chlamydia 
pneumoniae infection and AMD 
62 . Recent research suggests that serum CRP could be a n 
important biomarker for AMD 
45;65 . However it is unclear why CRP levels associate wit h 
AMD. 
   
The factors influencing basal CRP levels and levels re ached during inflammation are not 
fully understood. Interleukin 6, the main inflammatory  cytokine stimulus for CRP
166  has 
also been recently associated with AMD 
65 . In the absence of acute inflammation, CRP 
levels appear stable
167 , with absolute levels being influenced by age
168 , sex
169 , body mass 
index (BMI)
170 , and smoking
171 . Studies in families have suggested that CRP level i s a 
heritable trait 
172;173 , but the genes involved in this regulation are unknown
169 . However  
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several single nucleotide polymorphisms (SNP's) have  been demonstrated recently in the 
human CRP gene, many of which appear functional. Of these, 1 059G/C (exon 2, rs1800947) 
and 1444C/T (3' UTR region, rs113012959) seem to influenc e CRP levels both at baseline 
and  during  inflammation
174 .  A  recent  study  has  also  identified two  functional pro moter 
SNP's ( 409G/A, rs3093062 and  390C/T/A, rs3091244) in th e CRP gene which seem to 
affect protein transcription and baseline CRP levels
175 . 
    
The recent finding of a complement factor H coding pol ymorphism (1277T/C, rs1061170) 
in association with nearly 50% of AMD cases
46 48;176  may also be of particular interest in the 
context of CRP. Firstly, because it is located near  a suspected AMD susceptibility locus on 
chromosome  1q,  a  region  showing  substantial  linkage  di sequilibrium and secondly, this 
Y402H  variant  located  on  SCR7  domain  of  the  CFH  prot ein  has  been  implicated  as  a 
binding site for CRP at the protein level. It has bee n proposed that CFH through its direct 
binding to CRP normally reduces complement mediated de position in AMD and that this 
process may therefore be defective due to the variant C FH protein. We therefore analysed 
the CFH variant 1277T/C (Y402H) in our study cohort to  evaluate any possible correlation 
with CRP levels. 
 
Adhesion molecules such as Intercellular Adhesion Molec ule 1(ICAM1) play a key role in 
autoimmune disorders and soluble forms (sICAM1) of thes e adhesion molecules can be 
measured in serum. CRP is known to have a direct pro i nflammatory effect on endothelial 
cells by stimulating ICAM1 expression 
177 , which may be relevant in AMD. In the eye, 
ICAM1 is expressed on retinal pigment epithelium (RPE) and chor oidal vascular endothelial 
cell surfaces where it mediates leucocyte adhesion and mig ration
178 . In an animal model of 
choroidal neovascularization, ICAM 1 deficiency is ass ociated with less severe choroidal  
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neovascular  membranes  than  wild  type,  indicating  that  IC AM 1  is  necessary  in  the 
pathogenesis of advanced AMD
179 . 
   
Elevated ICAM1 expression has been demonstrated on vas cular elements and RPE cells in 
sub foveal choroidal neovascular membranes (CNV) from A MD patients
180 . Indeed, recent 
clinical  trials  using  intravitreal  triamcinolone  acet onide  in  the  treatment  of  neovascular 
AMD seem to support this role of ICAM1 in the pathogenes is of AMD
108;109;181 . This is 
because  one  modality  by  which  triamcinolone  seems  to  e xerts its effect is by reducing 
expression of ICAM1 in RPE and vascular endothelial cells
182 .  
   
Raised CRP has previously also been associated with i ncreased expression of ICAM1 in 
atherosclerosis,  especially  in  the  coronary  artery  endo thelial  cells
183 .  We  therefore 
investigated CRP and ICAM1 in AMD as both inflammat ory markers seem interrelated and 
important  for  the  development  of  atherosclerosis
184;185 ,  a  disease  which  shares  many 
epidemiological risk factors with AMD. Two coding SN Ps reported in the ICAM 1 gene (a 
single copy gene) are known to be common in all populations an d have been associated with 
several  inflammatory  diseases.  These  are  located  in  exon s  4  (12959G/A,  R241G, 
rs1799969)  and  6  (13848G/A,  E469K,  rs5498).  While,  R241 G  has  been  significantly 
associated  with  rheumatoid  arthritis
186 ,  inflammatory  bowel  disease
187   and  giant  cell 
arteritis
188 , E469K has been predominantly associated with Bechet's dis ease (both ocular and 
systemic)
189 191  and Alzheimer's disease 
192 .  
   
Increasingly  evidence  is  emerging  that  variations  i n  cytokine  expression  (and  in  the 
underlying genes which control their expression) may  modulate susceptibility to age related 
macular degeneration (AMD). Cytokines such as interl eukin 6 (IL 6), interleukin 8 (IL 8)  
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and vascular endothelial growth factor (VEGF) are relea sed by degenerating retinal pigment 
epithelial cells and associated with drusen in AMD
12;193 . VEGF induces the expression of 
ICAM1 on vascular endothelium
194 . Studies have shown increased VEGF expression in the 
RPE of donor eyes with neovascular AMD
195  and in cultured RPE from surgically removed 
CNV
196 . C reactive protein (CRP) has been The main inflammat ory cytokine stimulus for 
CRP (shown to be a biomarker for AMD 45;65) is interle ukin 6 and this has also been 
recently associated with AMD.
65;166  
 
Pro inflammatory  cytokines  have  also  been  shown  to  up  reg ulate  intercellular  adhesion 
molecule 1 (ICAM1) at microglial sites
194  which along with locally released cytokines may 
lead to the recruitment of inflammatory cells seen in  AMD.  IL 8 is a primary mediator of 
angiogenesis and this has been demonstrated in various ca rcinomas
197;198 . IL 10 is a potent 
anti inflammatory  cytokine  produced  by  T  cells,  macrop hages,  and  retinal  pigment 
epithelial  cells.
199;200   It  strongly  inhibits  antigen specific  T  cell  prolife ration,  cytokine 
production, and down regulates both HLA class 1 and cla ss 2 antigen expression
201;202 . IL 
10 is also important in the induction of antigen speci fic anergy or tolerance.
203  Genotypes 
associated with  high  IL 10 expression have a  protecti ve role (possibly via inhibition of 
angiogenesis)
204;205   while  genotypes  associated  with  high  IL 8  expression  co uld  be  risk 
factors for stimulation of angiogenesis in AMD.  
   
This part of the study was therefore done to determine  if biomarkers like CRP and sICAM1 
were  independent  risk  factors  for  AMD  development  in  a   well  defined  UK  cohort. 
Functional polymorphisms for biomarkers (CRP  409G/A ,  390C/T/A, 1059G/C, 1444C/T 
and ICAM1 12959G/A, 13848G/A) were evaluated for any effec t on serum levels. Based on 
the evidence for a possible role of cytokines in AMD w e chose four known expression  
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related  cytokine  polymorphisms  in  interleukin  genes  ( pro inflammatory  IL  1β   511C/T 
(rs16944), IL 6  174C/G (rs1800795), IL 8  251A/T (rs407 3) and anti inflammatory IL 10  
1082G/A (rs1800896) to test the hypothesis that they may  be associated with AMD.  
   
Additionally,  other  expression related  cytokine  poly morphisms  in  VEGF  ( 2578C/A  or 
rs699947,  1154G/A or rs1570360,  634G/C or rs2010963 , +936C/T or rs3025039) genes 
were evaluated for any association with AMD. Finally,  the study also explores the plausible 
link between serum CRP and the CFH Y402H polymorphism a s this CFH variant alters the 
binding properties of CFH to CRP which may lead to com plement mediated AMD damage. 
 
4.2   METHODS 
4.2.1   SUBJECTS AND METHODS 
AMD patients and normal controls over age 55 were recru ited as per methods described in 
chapter 2 (section 2.4.10). AMD photographs were graded  by a masked observer into 4 
groups of increasing disease severity as described in t he AREDS study 
206 . The CNV group 
was further categorised into occult, minimally classic  and predominantly classic sub groups. 
General  health  was  assessed  and  care  was  taken  to  exclu de  patients  who  reported  any 
infective illness in the preceding month. Patients wi th a history of chronic joint or organ 
related inflammation were also excluded from the stud y. Information was also obtained 
about relevant past medical history, smoking history, oc ular history, use of medications, 
vitamin  or  dietary  supplementation;  and  height,  weight,  body  mass  index  (BMI) 
measurements recorded. Serum separated during DNA extrac tion and stored at –20º C was 
utilised for CRP analysis. 
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4.2.2   MEASUREMENT OF CRP AND ICAM1 
Serum CRP levels were measured using an automated Adv ia 1650 clinical analyser (Bayer). 
In  this  method,  CRP  in  the  serum  sample  combines  sp ecifically  with  anti human  CRP 
antibodies in the buffer antibody reagent mix to form an aggregat e. This insoluble aggregate 
causes an increased turbidity which is then measured  optically; this is proportional to the 
amount of CRP in the sample. The sensitivity or linea r range of detection for CRP levels 
with this analyser was 1 to 180 mg/l. Quality control  for the analyser was done using the 
recommended graphical calibration software using recom mended controls and diluents from 
the manufacturer.  
 
Immunoassay for sICAM 1 was done using a solid phase E LISA kit (R & D systems Inc, 
UK). This assay employs a quantitative sandwich enzyme  immunoassay technique using 
recombinant  human  ICAM 1  and  antibodies  raised  again st  the  recombinant  factor.  The 
intensity of colour development was measured using a  microplate reader (Anthos 210) at 
450  nm  and  with  correction  set  at  620  nm.  All  samples  were  analysed  using  the 
accompanying software (stingray), and results obtained  showed recommended linear curves 
that were parallel to the standard obtained using the re combinant parameter kit standards. 
 
4.2.3   SNP GENOTYPING USING 5' NUCLEASE ASSAY 
All SNP's were genotyped using the 5' nuclease assay for  allelic discrimination. Primers and 
individual fluorogenic TaqMan probes (consisting of an  oligonucleotide labeled with both a 
fluorescent reporter dye   FAM™ and a quencher dye  VIC
® ) were designed using Primer 
Express software (version 2.0; sequences shown in table  13). For the CRP  390 triallelic 
SNP,  an  additional  TET  probe  was  selected.  These  were   then  obtained  from  Applied 
Biosystems (UK). All assays were performed using the  supplied Q PCR buffer (2.5  l),  
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PCR probe mix (0.125  l) and 20 ng of genomic DNA in 2. 375  l dH2O to make a 5  l 
reaction volume (384 well plate). The PCR thermocycling  protocol consisted of 10 min @ 
95°C, followed by 40 cycles of 15 sec @ 92°C and 1 min @  60°C. Each genotyping plate 
contained  8  wells  without  any  DNA  template  (water  con trols)  and  randomly  selected 
duplicate  samples  (10%  of  plate  samples).  Allelic  le vel  genotyping  from  fluorescence 
measurements were then obtained using the ABI PRISM
®  7900HT Sequence Detection 
System. SDS version 2.1 software was used to analyse r eal time and endpoint fluorescence 
data (figure 7). 
 
Table 13 . Primer and probe sequences used for 5' nuclease (TaqMan) genotyping.   
Primer / Probe         Sequence 
CRP 1444 forward         5' GGTCTGGGAGCTCGTTAACTATG 3' 
CRP 1444 reverse        5' CCAACTTGAAATAAAAATGAAAACA AAACACCT 3' 
CRP 1444 T probe      VIC  TTTTGGACC A TTTCCCA – MGB 
CRP 1444 C probe      FAM   TTGGACC G TTTCCCA – MGB 
CRP 1059 forward         5' TGGAAATGTGAACATGTGGGACTT 3' 
CRP 1059 reverse        5' CCCGCCAAGATAGATGGTGTTAATC  3' 
CRP 1059 G probe       VIC   CATCTGGTGA C AGCACA – MGB 
CRP 1059 C probe    FAM   TCTGGTGA G AGCACA – MGB 
CRP 409 forward         5' GGGCTGAAGTAGGTGTTGGA 3' 
CRP 409 reverse        5' GGTAACATATTAAACGAGTGGCCATCT  3' 
CRP 409 G probe      VIC   CTACCAC C TGCACCC   MGB 
CRP 409 A probe      FAM   CTACCAC T TGCACCC   MGB 
CRP 390 forward  5' CTACCACGTGCACCCAGATG 3' 
CRP 390 reverse  5' TATCCTGCGAAAATAATGGGAAA 3' 
CRP 390 T probe  VIC   CCACT A GTTTAATATGTTACC   MGB 
CRP 390 C probe  FAM   CCACT G GTTTAATATGTT   MGB 
CRP 390 A probe  TET   CCACT T GTTTAATATGTTACC   MGB 
CFH 1277 forward         5' CCATGCCTCAGAAAATGTTATTTTCCT T 3' 
CFH 1277 reverse        5' GGCAGGCAACGTCTATAGATTTACC 3' 
CFH 1277 C probe      VIC   TTTCTTCCAT G ATTTTG   MGB 
CFH 1277 T probe      FAM   TTCTTCCAT A ATTTTG   MGB 
ICAM1 12959 forward        5' CAGGGGACCGTGGTCTGTTCC 3' 
ICAM112959 reverse         5' AACTTGGGGTGTCAGTGGATAC 3' 
ICAM1 12959 A probe       VIC   TGGGAACAGCC T GTC   MGB 
ICAM1 12959 G probe       FAM   TGGGAACAGCC C GTC   MGB 
ICAM1 13848 forward        5' TCGAGATCTTGAGGGCACCTA 3' 
ICAM1 13848 reverse         5' ATGTGCTCTGTGAGTGAGCCG 3' 
ICAM1 13848 A probe        VIC   CACGGTCACCT T GCGGGT   MGB  
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ICAM1 13848 G probe  FAM   ACGGTCACCT C GCGGGTG   MGB 
IL 1B 511 forward  5' GGTCTCTACCTTGGGTGCTGTT 3' 
IL 1B 511 reverse  5' TCCTCAGAGGCTCCTGCAAT 3' 
IL 1B 511 C probe  VIC   TGCCTC G GGAGCT   MGB 
IL 1B 511 T probe  FAM   TCTGCCTC A GGAGC   MGB 
IL 6 174 forward  5' GCTGCACTTTTCCCCCTAGTT 3' 
IL 6 174 reverse  5' GCTGATTGGAAACCTTATTAAGATTGT 3' 
IL 6 174 G probe  VIC   CTTTAGCAT C GCAAGAC   MGB 
IL 6 174 C probe  FAM   CTTTAGCAT G GCAAGAC   MGB 
IL 8 251 forward  5' GTCACATGGTCTATGATAAAGTTATCTAGAAATA  3' 
IL 8 251 reverse  5' TACATTTAAAATACTGAAGCTCCACAATTT 3' 
IL 8 251 A probe  VIC   AAGCATACA T TTGAT AATT   MGB 
IL 8 251 T probe  FAM   AAGCATACA A TTGATAATT   MGB 
IL 10 1082 forward  5' ACACACAAATCCAAGACAAACACTACTAA 3' 
IL 10 1082 reverse  5' GGAGGTCCCTTACTTTCCTCTTACC 3' 
IL 10 1082 G probe  ATCCCTACTTCCCC C TCCCAAAGAA   MGB 
IL 10 1082 A probe  CCCTACTTCCCC T TCCCAAAGAAGC   MGB 
VEGF 2578 forward     5' TCAGTCCATGCCTCCACAGA 3' 
VEGF 2578 reverse      5' GGAACAAAGTTGGGGCTCTGA 3' 
VEGF 2578 A probe      VIC   TATCCACCCAGATC T TGCCAGGGTC   MGB 
VEGF 2578 C probe   FAM   CCACCCAGATC G TGCCAGGGT   MGB 
VEGF 1154 forward   5' CGGGCCAGGCTTCACTG 3' 
VEGF 1154 reverse   5' GGCGGGGACAGGCGA 3' 
VEGF 1154 A probe   VIC   CTCAGCCC T TCCACA   MGB 
VEGF 1154 G probe   FAM   CTCAGCCC C TCCAC   MGB 
VEGF 634 forward   5' TCCAGAGAGAAGTCGAGGAAGAGA 3' 
VEGF 634 reverse   5' CCCCAAAAGCAGGTCACTCA 3' 
VEGF 634 C probe   VIC   TGCCCCTGTC G CTTTCGCTG   MGB 
VEGF 634 G probe   FAM   TTGCCCCTGTC C CTTTCGCTG   MGB 
VEGF 936 forward  5' ACTCCGGCGGAAGCATTC 3' 
VEGF 936 reverse  5' AGCAAGAAAAATAAAATGGCGAATCCA 3' 
VEGF 936 C probe  VIC   CAAGAGGGACC G TGCTG   MGB 
VEGF 936 T probe  FAM   AAGAGGGACC A TGCTG   MGB 
Forward and reverse sequences are primers. VIC, FAM a nd TET probe sequences have 
positions of single nucleotide polymorphisms marked in  bold case. MGB, minor groove 
binding probe. 
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Figure 7. Real time amplification and allelic discrim ination plots from Taqman genotyping 
assay. 
4.2.4   STATISTICAL METHODS 
Power calculations were performed utilizing the Epi I nfo statistical package (Revision 2, 
2003)  provided  by  the  Center  for  Disease  Control  and   Prevention  (CDC).  Calculations 
revealed that the study would have a power of 89% based  upon 500 cases and 500 controls 
to  detect  a  15%  difference  in  CRP  and  sICAM  levels  between  the  groups.  Power 
calculations  for  gene  polymorphisms  were  done  using  repo rted  UK/European  allele  
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frequencies.  P  values were evaluated by two sided Chi square tests wi th Yate's correction 
and 1
df . The level of statistical significance in the study wa s set at  P C  < 0.05.  
 
Allelic  and  genotype  distributions  for  each  SNP  were  tested  for  conformity  to  Hardy 
Weinberg equilibrium using control subjects. Alleles at  each locus were said to be in Hardy 
Weinberg equilibrium if the observed homozygote and he terozygote frequencies did not 
differ  significantly  ( P >0.05)  from  expected  frequencies.  P   values  were  evaluated  using 
Pearson’s chi squared statistic. The level of statist ical significance in the study was set at  P  
< 0.05. All statistical analyses were performed using  the SPSS statistical software package 
version 12.0. Haploscore software was utilized for CRP,  ICAM1, IL and VEGF haplotype 
frequency estimation to test haplotypic effects on CR P and ICAM1 levels.  
 
Non parametric data (CRP and sICAM) underwent log trans formation to achieve a normal 
distribution of variables before any statistical parame tric testing. For the CRP analysis, the 
total study sample was analysed in groups based on CRP  levels > 2 mg/L, > 4 mg/L and > 5 
mg/L similar to previous CRP studies
45;207;208 . The effect of each CRP/ICAM1 genotype on 
CRP/sICAM1 levels between cases and controls was ass essed by ANOVA and Chi square 
two tailed tests. Logistic regression analysis was ca rried out for CRP and sICAM1 levels 
using data on age, sex, body mass index (BMI), smoking  status and the CRP or ICAM1 
genotype as covariates in the regression model. This w as done between all the AREDS 
groups and with the control group. All statistical ana lyses were performed using the SPSS 
statistical software package version 12.0. 
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4.3   RESULTS  
Baseline demographics of the unrelated Caucasian cohort re cruited from a clinic population 
(581 cases with AMD and 593 normal controls) are desc ribed in table 14. AREDS grading 
data from fundus photographs were available for 573 (98. 6%) of the 581 AMD cases (table 
16), based on this criteria the group was divided i nto 4 groups of increasing AMD severity. 
For the interleukin analysis, data from 478 cases with  AMD and 555 normal controls was 
available. CNV grading data from fundus photographs and  angiograms were available for 
283 (59.2%) AMD cases in this cohort. 
 
Table 14. Basic demographic characteristics of the cauc asian study population.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  AMD CASES 
total n = 581 (%) 
CONTROLS  
total n = 593 (%) 
Age 
         Mean  
  n=581 
  78.4 
  n=593 
  69.1            
         Range    55   101    55   91 
         SD    8.65    9.76 
Sex 
          Female 
          Male 
  n=581 
  330 (64.2)       
  184 (35.8) 
  n=593 
  308 (55.0) 
  252 (45.0) 
BMI 
          Mean 
          SD 
  n=237 
  26.48 
  4.76 
  n=407 
  27.27 
  4.70 
Smoking status 
          Current smokers 
          Past smokers 
          Non smokers 
  n=460 
  140(30.4) 
  145(31.5) 
  175(38.0) 
  n=432 
  81(18.7) 
  213(49.3) 
  138(31.9)  
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4.3.1   CRP LEVELS AND CRP GENE POLYMORPHISMS  
CRP levels were available for 305 cases and 384 contro ls (table 15). Mean levels were 
significantly  higher  in  AMD  cases  as  compared  to  con trols  (5.75  mg/l  vs.  3.66  mg/l, 
P =0.0001, CI=0.83 3.27). CRP levels were also higher in  AREDS groups II, III and IV as 
compared to AREDS group I (table 15). In the multivar iate regression analysis based on 
different CRP values, all the three CRP groups had si gnificantly higher odds ratio (OR) for 
AMD when compared to the control group (table 17). The  disease association was nearly 2 
fold in the CRP > 2 mg/l (OR=1.68,  P c =0.002) group, and over 2 fold in the CRP > 4 mg/l 
(OR=2.11,  P c =0.0004)  and  CRP  >  5  mg/l  (OR=2.28,  P c =0.0001)  groups.  The  most 
significant  CRP  association  was  seen  in  AMD  patient s  who  were  current  smokers 
(OR=1.92,  P c =1.28e 007),  the  strongest  correlation  being  in  the  CRP  > 4mg/l  and 
CRP>5mg/l groups (table 17).  
 
Table 15. CRP and sICAM1 levels in AMD cases and controls .   
  CRP, mg/l, n=305  sICAM1, ng/ml, n=384 
AMD cases, n=305  4.79 ± 4.78 (1.35 ± 0.74)  283.50 ± 76.98  (5.62 ± 0.24) 
Controls, n=384   3.51 ± 3.14 (1.06 ± 0.59)  264.87 ± 62.65  (5.55 ± 0.21) 
OR,  P  value   1.90, 3.20e 005   3.34, 0.014 
OR,  P c  value*  1.91, 1.28e 003  2.90, 0.037 
Quantitative data are presented as mean with standard dev iation. Corresponding log values 
are presented in parenthesis. * P c  value corrected for current smoking status. 
 
Table 16. AREDS sub grouping of AMD cases and mean CRP l evels. 
AREDS Grading 
n = 573 (%) 
AMD Cases with CRP 
levels, n=305 (%) 
Mean CRP levels ± 
SD*  
Grade I – 29 (5.1)  20 (6.5)  4.40 ± 2.71   
Grade II   84 (14.7)  53 (17.4)  4.09 ± 3.29 
Grade III   159 (27.7)     85 (27.9)  4.74 ± 4.68 
Grade IV   301 (52.5)  147 (48.2)  5.11 ± 5.03 
*SD = Standard Deviation. 
 
  
 
83  
 
Table 17. Multivariate logistic regression analysis f or CRP and sICAM1 levels in AMD 
cases and controls.  
  CRP > 2 mg/l  CRP > 4 mg/l  CRP > 5 mg/l  sICAM1 
Cases (n),Controls (n)   305, 384   154, 104  131, 86   19 4, 278 
CRP/sICAM1   1.68 (0.002)*  2.11 (0.0004)*  2.28 (0.0001)*  1 .50 (0.37) 
Age (years)  1.14 (0.01)*  0.13 (0.01)*  1.13 (0.01)*  1.12  (0.01)* 
Sex (F/M)  1.45 (0.08)  1.18 (0.40)  1.16 (0.45)  1.54 (0.06 ) 
BMI (kg/m
2 )  1.02 (0.32)  1.00 (0.82)  1.00 (0.80)  1.02 (0.32) 
Current smokers  1.36 (0.06)  2.77 (4.91e 010)*  2.26 (5.50e  005)*  4.86 (1.53e 006)*  
Past smokers  1.0 (0.99)  0.96 (1.01)  0.99 (0.98)  1.37 ( 0.33) 
* Significant corrected   P c  values shown in parenthesis next to each Odds Ratio. 
 
The observed genotype and allele frequencies for the CRP  polymorphisms tested in the 
control  population  was  found  to  be  in  Hardy Weinberg  equilibrium.  CRP  genotype 
frequencies in AMD cases and normal controls were as  shown in table 18. The genotype 
distributions were similar for the 1444C/T 3' UTR, 1059 G/C exonic,  409G/A promoter and 
the  triallelic  promoter   390T/C/A  CRP  polymorphisms  i n  both  groups.  No  significant 
genotype  associations  were  found  with  CRP  levels  or  A MD  status  on  analysis  after 
correcting for multiple variables (data not shown). 
 
Following the AREDS categorization in the AMD group,  a multivariate logistic regression 
analysis was performed between CRP levels within these A REDS groups and the different 
CRP genotypes (1444C/T, 1059G/C,  409G/A and  390 C/T/A ) in relation to age, sex, BMI 
and smoking status. No significant associations were f ound with these comparisons. 
 
 
 
 
 
 
 
  
 
84  
Table 18. CRP genotypes and CRP associations for indivi dual 1444C/T, 1059G/C,  409G/A 
&  390 T/C/A CRP polymorphisms.  
 
Genotypes  AMD cases   CRP mg/L (n)  Controls  CRP mg/L (n) 
1444C/T  
rs113012959 
 n=506  n=217  n=552  n=295 
CC  233  4.43± 4.16 (114)  277  3.22± 2.57 (169) 
CT  229  3.95± 3.80 (98)  210  3.51± 3.06 (142) 
TT  39  4.48± 3.99 (21)  63  3.15± 2.29 (37) 
1059G/C  
rs1800947      
n=480  n=205  n=559  n=295 
GG  404  4.26 ± 4.16 (194)  486  4.27± 4.06 (194) 
GC  61  3.65± 3.02 (30)  72  3.38± 2.88 (45) 
CC  15  5.47± 4.75 (9)  01  1.90±0.00 (1) 
  409G/A  
rs3093062 
 n=505  n=232  n=559  n=304 
GG  500  4.27± 4.08 (228)  557  3.38± 3.24 (302) 
GA  05  2.97± 2.15 (4)  02  1.90± 0.00 (2) 
AA                             
 390T/C/A 
rs3091244        
n=477  n=204  n=476  n=253 
CC  195  4.52 ± 4.24 (91)  185  3.30± 2.36 (113) 
CT  167  4.17± 4.05 (72)  171  3.53± 3.22 (114) 
AC  40  3.74± 3.32 (22)  53  3.48± 3.02 (34) 
AT  31  4.47± 2.57 (14)  23  2.65± 1.23 (16) 
TT  37  4.41± 4.00 (20)  40  4.38± 3.80 (24) 
AA  01      03  2.30± 0.69 (3) 
* P C  values for each genotype and CRP levels or AMD status  after adjusting for age, sex, 
BMI, Current smokers and Past smokers were not Significan t (data not shown). 
 
4.3.2   ICAM1 LEVELS AND ICAM1 GENE POLYMORPHISMS  
sICAM1 levels were found to be higher in AMD cases as compa red to controls (Mean levels 
of 301.5 ng/ml in cases vs. 271.8 ng/ml in controls,  P =0.014), this remained significant 
( P c =0.037) when corrected for AMD co variables (table. 1 5). However, when the smoking  
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status was introduced into the regression model (tabl e. 17), a strong association was noted 
only  with  current  smokers  (OR=4.86,   P c = 1.53e 006)  in  the  AMD  group.  A  similar 
association with smoking was not seen in the control grou p. 
 
Table  19.  ICAM1  genotypes  and  sICAM1  associations  for  i ndividual  12959G/A 
(rs1799969) & 13848G/A (rs5498) polymorphisms in the study g roups. 
 
Genotypes  AMD 
cases  
sICAM1 
(ng/ml) 
Controls  sICAM1 
(ng/ml) 
Genotype-sICAM1 
association  P C   value 
(OR,CI) 
12959G/A  
rs1799969  
 n=504  n=125  n=549  n=231   
GG  400  288.31± 68.84  444  281.30± 172.96  0.004 (2.88 , 1.05 4.07)* 
GA  100  275.89± 114.46  104  244.16± 46.57  NS 
AA  04          01            
13848G/A  
rs5498       
n=503  n=127  n=552  n=230   
GG  147  285.31± 66.74  151  312.74± 316.23  NS 
GA  240  277.84± 74.85  278  263.98± 64.12  NS 
AA  116  300.60± 95.35  123  264.96± 65.28  NS 
*
  P C  values for sICAM1 levels in the total group irrespect ive of case or control status.  P C  
values  for  each  genotype  and  AMD  status  after  adjusti ng  for  age,  sex,  BMI,  Current 
smokers and Past smokers were not Significant (data not  shown). NS = Not Significant. 
 
Observed genotype and allele frequencies for the ICAM1 po lymorphisms were in Hardy 
Weinberg equilibrium. Frequency distributions in AMD  cases and normal controls were as 
shown in table 19. Genotype distributions for the two  ICAM1 polymorphisms were similar 
among AMD cases and controls. On performing logistic re gression analysis, sICAM1 levels 
were found to be significantly associated with the 1 2959 GG genotype irrespective of the 
case  or  control  status  (OR=2.88,  P =0.004).  None  of  the  13848  genotypes  showed  any 
association with sICAM1 levels. Also, no significant associa tions were found on performing 
logistic regression  analysis for sICAM1 levels and t he different  ICAM1 12959G/A and  
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13848G/A genotypes in relation to age, sex, BMI and s moking status between the four 
AREDS groups (data not shown). 
 
4.3.3   CFH Y402H POLYMORPHISM AND CRP LEVELS 
CFH  1277  C/T  (Y402H)  genotyping  data  was  available  for   581  AMD  cases  and  593 
controls. Of these, 227 AMD cases and 272 controls ha d both genotyping and CRP data. 
Genotype frequency distributions were as shown in table 20.  The heterozygous CT genotype 
had  the  commonest  representation  with  similar  frequencies   in  cases  and  controls.  The 
homozygous CC genotype was more often present in AMD  cases (0.31 vs. 0.14,  P c = 6.92e 
008) giving an OR for disease of 4.43. Correspondingly , the homozygous TT genotype was 
over represented in controls. Individual allelic dis tributions also differed in the two groups, 
with  the  C  allele  being  more  significantly  represente d  in  AMD  cases  ( P c = 1.54e 007, 
OR=2.05). Mean CRP levels were similar for the indivi dual CFH genotypes in cases and 
controls,  both  ANOVA  and  logistic  regression  analysis  d id  not  reveal  any  significant 
association for any of these CFH genotypes with CRP lev els in the study groups. Finally, 
adjusting for age during the logistic regression analysi s for all the SNP's analysed in the 
study did not alter the odds ratio for disease significantly . On the other hand, regression with 
BMI as the dependant variable for all the CRP, CFH and ICA M1 SNP's tested revealed 
large significant odds ratios of nearly 5 fold magnitud e (table 21).  
 
Six common and unique haplotypes were inferred from the  Haplotypic analysis of the CRP 
SNP's, these were selected based on their minimum frequenc y being greater than 0.05 in 
either cases or controls. Each haplotype was then test ed for association with CRP levels. 
The overall haplotypic distribution was largely simil ar between cases and controls with the 
most frequent haplotype being GCGC (0.38 in cases vs. 0.4 2 in controls). None of the CRP  
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haplotypes with moderate frequencies showed any associati on with any category of CRP 
levels. When looking at higher CRP levels of >3mg/l (n=32 AMD ca ses, n=21 controls), the 
association of Y402H with AMD in these individuals was  no longer significant. 
 
Table 20. CFH 1277 T/C genotype (rs1061170) and allele d istribution in AMD cases and 
controls.  
 
1277 T/C  
Genotypes 
rs1061170  
AMD 
cases 
n=581 
 CRP  
mg/l     
 n=227 
Controls 
  n=593 
CRP 
mg/l    
n=272 
Genotype-AMD 
association 
P C   value (OR,CI)*  
Genotype-CRP 
association 
P C   value 
(OR,CI)* 
CC  0.31 
(167) 
3.96± 2.90 
(n=92) 
0.14 (75)  3.21± 2.76 
(n=42) 
6.92e 008  
(4.43, 3.54 4.90) 
     NS 
CT  0.44 
(258) 
5.41± 5.34 
(n=130) 
0.47 (261)  3.54± 3.23 
(n=161) 
                         NS 
TT  0.25 
(132) 
4.82± 4.41 
(n=68) 
0.39 (215)  3.42± 3.14 
(n=145) 
                         NS 
C Allele  0.54            0.37          1.54e 007  
(2.05, 1.74 2.67) 
        
T Allele  0.46           0.63                                       
 
*  P C  =  P  values for genotypes after adjusting for age, sex, BMI,  Current smokers and Past 
smokers. NS = Not Significant. 
 
4.3.4   INTERLEUKIN AND VEGF GENE POLYMORPHISMS  
Genotype distributions were largely similar for most  of the four IL and VEGF variants 
tested  in  the  study  and  in  Hardy Weinberg  equilibrium  ( tables  22  and  23).  Genotype 
distributions were in Hardy Weinberg equilibrium in th e control groups. The IL 8 251AA 
genotype was found in a larger proportion of AMD cases  (35% vs.27%). This genotype was 
significantly associated with AMD both before ( P =0.037, OR=1.21, 95% CI=1.01 1.44) and 
after correcting for co variables like age, sex, BMI, current s moking and past smoking status 
( P C = 0.043, OR=1.20, 95% CI=1.0 to 1.50). Fluorescein angiographic data  was available for 
283 AMD patients. This subset of patients were then fu rther categorised into CNV or dry 
AMD  phenotypes  (table  25).  The  CNV  group  included  occul t,  minimally  classic  and 
predominantly classic CNV forms. However, no significa nt difference in allele frequencies 
was found on testing IL 8 251A risk allele frequencies  in total CNV vs. dry AMD and total  
 
88  
CNV  vs.  controls.  Further  analysis  stratifying  by  CNV   subtype  showed  a  marginally 
significant difference in allele distribution between t he minimally classic CNV group and 
normal controls, without correcting for multiple tes ting ( P =0.04, OR=1.59, 95% CI =0.92   
2.71). Consistent with established data, we found evide nce for a strong association between 
AMD status and smoking behaviour dichotomised as never  smoked / ever smoked ( P  = 2.0 
x 10
 14 ). However, we found no significant association betwee n IL 8 genotype status and 
smoking behaviour (data not shown). 
 
Table 21. Available demographic characteristics of the I nterleukin study population.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  AMD CASES 
total n = 478 (%) 
CONTROLS  
total n = 555 (%) 
Age 
          Mean  
  n=478 
  78.8 
  n=555 
  69.0            
          Range    55   101    55   91 
          SD    7.9    9.7 
Sex 
          Female 
          Male 
  n=478 
  312 (65.4)       
  166 (34.2) 
  n=555 
  306 (55.1) 
  249 (44.9) 
BMI 
          Mean 
          Range 
          SD 
  n=469 
  26.3 
  13.9 – 43.0   
  4.7 
  n=551 
  26.5 
  15.7 – 55.4 
  4.9 
Smoking status 
          Ever smoked 
          Never smoked 
  n=478 
  301 (63.0)     
  177 (37.0) 
  n=555 
  217 (39.1) 
  338 (60.9) T
a
b
l
e
 
2
2
.
 
L
o
g
i
s
t
i
c
 
r
e
g
r
e
s
s
i
o
n
 
a
n
a
l
y
s
i
s
 
f
o
r
 
t
h
e
 
g
e
n
e
 
v
a
r
i
a
n
t
s
 
a
d
j
u
s
t
i
n
g
 
f
o
r
 
a
g
e
 
a
n
d
 
B
M
I
.
 
 
 
R
e
g
r
e
s
s
i
o
n
 
v
a
r
i
a
b
l
e
 
C
R
P
 
1
4
4
4
C
/
T
 
C
R
P
 
1
0
5
9
G
/
C
 
C
R
P
 
-
4
0
9
G
/
A
 
C
R
P
 
-
3
9
0
T
/
C
/
A
 
I
C
A
M
 
1
2
9
5
9
G
/
A
 
I
C
A
M
 
1
3
8
4
8
G
/
A
 
C
F
H
 
1
2
7
7
C
/
T
 
O
R
 
w
i
t
h
o
u
t
 
A
g
e
 
1
.
3
3
 
(
0
.
0
3
)
*
 
0
.
8
9
 
(
0
.
2
9
)
 
2
.
7
5
(
0
.
2
3
)
 
1
.
0
1
(
0
.
9
6
)
 
0
.
8
9
 
(
0
.
3
9
)
 
1
.
0
0
 
(
0
.
8
9
)
 
3
.
5
7
 
(
3
.
6
1
e
 
0
1
1
)
 
A
g
e
 
a
d
j
u
s
t
e
d
 
O
R
 
1
.
3
4
 
(
0
.
0
4
)
*
 
0
.
9
6
 
(
0
.
7
5
)
 
2
.
3
2
(
0
.
3
9
)
 
1
.
0
6
(
0
.
6
3
)
 
0
.
9
4
 
(
0
.
7
0
)
 
0
.
9
1
 
(
0
.
3
8
)
 
3
.
7
2
 
(
7
.
1
5
e
 
0
1
1
)
 
O
R
 
f
o
r
 
B
M
I
 
 
4
.
8
6
 
(
1
.
5
4
e
 
0
0
6
)
 
5
.
0
1
 
(
7
.
4
6
e
 
0
0
7
)
 
5
.
0
2
 
(
6
.
8
9
e
 
0
0
7
)
 
5
.
2
4
 
(
2
.
3
3
e
 
0
0
7
)
 
4
.
9
4
 
(
1
.
0
3
e
 
0
0
6
)
 
4
.
9
5
 
(
9
.
6
6
e
 
0
0
7
)
 
5
.
0
5
 
(
6
.
0
1
e
 
0
0
7
)
 
P
 
v
a
l
u
e
s
 
s
h
o
w
n
 
i
n
 
p
a
r
e
n
t
h
e
s
i
s
 
a
f
t
e
r
 
e
a
c
h
 
O
d
d
s
 
R
a
t
i
o
,
 
*
 
s
i
g
n
i
f
i
c
a
n
t
 
v
a
l
u
e
s
.
 
 
 
T
a
b
l
e
 
2
3
.
 
I
L
 
g
e
n
o
t
y
p
e
 
f
r
e
q
u
e
n
c
i
e
s
 
a
n
d
 
t
h
e
i
r
 
a
s
s
o
c
i
a
t
i
o
n
 
w
i
t
h
 
A
M
D
 
c
a
s
e
s
 
a
n
d
 
n
o
r
m
a
l
 
c
o
n
t
r
o
l
s
.
 
 
 
I
L
 
1
β
 
 
5
1
1
C
/
T
 
(
r
s
1
6
9
4
4
)
 
I
L
 
6
 
 
1
7
4
G
/
C
 
(
r
s
1
8
0
0
7
9
5
)
 
I
L
 
8
 
 
2
5
1
A
/
T
*
 
(
r
s
4
0
7
3
)
 
I
L
 
1
0
 
 
1
0
8
2
G
/
A
 
(
r
s
1
8
0
0
8
9
6
)
 
 
C
a
s
e
 
 
 
 
n
=
4
7
5
 
(
%
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C
o
n
t
r
o
l
 
 
n
=
5
4
8
 
(
%
)
 
C
a
s
e
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n
=
4
6
2
 
(
%
)
 
C
o
n
t
r
o
l
 
n
=
5
5
3
 
(
%
)
 
C
a
s
e
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n
=
4
7
4
 
(
%
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C
o
n
t
r
o
l
 
n
=
5
4
0
 
(
%
)
 
C
a
s
e
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n
=
4
7
3
 
(
%
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C
o
n
t
r
o
l
 
 
n
=
5
5
1
 
(
%
)
 
I
L
 
G
e
n
o
t
y
p
e
 
C
C
 
2
1
8
 
(
4
6
)
 
2
5
1
 
(
4
6
)
 
G
G
 
1
5
6
 
(
3
4
)
 
1
7
8
 
(
3
2
)
 
A
A
 
1
6
6
 
(
3
5
)
 
1
4
7
 
(
2
7
)
 
G
G
 
1
2
6
 
(
2
6
)
 
1
4
0
 
(
2
5
)
 
 
C
T
 
2
2
5
 
(
4
7
)
 
2
4
0
 
(
4
3
)
 
G
C
 
2
2
3
 
(
4
8
)
 
2
7
0
 
(
4
9
)
 
A
T
 
2
0
6
 
(
4
3
)
 
2
6
9
 
(
5
0
)
 
G
A
 
2
3
0
 
(
4
9
)
 
2
7
0
 
(
4
9
)
 
 
T
T
 
3
2
 
(
7
)
 
5
7
 
(
1
1
)
 
C
C
 
8
3
 
(
1
8
)
 
1
0
5
 
(
1
9
)
 
T
T
 
1
0
2
 
(
2
2
)
 
1
2
4
 
(
2
3
)
 
A
A
 
1
1
7
 
(
2
5
)
 
1
4
1
 
(
2
6
)
 
I
L
 
A
l
l
e
l
e
 
C
 
6
6
1
 
(
7
0
)
 
7
4
2
 
(
6
8
)
 
 
G
 
5
3
5
 
(
5
8
)
 
6
2
6
 
(
5
7
)
 
A
 
5
3
8
 
(
5
7
)
*
 
5
6
3
 
(
5
2
)
 
G
 
4
8
2
 
(
5
1
)
 
5
5
0
 
(
4
9
)
 
 
T
 
2
8
9
 
(
3
0
)
 
3
5
4
 
(
3
2
)
 
 
C
 
3
8
9
 
(
4
2
)
 
4
8
0
 
(
4
3
)
 
T
 
4
1
0
 
(
4
3
)
 
5
1
7
 
(
4
8
)
 
A
 
4
6
4
 
(
4
9
)
 
5
5
2
 
(
5
1
)
 
P
 
v
a
l
u
e
 
O
R
 
(
9
5
%
 
C
I
)
 
0
.
3
6
 
1
.
0
9
 
(
0
.
9
1
 
1
.
3
2
)
 
0
.
5
6
 
1
.
0
5
 
(
0
.
8
8
 
1
.
2
6
)
 
0
.
0
3
7
*
 
1
.
2
1
 
(
1
.
0
1
 
1
.
4
4
)
 
0
.
6
4
 
1
.
0
4
 
(
0
.
8
8
 
1
.
2
4
)
 
*
 
P
 
v
a
l
u
e
s
 
b
y
 
χ
2
 
t
e
s
t
 
w
i
t
h
 
1
d
f
.
 
P
C
 
=
 
0
.
0
4
3
,
 
O
R
=
1
.
2
0
,
 
9
5
%
 
C
I
=
1
.
0
 
t
o
 
1
.
5
0
 
(
P
 
v
a
l
u
e
 
a
d
j
u
s
t
e
d
 
f
o
r
 
a
g
e
,
 
s
e
x
,
 
B
M
I
,
 
C
u
r
r
e
n
t
 
s
m
o
k
i
n
g
 
a
n
d
 
P
a
s
t
 
s
m
o
k
i
n
g
 
s
t
a
t
u
s
)
.
 
P
S
:
 
s
a
m
p
l
e
 
s
i
z
e
 
(
n
)
 
d
a
t
a
 
i
s
 
l
e
s
s
 
f
o
r
 
s
o
m
e
 
I
L
 
g
e
n
o
t
y
p
e
s
 
d
u
e
 
t
o
 
f
e
w
 
f
a
i
l
e
d
 
g
e
n
o
t
y
p
i
n
g
 
r
e
a
c
t
i
o
n
s
.
 
  
 
9
0
 
T
a
b
l
e
 
2
4
.
 
V
E
G
F
 
g
e
n
o
t
y
p
e
 
f
r
e
q
u
e
n
c
i
e
s
 
i
n
 
A
M
D
 
c
a
s
e
s
 
a
n
d
 
n
o
r
m
a
l
 
c
o
n
t
r
o
l
s
.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
V
E
G
F
-
6
3
4
G
/
C
 
C
a
s
e
 
n
=
4
9
0
 
 
 
C
o
n
t
r
o
l
 
n
=
5
5
8
 
 
 
 
 
 
 
 
 
 
 
 
V
E
G
F
+
9
3
6
C
/
T
 
C
a
s
e
 
n
=
4
5
9
 
 
 
C
o
n
t
r
o
l
 
n
=
5
4
9
 
 
 
 
 
 
 
 
 
 
 
 
 
V
E
G
F
-
1
1
5
4
G
/
A
 
C
a
s
e
 
n
=
4
8
7
 
 
C
o
n
t
r
o
l
 
n
=
5
4
7
 
 
 
 
 
 
 
 
 
 
 
 
 
 
V
E
G
F
-
2
5
7
8
A
/
C
 
C
a
s
e
 
n
=
4
9
0
 
 
 
 
 
C
o
n
t
r
o
l
 
n
=
5
6
0
 
C
C
 
4
9
 
(
0
.
1
0
)
 
5
7
 
(
0
.
1
0
)
 
C
C
 
3
4
5
 
(
0
.
7
5
)
 
3
9
7
 
(
0
.
7
2
)
 
A
A
 
5
0
 
(
0
.
1
0
)
 
5
5
 
(
0
.
1
0
)
 
A
A
 
1
3
5
 
(
0
.
2
7
)
 
1
4
8
 
(
0
.
2
6
)
 
C
G
 
1
9
3
 
(
0
.
3
9
)
 
2
4
4
 
(
0
.
4
4
)
 
C
T
 
1
0
4
 
(
0
.
2
3
)
 
1
4
1
 
(
0
.
2
6
)
 
A
G
 
2
0
3
 
(
0
.
4
2
)
 
2
2
6
 
(
0
.
4
1
)
 
A
C
 
2
3
5
 
(
0
.
4
8
)
 
2
6
9
 
(
0
.
4
8
)
 
G
G
 
2
4
8
 
(
0
.
5
1
)
 
2
5
7
 
(
0
.
4
6
)
 
T
T
 
1
0
 
(
0
.
0
2
)
 
1
1
 
(
0
.
0
2
)
 
G
G
 
2
3
4
 
(
0
.
4
8
)
 
2
6
6
 
(
0
.
4
9
)
 
C
C
 
1
2
0
 
(
0
.
2
5
)
 
1
4
3
 
(
0
.
2
6
)
 
 
T
a
b
l
e
 
2
5
.
 
R
i
s
k
 
f
o
r
 
C
N
V
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
I
L
 
8
 
 
2
5
1
A
/
T
 
g
e
n
o
t
y
p
e
s
 
a
n
d
 
a
l
l
e
l
e
s
 
i
n
 
c
o
m
p
a
r
i
s
o
n
 
t
o
 
d
r
y
 
A
M
D
 
a
n
d
 
c
o
n
t
r
o
l
 
g
r
o
u
p
s
.
 
 
 
I
L
 
8
 
-
2
5
1
A
/
T
 
G
e
n
o
t
y
p
e
 
A
l
l
 
C
N
V
 
n
=
 
1
5
0
 
(
%
)
 
D
r
y
 
A
M
D
 
n
=
1
3
3
 
(
%
)
 
C
o
n
t
r
o
l
s
 
 
 
n
=
5
4
0
 
(
%
)
 
A
A
 
 
4
8
 
(
3
2
.
0
)
 
3
9
 
(
2
9
.
3
)
 
1
4
7
 
(
2
7
.
0
)
 
A
T
 
6
8
 
(
4
5
.
3
)
 
6
7
 
(
5
0
.
4
)
 
2
6
9
 
(
5
0
.
0
)
 
T
T
 
3
4
 
(
2
2
.
7
)
 
2
7
 
(
2
0
.
3
)
 
1
2
4
 
(
2
3
.
0
)
 
I
L
 
8
 
 
2
5
1
A
/
T
 
A
l
l
e
l
e
 
 
 
 
A
 
1
6
4
 
(
5
4
.
7
)
 
1
4
5
 
(
5
4
.
5
)
 
5
6
3
 
(
5
2
.
0
)
 
T
 
1
3
6
 
(
4
5
.
3
)
 
1
2
1
 
(
4
5
.
5
)
 
5
1
7
 
(
4
8
.
0
)
 
†
V
e
r
s
u
s
 
D
r
y
 
A
M
D
 
(
P
 
v
a
l
u
e
,
 
O
R
,
 
9
5
%
 
C
I
)
 
‡
V
e
r
s
u
s
 
C
o
n
t
r
o
l
s
 
(
P
 
v
a
l
u
e
,
 
O
R
,
 
9
5
%
 
C
I
)
 
0
.
4
8
,
 
1
.
0
*
 
(
0
.
7
2
 
1
.
4
0
)
 
0
.
2
1
,
 
1
.
1
0
 
(
0
.
8
5
 
 
 
1
.
4
3
)
 
 
0
.
2
4
,
 
1
.
1
0
*
*
 
(
0
.
8
4
 
 
 
1
.
4
4
)
 
P
 
v
a
l
u
e
s
 
b
y
 
χ
2
 
t
e
s
t
 
w
i
t
h
 
1
d
f
.
 
A
n
a
l
y
s
i
s
 
w
a
s
 
r
e
s
t
r
i
c
t
e
d
 
t
o
 
2
8
3
 
p
a
t
i
e
n
t
s
 
i
n
 
t
h
e
 
A
M
D
 
g
r
o
u
p
 
w
h
e
r
e
 
f
l
u
o
r
e
s
c
e
i
n
 
a
n
g
i
o
g
r
a
p
h
i
c
 
d
a
t
a
 
w
a
s
 
a
v
a
i
l
a
b
l
e
.
 
†
A
l
l
e
l
e
 
a
s
s
o
c
i
a
t
i
o
n
 
f
o
r
 
C
N
V
 
a
s
 
c
o
m
p
a
r
e
d
 
t
o
 
d
r
y
 
A
M
D
 
a
n
d
 
a
s
 
c
o
m
p
a
r
e
d
 
t
o
 
n
o
r
m
a
l
 
c
o
n
t
r
o
l
s
‡
.
 
*
O
d
d
s
 
r
a
t
i
o
 
f
o
r
 
m
i
n
i
m
a
l
l
y
 
c
l
a
s
s
i
c
 
C
N
V
 
v
s
.
 
d
r
y
 
A
M
D
 
w
a
s
 
1
.
5
9
 
(
P
=
 
0
.
0
4
,
 
9
5
%
 
C
I
=
 
0
.
9
2
 
 
 
2
.
7
1
)
.
 
*
*
A
l
l
e
l
e
 
a
s
s
o
c
i
a
t
i
o
n
 
f
o
r
 
d
r
y
 
A
M
D
 
a
s
 
c
o
m
p
a
r
e
d
 
t
o
 
n
o
r
m
a
l
 
c
o
n
t
r
o
l
s
.
  
4.4   DISCUSSION 
Identifying genetic determinants associated with AMD
47;176;209;210  provides new insights into 
disease pathogenesis and also assists in defining an ‘at  risk' AMD population. This may 
allow  preventive  measures  to  be  instituted.  In  this  study   cytokine  polymorphisms  that 
functionally  influence  transcription  levels  and  are  ass ociated  with  autoimmune 
diseases
192;211  were tested for association with AMD. The postulated  common pathway of 
these  inflammatory  molecules  prompted  us  to  examine  th e  contribution  of  gene 
polymorphisms in the encoding genes to AMD susceptibil ity. To the best of our knowledge, 
none of the polymorphisms selected have been studied so f ar for association with AMD.  
 
The recent association of CFH with up to 50 % of case s of AMD has created a paradigm 
shift in our understanding of the pathogenesis of this disease. T his association implies that in 
many cases AMD results from uncontrolled complement a ctivation.  Evidence for another 
mechanism which may contribute to this susceptibility for imm une mediated attacks on RPE 
or endothelial cells comes from studies of the HLA  (Human Leukocyte Antigen) system, 
which is essential for the immune regulation of self a nd foreign peptides. Localization of 
HLA  class  I  and  DR  antigens  have  been  reported  in  the  c horiocapillaris  and  drusen, 
respectively
106;212 , and individuals harbouring the HLA Cw*0701 allele have  been found to 
have  an  increased  risk  of  developing  AMD
212 .  We  therefore  hypothesised  that  g enetic 
predisposition to inflammation may be important in a  significant proportion of AMD cases 
who could be prone to developing higher CRP or ICAM1 levels .   
 
AMD is similar to atherosclerosis which are both comp lex prevalent diseases of the elderly 
sharing many environmental risk factors. Raised CRP l evels have been demonstrated to be 
significantly associated with atherosclerosis (almo st two fold increased risk), even in the  
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presence of low cholesterol levels
63;213  and have been shown to be an independent predictor 
of the risk of first time heart disease or stroke. Treat ment of atherosclerosis and coronary 
heart disease has benefited from this insight as aspir in and statins have been shown to be 
most effective in patients with elevated CRP levels
214 . The present study, to our knowledge, 
is the first to investigate functional gene polymorphism s for CRP and ICAM1 in AMD and 
to explore the CFH Y402H polymorphism in relation to CR P. 
 
ICAM 1  is  a  ligand  for  lymphocyte  function  associated 1   (LFA 1)  and  complement 
receptor 3  (MAC 1)  proteins  making  it  an  important  partic ipant  in  many  immune  or 
inflammation  mediated  processes
215 .  While  IL 1beta,  IL 6  and  IL 8  all  have  regulatory 
functions  in  immune  responses,  inflammation  and  wound  he aling,  contributing 
synergistically to disease changes. IL 1beta stimulates  the production of IL 6 which is pro 
stimulatory for CRP secretion. These pro inflammator y effects have been demonstrated to 
include permeability changes involving microglia and M uller cells in the retina (Claudio et 
al.,  1994).  IL 8  is  an  important  activator  and  chemoat tractant  for  microglia  and  other 
inflammatory cells, it is induced by pro inflammatory  cytokines, bacterial or viral products 
and cellular stress 
192 .  
 
Our results from the CRP analysis suggest a signific ant disease association at levels as low 
as 2 mg/l. This association seems to be linear with t he disease risk rising by a factor of 3 for 
higher CRP levels greater than 5 mg/l. Although, a tre nd for association of increasing CRP 
levels with disease severity was identified, this was  not significant in our study possibly due 
to reduced patient numbers (and insufficient power) in  the AREDS sub groups. The CRP 
association in our cohort seems to be stronger compar ed to other similar studies. The levels 
reported by Seddon et al were in the range of 3.4 mg/l  in cases and 2.7 mg/l among controls  
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( P= 0.02)
45  while Swaroop et al recently reported a similar level of ass ociation with levels of 
3.42  mg/l  in  AMD  cases  and  2.30  mg/l  in  controls  ( P= 0.03)
216 .  Contrastingly,  a 
retrospective study by McGwin et al reported no diff erence in CRP levels in their AMD 
cases and controls (1.76 vs. 1.77). However, this nega tive result should be interpreted with 
caution as identification of AMD cases in this study w as done by photographs taken 10 
years after the CRP samples were collected for analysis
217 .    
 
After  correcting  for  co variables  which  affect  both  CR P  and  AMD,  none  of  the  CRP 
genotypes were found to associate with CRP levels. Th e presence of the 1444 T allele has 
been previously associated with both baseline and st imulated CRP levels in coronary heart 
disease studies
218;219 , however this association was not seen in our study.    
 
The reason/s underlying a CRP association with AMD rema in unclear. One possibility is 
that  the  soluble  levels  of  CRP  are  simply  reflecting  local  or  systemic  inflammation 
associated with AMD. Alternatively CRP may be directl y involved in the pathogenesis of 
AMD.  Also,  the  exact  mechanism  by  which  CRP  polymorphis ms  influence  CRP  gene 
expression  and  CRP  levels  is  not  fully  known.  CRP  acti vates  the  classic  complement 
pathway leading to the formation of membrane attack comp lexes (C5b 9) which results in 
cell  lysis.  Studies  which  recently  reported  a  strong  43%   attributable  risk  for  AMD  in 
patients with the Y402H CFH gene polymorphism (incre ased risk of AMD by 2.4 to 7.4 
fold)
46 48   pointed  to  an  interesting  CRP  binding  site  on  the  SC R7  domain  of  the  CFH 
protein
48 . CHF through its direct binding to CRP functions to red uce the deposition of C5b 9 
complexes  in  normal  individuals.  The  Y402H  CFH  variant   was  therefore  implicated  in 
altering the binding properties of CFH to CRP in turn l eading to complex mediated cell 
damage in AMD. However, in our study the presence of the  CFH Y402H variant did not  
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correlate  with  CRP  levels.  This  suggests  the  associati on  of  serum  CRP  with  AMD  is 
independent of CFH genotype.  
 
Our finding of a trend for higher serum ICAM1 levels  in AMD suggests a possible role for 
this molecule in the AMD disease process although this ne eds further evaluation. Continued 
smoking seems to be strongly additive to ICAM1 as demons trated in our results giving a 
large  five  fold  risk  for  development  of  AMD.  ICAM1  is  a mediator of VEGF induced 
angiogenesis
220   and  has  been  reported  to  mediate  oxidative  damage  in  A MD 
221 . 
Experimental  studies  on  ICAM1  and  leukocyte  function as sociated  antigen  (LFA 1) 
deficient  mice  have  shown  significantly  less  CNV  devel opment  in  response  to  laser 
photocoagulation
179 , while increased expression on RPE cells has been demonstrated i n sub 
foveal CNV from AMD patients
180 . Abnormal expression of ICAM1 may therefore lead to 
increased susceptibility to immune mediated attacks. 
 
Of the ICAM1 SNP's tested in the study, the 12959 GG var iant correlated with increased 
ICAM1  levels  showing  a  3  fold  AMD  risk  even  after  correc ting  for  co variables  like 
smoking.  The   12959G/A  (R241G)  polymorphism  is  located  in  a  macropha ge  adhesion 
molecule 1 (MAC 1) binding domain and sICAM1 levels ha ve been previously associated 
with this polymorphism 
222 . ICAM1 polymorphisms also appear to show different r acial 
distributions
223 , which might be important for AMD. In contrast to Europ ean populations, 
the  korean  and  Japanese  populations  do  not  appear  to  exhi bit  the  ICAM1  12959G/A 
(R241G) polymorphism
224  and both early and late stage ARM has been reported to be  less 
common as compared to western populations
225 . 
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The  interleukin  8   251A/T  polymorphism  has  been  previo usly  associated  with  many 
inflammatory diseases and cancers
226;227 . Our results show a similar association for AMD 
and the homozygous  IL 8 251AA  genotype  ( P =0.037). This significance was preserved 
even  after  correcting  for  factors  such  as  smoking  ( P C =  0.043). This is of note as  IL 8 
production has previously been associated with smoking a nd the IL8  251A/T genotype has 
been found to deter the initiation of smoking behaviour in  a Japanese population.
228  This 
pro angiogenic  genotype  has  also  been  shown  to  induce  ang iogenesis  in  rat  cornea.
229  
Human  recombinant  IL 8  implanted  into  rat  cornea  was  found  to  induce  vascular 
proliferation and a similar proliferation and chemo taxis was also seen in human umbilical 
vein endothelial cells in this study. The IL 8 251 AA  genotype seems to act by influencing 
IL 8 production. In a study of patients with respirato ry bronchiolitis the highest serum levels 
of IL 8 were associated with the AA genotype.
226  Alternatively, this polymorphism may 
also be in linkage disequilibrium with functional varia nts elsewhere in the IL 8 loci or in 
neighbouring genes.  
 
During the above analysis, the mean age of our control  population was found to be lower 
compared  to  our  cases  (mean  age  69.1  vs.  78.4),  howe ver,  controlling  for  age  during 
regression analysis did not alter the described associations. BM I was a significant covariable 
in the study which seemed to correlate with all the CRP, CFH  and ICAM1 SNP's tested by a 
5 fold magnitude. All cases and controls in the study w ere aged 55 or older and therefore in 
the at risk age group/range in which AMD is defined a s occuring
230 232 . Although the mean 
age of our controls was slightly lower, this would me an that any genotype association found 
would represent an underestimate rather than an over estimate. True genotype associations 
with AMD may therefore be stronger than that indicated  by this study. 
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In summary, our results demonstrate that the homozygou s IL 8 251 AA genotype (A allele) 
is  a  risk  factor  for  AMD.  Furthermore,  our  findings  in dicate  that  although  the  ICAM1 
R241G polymorphism does not have an independent effect on  the risk of AMD, it may 
interact  synergistically  with  the  IL 8  polymorphism  e specially  in  AMD  patients  with  a 
smoking history. While ICAM1 R241G polymorphism seems to  directly induce ICAM1 
production in AMD as suggested by our data, the exact m echanism by which the IL 8 251 
AA genotype affects the risk of AMD is unclear. Individua ls carrying one or both of these 
high risk IL and ICAM1 genotypes could be predisposed to chro nic inflammatory responses 
in the retina, which in turn could lead to AMD progres sion. The association of raised CRP 
levels with AMD in the study confirms recent findings . Although none of the tested CRP 
gene  variants  could  be  linked  to  CRP  levels  or  AMD  sta tus,  it  is  possible  that  an 
unidentified but causal gene variant exists in the CRP  locus. Although a recent study has 
shown significant linkage to the VEGF region 
233 , none of the VEGF variants tested in this 
study were found to associate with AMD.  
 
Following  on  from  these  hypothesis generating  study,  re plication  studies  are  needed  to 
confirm these associations.  In addition, where possib le these should be complemented by 
functional studies to determine the contribution of th is gene to the development of AMD 
and the angiogenic processes in AMD. This would help de velop genetic screening tests to 
identify individuals at risk of developing AMD or those who may  benefit from focused anti 
inflammatory treatments. 
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CHAPTER FIVE: MUTATION SCREENING OF CANDIDATE GENES  
IN AMD  
5.1   INTRODUCTION 
AMD is characterized by many retinal changes including struct ural changes in the Bruch 
membrane
234;235 . The changes that develop within the Bruch membrane include diffuse 
thickening, accumulation of drusen, basal laminar, and basal linear depos its
234 , collagen 
cross linking in the inner and outer collagen layer and calcification  or fragmentation of the 
elastin layer
235 . These age related changes within the bruch's membrane has als o been 
recently reported to affect the gene expression profile of the RPE
236 . 
 
Many candidate genes have been associated with AMD sta tus, of which the fibulin group of 
genes  are  significant.  Among  these,  fibulin  5  and  fi bulin  6  (hemicentin 1)  have  been 
strongly associated with AMD, while fibulin 3 is mutat ed in Doynes disease. Other genes 
like cystatin C (CST3)
41 , superoxide dismutase (SOD)
42 , toll like receptor 4 (TLR4)
156 and 
ApoE have all shown some positive findings in recent evaluati ons.   
 
In a recent analysis of the fibulin group of genes, St one et al screened fibulin 1, 2, 4 and 5 
genes in a cohort of 402 patients with AMD and 429 age  matched controls. They reported 7 
different missense mutations in the fibulin 5 gene
38 . These sequence changes were seen in 
1.7% of AMD patients,  but none were found in the con trol individuals (P = 0.006). A 
similar mutation screening of the fibulin 5 gene in our  cohort at Southampton had recently 
found AMD associations with 2 novel missense mutation s. Fibulin 5 which is essential for 
elastinogenesis therefore appears to be important in the de velopment of AMD whereby 
mutations in this region could disrupt elastin formati on in the bruch's membrane.   
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Elastin is a major part of the bruch's membrane with b arrier functions in the retina, this has 
been shown to be affected during the AMD disease proce ss (as above). Tropoelastin is the 
building block of elastin which requires a key polymerisa tion process catalysed by lysyl 
oxidase. Further, the process of repair and elastinogenes is requires the interaction of fibulin 
5 gene with lysyl oxidase like 1 (LOXL1; shown to be expr essed in the human eye), and 
this interaction has been found to be essential for e lastic fibre homeostasis (figure 8). We 
therefore hypothesised and screened for mutations in th is gene which could affect elastin 
formation in bruch’s membrane, thereby contributing to A MD.  
  
 
 
 
Figure 8. Fibulin5 and LOXL1 interactions at the protein l evel. 
 
 
5.2   METHODS 
376 AMD patients and 376 normal controls were recruite d for this part of my study. The 
inclusion criteria and AMD phenotypying methodology used w as as described previously.   
5.2.1   PRIMER DESIGN 
The  LOXL1  gene  sequence  was  obtained  from  the  Ensembl  ge nome  browser 
(www.ensembl.org)  and  primers  were  designed  using  the  P rimer  3  online  software 
(http://frodo.wi.mit.edu/cgi bin/primer3/primer3_www.cg i).    Primer  lengths  were  kept 
between 20 and 25 base pairs long, Tm   was  ≤  61 ° C and product length to  <  300 base pairs 
long.  Although LOXL1 has only 8 exons, a total of 20  primers sets were needed to amplify 
this gene in smaller dHPLC recommended amplicons (Ta ble 2.1).  Exon 1 in particular had 
T
T +  
+  
+   +  
+   +  
  LOX
Fibulin
5   Elastin  
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a  very  large  amplicon  and  in  order  to  maintain  a  produ ct  size  of  <   300  base  pairs,  8 
overlapping primer sets were needed to amplify all th e regions in this exon.  All primers 
were obtained from Operon Biotechnologies (www.operon.co m) in lyophilised form. These 
were then diluted to a concentration of 100 M/ l (usi ng deionised water) and stored at  
20ºC.  Sub aliquots of 20 M were made and stored at  4 ºC for easy use and to prevent any 
degradation by repeated defrosting cycles. 
 
5.2.2   OPTIMISING PCR 
Optimisation was done to provide the best conditions for  PCR and to ensure adequate single 
band product amplification.  All primer sets were opti mised by variying two parameters, 1) 
Mg++ concentration and 2) Annealing temperature. PCR w as carried out in a total volume 
of 10   l (each 10   l reaction containing 1X strength PCR buffer, 0.4   M of each primer, 
0.2mM  dNTPs,  1.0 2.0mM  MgCl  (varied),  0.2U/   l  T aq  polymerase  (Invitrogen 
Corporation,  USA),  50ng  of  genomic  DNA  and  PCR  accordi ng  to  the  gradient 
program/protocol on a MJ research PTC225 Peltier Therma l Cycler). The quality of the 
PCR product was then checked on 1% agarose gel. 
 
In some cases were optimisation failed, 1.3mM Betaine (a PCR  enhancing agent) was added 
to the reaction and a touch down PCR method was use d to achieve better results. The touch 
down method involves starting at an annealing temperatu re  ≈  5 ° C above the predetermined 
T m  and  followed  by  a  20  cycle  touch  down  phase  in  which  the  annealing  temperature 
dropped by 0.5 ° C to 5 ° C below the primer T m.   After the 20 cycle touch down phase, the 
PCR then follows a normal cycle of denature (at 94 ° C for 30secs), then Annealing (at 55 ° C 
for 30secs), and finally synthesis (at 72 ° C for 30secs) which is repeated for an additional 14 
cycles and then ends at 10 ° C forever.  
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5.2.3   DHPLC MUTATION SCREENING  
Following  successful  PCR  amplication,  DHPLC  analysis  was  employed  to  screen  the 
LOXL 1 amplicons in the above cohort. DHPLC identifies  mutations and polymorphisms 
based  on  detection  of  heteroduplex  formation  between  m ismatched  nucleotides  in  PCR 
amplified DNA by liquid chromatography. DNA is mixed w ith an ion pairing agent like 
triethylammonium  acetate  (TEAA)  and  is  passed  through   a  column  comprised  of  a 
polystyrene divinylbenzene  copolymer  which  binds  the  DNA.  A  linear  gradient  of 
acetonitrile allows separation of fragments based on  size and/or presence of heteroduplexes. 
When this mixed population is analyzed by HPLC under  partially denaturing temperatures, 
the heteroduplexes elute from the column earlier than  the homoduplexes because of their 
reduced melting temperature. As the fragments elute, t hey are UV detected (260 nm) and the 
resulting wave forms produced on a computer.  
 
5.2.4   WAVEMAKER METHODS AND DHPLC CONDITIONS 
First, the target region's sequence was evaluated for u niformity of T m  with an amplicon size 
<  300  base  pairs.  If  this  condition  was  not  satisfie d,  alternative  primers  were  chosen. 
Mutation screening assay methods for each amplicon was  then designed using established 
protocols using the WAVEMAKER software. This software  allowed both the calculation of 
melting profiles and generation of elution profiles. Mel ting curves of the PCR product were 
calculated and the highest temperature (Oven temperatu re or DHPLC melt T m)  at which the 
target  sequence  was  predicted  to  be  >90%  duplex  was  chose n  for  assay  performance. 
Sometimes, WAVEMAKER suggested an assay temperature  that was too high for optimal 
resolution of sequence variation, while for the GC ri ch regions the predictions made tended 
to be generally too low. Therefore empirical melt ev aluation and optimisation for screening  
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these  amplicons  was  also  done.  In  total,  each  amplic on  was  screened  using  2  to  3 
WAVEMAKER methods with varying DHPLC melt temperatures  (table 25). 
 
All buffers were freshly made up every week. Loading,  elution and washing of the DHPLC 
column was carried out with varying combinations of t hree buffers injected at a flow rate of 
0.9 ml/min: Buffer A contains 100 mM triethylamine a cetate (TEAA), pH 7.0 and 0.025% 
acetonitrile,  Buffer  B  contains  25%  acetonitrile,  100  mM TEAA, pH  7.0, and 0.1 mM 
EDTA,  and  Buffer  D  contains  75%  acetonitrile.  Loadi ng  and  elution  buffers  were 
combinations  of  buffers  A  and  B,  whose  relative  propor tions  formed  a  gradient over  a 
specified time interval.  Buffer  D was used to  wash the   column. DHPLC elution buffer 
gradients were generated by WAVEMAKER software. The  column was cleaned after each 
run with 100% buffer C at a flow rate of 0.9 ml/min  and a temperature of 80 ºC for 15 
minutes.  The temperature was then reduced to 50 °C an d the column equilibrated with 
50:50 A and B for at least 30 mins before each run.  Prior to running samples through the 
system needle and injection port were washed 15 times.  Following the gradient elution, all 
remaining bound material was washed from the column f or 36 seconds with buffer D and 
the column was re equilibrated with the loading buffer  for 156 seconds. Sample elution was 
monitored by absorbance at 260 nm. All DNA samples whi ch showed suspected mutation 
wave patterns were further analysed by automated seque ncing to confirm the location and 
nature of the mutation as described below. Some suspe cted mutations were also screened by 
restriction digests and Taqman genotyping in a larger coh ort of AMD cases and normal 
controls. 
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5.2.5   RESTRICTION DIGESTS AND GENOTYPING 
A suspected LOXL1 exon 4 mutation pattern was seen in 2 1 AMD cases (n=192) and 15 
normal  controls  (n=192)  following  dHPLC.  BsaJ 1  enzyme  derived  from  Bacillus 
stearothermophilus (New England Biolabs inc, UK) was u sed to analyse the bigger case 
control  cohort  for  the  suspected  change  seen  on  sequencing  ie,   5'  CC G/T AGG  3'  (see 
adjoining  figure).  The  enzyme  recognition  site  was  bet ween  bases  in  bold  letters,  5' 
CC NN GG 3'. All DNA samples were incubated with the provided NE  buffer at 60° C.  
 
 
 
Taqman  genotyping  was  utilised  (described  previously)  usi ng  appropriate  designed 
probes/primers to genotype the LOXL1 3’ UTR T/C Chang e (rs3522) in the larger study 
cohort (seen in 53/188 AMD cases and 20/188 controls with d HPLC). 
 . 
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 5.2.6   AUTOMATED DNA SEQUENCING  
Automated sequencing was done to characterise the mutations dete cted by dHPLC.  The Big 
Dye® Terminator v1.1.1 Cycle Sequencing Kit and the ABI P RISM ® 3100 Genetic Analyser 
were used for this sequencing method. Samples to be s equenced were selected and batch 
analysed (50 l PCR reactions were carried out for ea ch sample and then electrophoresed on 
a 2% Agarose Gel to ensure adequate PCR and a single prod uct). The clear band product 
corresponding to the right sized amplicon when compared to  a 100bp PCR ladder was then 
purified using the Qiagen purification Kit (Qiagen Ltd,  UK) following the manufacturer’s 
protocol. After purification, a 20 l sequencing reactio n (using half strength Big Dye) was 
carried out on the Thermal Cycler.  The reaction co ntains 4 l Big Dye kit, 2 l 5X Buffer, 
3.2 l of 1 M primer, 3 – 10ng of the purified PCR product  and 10.8 l sterile water.  Two 
sequencing reactions were performed per sample fragmen t (One in the forward orientation 
using the forward primer and one in the reverse orienta tion using the reverse primer). A 
Qiagen DyeEx 2.0 Spin Kit (Qiagen Ltd, UK) was used to  remove excess big dye and 
precipitate the DNA from the sequencing reaction.  The prod ucts from this were then re 
suspended in HiDi formamide and transferred to a 96 we ll optical plate approved for use in 
the ABI P RISM ® 3100 Genetic Analyser. This is then set to denatur e at 94ºC for ten minutes 
and 4ºC after that until it is ready to be loaded in to the sequencer.  The sequencer is loaded 
according to the settings recommended in the handbook and  left to run as long as necessary 
(~ 45mins for 16samples). Sequencing results were analys ed by visual inspection of the 
sequence printout on sequence analysing software (BioEdi t Version 7.0) and by sequence 
comparison using the BLAST algorithm from NCBI. 
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5.3   LOXL1 RESULTS  
Following the initial dHPLC screening, possible mutat ion changes were detected in Exons 
4,5 and in the 3' UTR region. The LOXL1 exon 4 G/T change  which seemed plausible on 
sequencing  was  not  confirmed  on  restriction  digests,  w hile  the  exon  5  change  was  a 
synonymous  one  (ATC/ATT  change,  Ile  520  Ile)  which  was  therefore  not  investigated 
further. The 3'UTR (rs3522) genotype distribution was fo und to be similar in cases and 
controls without any significance (table 27). 
 
Table 27.  LOXL1 3'UTR (rs3522) genotype distribution in  the cohort. 
 
LOXL1 genotype   AMD cases  
n=354 
Normal controls  
n=352 
P  values  
CC (%)                      107 (30.2)  99 (28.1)  0.59 
CT (%)   188 (53.1)  178 (50.5)  0.54 
TT (%)  59 (16.6)  75 (21.3)  0.13 
Chi square  P  values using Yate's correction and 1
df . Chi square  P  value with 2
df  
= 0.28. 
 
5.4   PEDF AND CRYAA FUNCTIONAL MUTATIONS 
Pigment Epithelium Derived Factor (PEDF), a serine  protease inhibitor (serpin) expressed 
in  RPE  cells  is  an  important  candidate  gene  for  inhe rited  retinal  diseases  and  other 
photoreceptor retinal degenerations. It is a potent in hibitor of angiogenesis and has been 
shown to be highly expressed in the young adult RPE with  progressive loss during cell 
senescence
237 . A significant reduction of PEDF has been reported in  the choroid of AMD 
subjects when compared to the choroid of aged contro l subjects
238 , suggesting that a loss of 
PEDF  in  the  eye  could  be  functionally  important  in  th e  pathogenesis  of  AMD  (CNV 
development). In mice models of retinal neovasculariz ation, intravitreous injections of a 
PEDF  vector  has  been  shown  to  significantly  inhibit  neo vascularization
239 .  This  
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antiangiogenic activity has also now been shown in a hum an phase I clinical trial of AMD 
patients after an intravitreal injection of PEDF expres sing adenoviral vector
240 .  
 
The Crystallin   alpha A (CRYAA) gene encodes a member  of the small heat shock protein 
(sHSP)  family  of  molecular  chaperones  and  is  primaril y  expressed  in  the  ocular  lens. 
Missense mutations in  CRYAA  have been associated with an autosomal dominant form o f 
'nuclear' cataract segregating in a four generation Ca ucasian family. This may be important 
AMD as both senile cataract and AMD share common risk  factors like age, smoking, UV 
exposure, etc. 
 
To explore the possible role of functional SNP's in this single co py PEDF gene in AMD, we 
identified  and  genotyped  two  SNP's  which  may  affect  transcription  in  the  5’UTR 
(rs12948385)  and  5’flanking  promoter  regions  (rs12948385 ).  Aditionally,  the  functional 
CRYAA promoter SNP (rs13053109) was also tested for any  association with AMD. 
 
5.5   METHODS  
233 AMD patients and 233 normal controls were recrui ted for this study. The inclusion 
criteria and AMD phenotyping methodology used was as describe d previously.  Primers and 
individual  fluorogenic  TaqMan  probes  were  designed  usi ng  Primer  Express  software. 
Genotyping was done using the 5' nuclease assay for allelic  discrimination. 
 
5.6   PEDF AND CRYAA RESULTS  
Genotype  distributions  for  the  PEDF  and  CRYAA  promot er  SNP's  tested  were  largely 
similar in the study groups and in Hardy Weinberg equil ibrium (tables 28 and 29). Among 
the PEDF promoter SNP's tested, a common GG genotype  for rs12948385 was found more  
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commonly in the control group with a  P  value nearing significance. No significance was 
found on chi square testing for the CRYAA promoter SN P genotype distribution in the 
study group.  
 
Table 28. Genotype distributions for PEDF 5' promoter SNP 's in the study population. 
rs9913583   
genotypes 
AMD 
cases 
n=232 
Normal 
controls 
n=233 
P  
values 
rs12948385  
genotypes 
AMD 
cases 
n=222 
Normal 
controls 
n=226  
P  
values  
CC  (%)                    218 (93.3)  227 (97.6)  0.07  GG (%)  84 (37.8)  106 (46.9)  0.05 
CA (%)    14 (6.7)   06 (2.4)  0.07  GA (%)  100 (45.1)  92  (40.7)  0.39 
AA (%)  0 (0)  0 (0)    AA (%)  38 (17.1)  28 (12.4)  0.18 
Chi square  P   values  using  Yate's  correction  and  1
df .  Chi square  P   value  with  2
df  for 
rs12948385 = 0.11. 
 
 
Table 29.  CRYAA promoter SNP (rs13053109) genotype dist ribution in the study cohort. 
 
rs13053109   
genotypes 
AMD cases  
n=233 
Normal 
controls 
n=230 
P  
values 
GG  (%)                     104 (44.6)  104 (45.2)  0.92 
GC (%)    107 (45.9)   97 (42.2)  0.45 
CC (%)   22 (9.5)   29 (12.6)  0.30 
Chi square  P  values using Yate's correction and 1
df . Chi square  P  value with 2
df  = 0.48. 
 
 
5.7   DISCUSSION  
Understanding  the  mechanism  of  AMD  development  is  critical  to  de veloping  new 
treatments for this disease. In addition to testing various immune pa thways, we evaluated 
critical  genes  encoding  structural  membrane  proteins  which  may   have  functional 
implications in AMD. This is important as previous studies have shown t hat the structural 
changes within Bruch's membrane precede   and influence RPE changes by at least one or 
two decades
234;241 .  
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Although the fibulin group of genes have been strong assoc iated of with AMD and novel 
fibulin5 missense mutations have been found in our co hort, mutation screening of LOXl1 
gene (responsible for basement membrane integrity and  elastinogenesis), and testing for 
promoter region SNP's in PEDF and CRYAA genes did not  yield significant results in this 
study.  This  was  despite  an  adequately  powered  study  (80%   power  to  detect  significant 
differences in genotype frequencies between cases and  controls at an alpha level of 0.05, for  
genotypes occurring at 10% frequency in controls the d etectable odds ratios were 2.3 for a 
predisposing  genotype  and  0.5  for  a  protective  genotype   with  95%  confidence.).  These 
findings need to be further confirmed by studying other p opulation cohorts and also perhaps 
by LD based studies. 
 
5.8   EVALUATING A NOVEL TCOF1 MUTATION ASSOCIATED 
WITH A TREACHER COLLINS- MACULAR DEGENERATION 
PHENOTYPE IN AMD  
Treacher Collins Syndrome (TCS) results from defects  in a nucleolar trafficking protein 
(Treacle) coded for by the TCOF1 gene
242 . The purpose of this report is firstly, to describe 
an isolated male with TCS associated with macular de generation who also had a novel 
TCOF1 gene mutation, and secondly to evaluate this mutat ion in a well characterised cohort 
of 95 patients with age related macular degeneration (A MD). 
 
5.8.1   CASE REPORT 
A 44 year old male presented with a 1 month history of  metamorphopsia to Southampton 
Eye Unit. He had minimal dysmorphic features but was  noted to have an antimongoloid 
slant of the palpebral fissures with mild flattening of  the midface. Sensorineural deafness  
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had been diagnosed from childhood but the external ear s were normal in appearance. Best 
corrected visual acuity was 6/9 ( 2.25 DS) right ey e and 6/24 ( 1.50 DS) left eye. Ocular 
examination  revealed  bilateral  posterior  embryotoxon  wi th  adhesions  between  iris  and 
Schwalbe’s line, and iris hypoplasia. No eyelid colobomat a were present. Posterior segment 
examination (fig.10) revealed atrophic macular degenerat ion in both eyes and a choroidal 
neovascular membrane (CNV) in the left eye confirmed  on fluorescein angiography. No 
drusen were seen in either eye. Mutation screening o f  T COF1  gene was instigated because 
his facial appearance and deafness suggested possible T CS. A mutation was identified in 
exon 13 (2055 del AG), which is predicted to create a  premature stop codon. In view of this 
unique genotype and phenotype we wished to evaluate whet her this mutation in the  T COF1  
gene  was  commonly  associated  with  macular  degenerati on.  95  Caucasian  patients  with 
AMD  were  therefore  screened  for  the  2055  del  AG  mutation  by   denaturing  high 
performance liquid chromatography (dHPLC)
243 , using the DNA from our patient with TCS 
as a positive control (fig. 11). The spectrum of AMD i n this cohort was AREDS grade I (21 
patients); AREDS grade II (20 patients); AREDS grade  III (19 patients) and AREDS grade 
IV (35 patients)
244 . No abnormal chromatograms were detected in any of these  patients.  
 
Figure 10. Both eyes showing atrophic macular degeneratio n. The left eye in addition has 
subretinal hemorrhage (white arrow) with CNV.   
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Figure 11. Mutation screening chromatograms. A. a double  peak is seen indicating the base 
pair mismatch in the proband. B. a normal wave tracing fro m a screened AMD sample. 
 
5.8.2   DISCUSSION 
Ophthalmological  features  in
  TCS  may  be  extensive,  but  rarely  involve  intraocular
 
structures.  Common  features  include  astigmatism,  defec tive  inferior  lateral
  angle  of  the 
orbit, caudal displacement of the superolateral
  orbit, coloboma of the lateral part of the 
lower lid, pseudocoloboma of the eyelids, lateral cant hal dystopia, nasolacrimal obstruction, 
orbital and limbal dermoids and microphthalmos
245 . Hansen et al
246  have observed bilateral 
iris, choroid and optic nerve colobomata.   Cataracts, lacrimal duct atresia, pupillary
  ectopia, 
distichiasis, and uveal colobomas have been reported
  less frequently. A solitary case with 
aniridia, sclerocornea and retinal maldevelopment has als o been reported 
247 . We believe this 
is the first report of atrophic macular degeneration and  CNV demonstrated in a patient with 
a proven molecular diagnosis of TCS.  
 
Disease expressivity is highly variable in TCS, rangi ng from the clinically undetectable to 
death in the perinatal period 
248 . The late clinical presentation in our case may be expl ained 
by  the  mild  phenotype  in  the  spectrum  of  TCS.  The  TCS  C ollaborative  Group
249   first 
identified different mutations in the  T COF1  gene in each of 5 unrelated families with TCS. 
All of the mutations were predicted to result in a p remature stop codon leading to premature  
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termination of the protein product. Since then over 100  disease causing mutations have been 
reported
250  throughout the  T COF1  gene in patients with TCS, which represented a detect ion 
rate of 60%. Our patient has a 2055 del AG mutation in  exon 13 of the  T COF1  gene which 
has not been previously reported. We speculated that there m ay be a causal relationship 
between the mutation and the macular degeneration seen in  our patient with TCS.  
 
The specific role of  T COF1  in the molecular pathogenesis of TCS remains elusive,  but 
mechanisms such as
  abnormal neural crest cell migration and abnormal cell  death seem 
important
251 .  T COF1   is  expressed  in  the  human  eye  and  apoptotic  regressio n  has  been 
described in organs such as ears and kidneys in animal  models of TCS
252 . Therefore, it 
seemed possible that this  T COF1  mutation may also trigger cellular apoptosis resulti ng in 
atrophic macular degeneration. However, we tested for  the presence of this mutation in 95 
patients with AMD but did not identify any mutation  carriers in this cohort. It is possible 
that this macular finding is incidental to TCS and th e  T COF1  mutation. The early age of 
onset of macular degeneration in this patient is als o atypical for AMD. We also note that the 
macular degeneration seen in this patient is more se vere than would be expected with his 
low degree of myopia. It is therefore possible that  patients with TCS may have an increased 
risk of developing macular degeneration. 
 
In summary, we describe a new clinical phenotype in a pat ient with molecularly proven 
TCS  and  a  novel  T COF1   mutation.  Although  most  cases  of  TCS  present  early  i n  life, 
ophthalmologists need to review adults with TCS to se e if macular degeneration is more 
widespread  than  reported.  This  mutation,  however,  does  n ot appear to be implicated in 
AMD.  
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CHAPTER SIX: EVALUATING COMPLEMENT FACTOR H IN AMD 
AND CARDIOVASCULAR DISEASES.  
 
Among  the  various  factors  involved  in  the  pathogenesis  of  e pidemiologically  similar 
diseases like AMD, atherosclerosis and heart disease,  inflammation has been foremost with 
recent  evidence  pointing  towards  various  immune  related  pathways.  Inflammation often 
leads to tissue damage caused by lymphocyte mediated  attack against self proteins. The 
activation of these and other tissue based macrophage c ells is further influenced by various 
inflammatory  mediators  like,  pentraxins  (C reactive  pro tein  or  CRP),  complement 
components, prostaglandins, chemokines, cytokines, cellu lar adhesion molecules, proteases, 
protease inhibitors, and free radicals. 
 
6.1   COMPLEMENT FACTOR H IN UK COHORT AND RESPONSE 
TO PDT TREATMENT 
Complement factor H (CFH), a key inhibitor of the al ternative complement pathway has 
been  implicated  in  patients  with  age related  macular  d egeneration  (AMD).  Many  key 
publications have reported a highly significant CFH gene  coding polymorphism (rs1061170, 
Y402H) which has been seen in nearly 50% cases of AMD
46 48;176  . A defective factor H 
protein has been hypothesised to influence AMD related inf lammatory processes including 
angiogenic processes leading to choroidal neovascularisation  (CNV) formation
253 .  
 
This CFH variant may also partly answer the question a s to why increased serum CRP 
levels are associated with AMD. CRP is known to activa te the classic complement pathway 
leading  to  formation  of  the  membrane  attack  complex  (C5 b 9).  Further,  drusen  with 
terminal complement deposition indistinguishable from  AMD have been observed in eyes  
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from patients with a kidney disease (membranoproliferat ive glomerulonephritis type II) that 
can be caused by mutations in CFH
50 . It is likely that allele specific changes in the acti vities 
of the binding sites for heparin and CRP may alter CFH’ s ability to suppress complement 
related damage to arterial walls, and might ultimate ly lead to vessel injury and subsequent 
neovascular AMD.  
 
Photodynamic  therapy  (PDT)  is  an  effective  treatmen t  for  AMD  related  CNV.  PDT 
produces  CNV  regression  by  various  cellular  mechanisms  wh ich  include  a  variety  of 
immunological processes. Some of these may influence  the complement pathway
254 . PDT 
has been shown to produce a transient inflammatory resp onse by increasing cytokine levels. 
Of these, interleukin 1β, interleukin 2 and TNF 7α all s eem to be important
254 . Also, antigen 
presenting cells (dendritic or Langerhans) have been repo rted to become less active while 
HLA class II antigens are significantly down regula ted after PDT which may also affect 
immune  responses
254 .  These  inflammatory  responses  might  stimulate  wound  he aling  or 
paradoxically lead to recurrent CNV. 
 
CFH is present in the retina of AMD patients. Immun olocalisation studies demonstrate CFH 
co localizing within drusen, the choroid bordering drusen and th e retinal pigment epithelium 
(RPE), and in both the basement membrane and wall of chor iocapillaries
176 . Functionally, a 
normal CFH has been shown to limit immune complex deposition  and prevent inflammatory 
scarring in mice models of kidney disease
255 . Damage to the neurosensory retina is reported 
as  minimal  and  reversible  after  PDT
254 .  However,  PDT  may  also  have  undesirable 
consequences  including  retinal  pigment  epithelium  dam age  and  choroidal 
hypoperfusion
254;256 . Further, the potential for collateral damage to oth er retinal cell types  
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including glial cells from multiple PDT applications  cannot be discounted. Inflammatory 
scarring may therefore be important in PDT. 
 
We therefore analysed the CFH Y402H (1277T/C) variant  in our study cohort to confirm the 
AMD associations reported. Aditionally we hypothesised that  mutant CFH could affect PDT 
outcomes  by  altering  immune  or  scarring  related  processe s.  To  answer  this,  we  first 
evaluated the magnitude of AMD/CNV risk conferred by  the CFH Y402H polymorphism in 
our UK cohort and then tested whether any of the high ris k CFH genotypes associated with 
visual outcomes following PDT for CNV in AMD patients.  
 
6.2   SUBJECTS AND METHODS 
AMD and normal controls over age 55 were recruited as per previ ous methodology. ETDRS 
visual acuities were recorded. Stereoscopic fundus p hotographs and fluorescein angiograms 
were  graded  independently  by  two  masked  observers  (SG  and  SH)  into  4  groups  of 
increasing disease severity as described in the AREDS  study
257 . 27 patients who underwent 
PDT treatments were identified from the AMD group and  followed up during a period of 15 
months.  
 
SNP GENOTYPING ASSAY 
Genotyping was done using the 5' nuclease assay for alle lic discrimination as described 
previously (see chapter 4, section 4.2.3 and table 13).  
 
STATISTICAL METHODS 
 
Genotype distributions for the CFH polymorphism were t ested for conformity to Hardy 
Weinberg equilibrium in both cases and controls. Allel es at each locus were said to be in  
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Hardy Weinberg equilibrium if the observed homozygote  and heterozygote frequencies did 
not differ significantly ( P >0.05) from expected frequencies. Individual CFH genotypes were  
analysed for AMD/CNV association using Fisher’s exact t wo tailed tests. The association 
with degree of visual loss following PDT therapy was a nalysed by non parametric Mann 
Whitney tests. Logistic regression analysis was perform ed using data on age, sex, body mass 
index (BMI), and smoking status as covariates in regres sion models. The level of statistical 
significance in the study was set at  P C  < 0.05. All statistical analyses were performed usi ng 
the SPSS statistical software package version 14.0. 
 
Table 30. Primer and probe sequences used for 5' nuclease (TaqMan)  genotyping (see 
chapter 4, table 13).   
 
Table 31. Basic demographic characteristics of the Caucasian study population.  
 
 
  AMD cases 
Total n = 557 (%) 
Controls 
Total n = 551 (%) 
PDT cases 
Total n=27 
Age 
         Mean  
  n=557 
  78.4 
  n=551 
  69.1            
n=27 
78.6 
         Range    55   101    55   91  65 93 
         SD    8.65    9.76  6.13 
Sex 
          Female 
          Male 
  n=557 
  330 (59.2)       
  227 (40.8) 
  n=551 
  308 (55.9) 
  243 (44.1) 
n=27 
13 (48.1) 
14 (51.8) 
BMI 
          Mean 
          SD 
  n=237 
  26.5 
  4.76 
  n=407 
  27.3 
  4.70 
n=24 
25.4 
4.98 
Smoking status 
          Current smokers 
          Past smokers 
          Non smokers 
  n=460 
  140(30.4) 
  145(31.5) 
  175(38.0) 
  n=432 
  81(18.7) 
  213(49.3) 
  138(31.9) 
N=27 
8 (29.9) 
12 (44.4) 
7 (25.7)  
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6.3   RESULTS 
Baseline demographics of the unrelated Caucasian cohort re cruited from a clinic population 
(557  cases  with  AMD,  551  normal  controls  and  27  case s  from  the  AMD  group  who 
underwent PDT) are described in table 31. CFH 1277 C /T (Y402H) genotyping data was 
available for all individuals. Genotype frequency distri butions were as shown in table 32. 
The homozygous CC genotype was more often present in A MD cases (0.28 vs. 0.13,  P   < 
0.0001) giving an OR for disease of 3.62. The associati on with AMD was also significant in 
the larger heterozygous CT group but with a lesser ri sk of AMD than in the CC group 
(OR=1.61,  P=  0.0008). Overall, the odds ratio for AMD was 1.90 for  the high risk C allele 
(< 0.0001). Adjusting for age during the logistic regressi on analysis did not alter the odds 
ratio for disease significantly. 
 
Table  32.  CFH  Y402H  genotype  association  in  AMD  cases  and 
controls. 
CFH 
Genotypes 
AMD  cases 
n=557 (%) 
Controls 
  n=551 (%) 
Genotype association 
 OR, 95%CI   ( P C   value)*  
CC  167 (0.28)  75 (0.13)  3.62, 2.56   5.14 (< 0.0001) 
CT  258 (0.44)  261 (0.44)  1.61, 1.22   2.12 (0.0008) 
TT  132 (0.23)  215 (0.36)                     
CFH Allele       
C  592  411 (0.37)  1.90, 1.60   2.25 (< 0.0001) 
T  522  691 (0.63)                    
* P C  =  P  values for genotypes (compared to TT) after adjusting  for age, sex, BMI, Current 
smokers and Past smokers.  
 
Further categorization was possible in 416 subjects i n the AMD group, who were divided 
into  4  groups  of  increasing  AMD  severity  using  AREDS  cr iteria  (table  33).  The  
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homozygous CC genotype was found to associate with all  the four AREDS groups with the 
strongest association seen in AREDS 4 group (OR=5.17,  P   < 0.0001). Although the odds 
ratio in AREDS 1 was similar to that in AREDS 3 (OR of 2.64 vs. 2.69) , the strength of this 
association in AREDS 1 was much weaker ( P   = 0.03 vs.  P   = 0.0008). The heterozygous CT 
genotype was found to associate with AREDS 4 group onl y (OR=1.78,  P   = 0.008). The C 
allele showed a similar risk trend for association  in all the four AREDS groups with odds 
ratios ranging from (1.61 to 2.33). 
 
The risk of various subtypes of CNV was then analysed in co mparison to controls (table 34). 
CFH genotypes were found to associate with the predominan tly classic CNV group only 
(OR for CC genotype=17.87,  P <0.0001, OR for CT genotype=9.06,  P =0.0002, combined 
OR=10.87,  P <0.0001).  Odds  ratio  for  the  presence  of  the  high ris k  C  allele  was  2.97 
( P <0.0001) in this CNV subtype. Allele associations were  also seen in the occult CNV 
(OR=3.09,  P <0.0001) and minimally classic CNV (OR=2.52,  P =0.001) subtypes, this was 
however not significant when genotypes were analysed in the se groups.  
 
The risk of developing classic or predominantly CNV wit hin the wet AMD group was then 
compared to the minimally classic and occult CNV (in cluding PED) group. Analysis was 
done for association with CFH genotypes (CC/CT) and al leles, no significant difference in 
the frequency of CFH genotypes or alleles was found bet ween the two groups (data not 
shown). 
 
Overall  76%  (425/557)  of  AMD  patients  had  the  CC  or  CT  g enotype.  Of  these,  4.8% 
patients (n=27/557) had undergone PDT treatments. In the PDT g roup, 93% (25/27) patients 
carried the high risk C allele (CC or CT). This difference  in the genotype distributions in the  
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PDT  group  and  the  AMD  group  was  significant  for  the  C C  genotype  (93%  vs.  76%, 
OR=5.48,  P  = 0.015).  
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 In  the  PDT  group,  27  patients  who  had  predominantly  c lassic  or  100%  classic  CNV 
(Snellen VA ≥ 6/60) were followed after PDT for a peri od ranging from 3 to 22 months 
(median = 22 months). Each patient on average had rece ived at least two PDT treatments 
(median  =  2,  range  =  1  to  5  treatments).  Other  demogra phics  of  this  PDT  cohort  are 
described  in  table  31.  In  this  group,  the  CC  and  CT  wer e  the  predominant  genotypes 
observed in 48% and 44% cases respectively. 
 
Table 35. CFH Y402H risk genotypes (CC and CT) and visual acuity 
following PDT. 
CFH 
Genotype  
PDT cases    
n=27 
ETDRS acuity loss  
(median, range)   
Genotype vs. ETDRS acuity  
loss    ( P   value)  
CC  13 (0.48)   12.0 (+23.0 to  70.0)  P  = 0.038*  
CT  12 (0.44)   3.5 (+20.0 to  80.0)  P  = 0.087 
TT  2  (0.08)   70.0 ( 65.0 to  75.0)    
*  Significant  P   values  (CC  and  CT  genotypes  compared  to  TT  genotype  usi ng  
nonparametric Mann Whitney test).  
 
 
Visual acuity data after PDT for each genotype are pre sented in table 35. Overall, 48% of 
CC cases (n=13) and 44% of the CT cases (n=12) had lost  15 or more ETDRS letters. The 
numbers were too small in the TT group for analysis  (n=2). The degree of ETDRS acuity 
loss was statistically significant in the CC group ( median loss of 12 letters,  P= 0.038). The 
loss  of  ETDRS  letters  in  the  CT  group  was  not  signif icant (median loss of 3.5 letters, 
P= 0.087). Although acuity loss was greatest in the TT gr oup (median loss of 70 letters), the 
sample size was small and  P  values were not obtainable. 
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6.4   DISCUSSION 
CFH is an essential inhibitor of the alternative comp lement pathway preventing uncontrolled 
complement activation
49 . Recent data also suggest that the CFH Y402H polymorp hism is a 
risk factor for several  AMD phenotypes including cho roidal neovascularisation (CNV), 
geographic atrophy and soft drusen 
258;259 . This study has sought to identify the risk of AMD 
and particularly CNV in a UK cohort conferred by the pr esence of this CFH polymorphism 
additionally exploring any effect of these CFH genotypes on PD T outcomes.  
 
 
In  this  UK  study,  the  strength  of  the  AMD  association  w ith the  high  risk CC and the 
heterozygous CT genotypes was similar to those repor ted in other Caucasian cohorts. The 
CC genotype showed a 5 fold risk in the AREDS 4 group  compared to controls. With in the 
AMD group, the association of predominantly classic C NV with the CFH C allele was 
highly significant. The magnitude of this risk was 5  times greater in patients with CC or CT 
genotypes. When compared to the control group, the ris k of predominantly classic CNV 
further increased by 17 fold in the CC group and 9 fold in the C T group. Recently, Haines et 
al reported similar raised odds ratios of 3.4 and 5.6  for the CT and CC genotypes when their 
analysis was restricted to CNV
46 . Zareparsi et al noted a similar raised frequency of C C 
genotypes in CNV
260 . In a recent report by Sepp et al, 81.8% of AMD pat ients with CNV 
were found to exhibit the high risk CFH genotypes, the  odds ratios for CNV being 5.1 for 
CC and 2.7 for CT genotypes
258 . The reported odds ratio for CNV risk was 4.34 in a  recent 
report from an Australian AMD cohort
209 . Our risk figures for CNV seem to be similar to 
the above reported rates. However, the correlation of CF H genotypes with predominantly 
classic CNV was higher than any of these reported asso ciations. We are not aware of any 
previous analysis of predominantly classic or other CNV  subtypes with CFH genotype. The  
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higher correlation for this CNV type may therefore reflec t a tendency for the CFH mutant 
protein to result in this subtype of CNV.  
 
A significantly increased frequency of CC and CT genoty pes (93%) was seen in the PDT 
group.The high risk CC genotype was found to associat e with the degree of visual loss 
following  PDT  in  this  study,  while  visual  acuity  was  unrelated  to  the  presence  of 
heterozygous  CT  and  homozygous  TT  genotypes.  Calculatio ns  revealed  that  the  PDT 
sample size (n=27) had 80% power to detect a minimum dif ference of 20 ETDRS letters 
(alpha error level = 5%) and 90% power to detect a 24 l etter difference. The power to detect 
any smaller differences in acuity would have been limi ted.   
 
Although sample sizes are adequate, the power to detect  the association of CFH Y402H 
genotype with predominantly classic choroidal neovascular ization may be limited given the 
close  prevalence  of  CFH  in  the  various  membrane  types,  c lassic,  minimally  classic  or 
occult. In addition, the type of neovascularisation may chang e over time in an individual and 
it is possible that some individuals in the AMD group  would have developed some form of 
occult  CNV  making  them  ineligible  for  PDT  therapy.  How ever  if  so,  the  associations 
described for the predominantly classic form of CNV wo uld be an underestimate. CFH risk 
genotype associations with predominantly classic CNV ma y therefore be stronger than we 
describe.  
 
In  conclusion,  there  was  a  highly  significant  trend  for   patients  with  the  risk  Y402H 
genotypes to develop predominantly classic CNV in AMD.  The CFH Y402H gene variant 
was also found to associate with visual outcomes foll owing PDT treatments for CNV. It 
may be that once CNV begins, downstream events such as V EGF expression and scarring  
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predict final visual outcome in addition to CFH genot ype. Visual acuity responses to PDT 
therefore seem to be related to CFH Y402H genotype. This  may be because of CFH related 
damage to the  retinal pigment  epithelium (RPE) allow ing CNV to develop more easily 
above the RPE. This is however an exploratory hypothesi s testing study. Further studies are 
needed to confirm the association reported here of a p redominantly classic CNV subtype in 
patients  with  Y402H  CFH  genotypes.  Such  genotype  –  pheno type  correlations  may 
ultimately assist in clinical treatment algorithms.  
 
6.5   COMPLEMENT FACTOR H IN CORONARY ARTERY DISEASE 
AND ATHEROSCLEROSIS 
Inflammation  is  one  of  the  most  important  factors  under lying  the  pathogenesis  of 
atherosclerosis and coronary heart disease, with recent  evidence indicating the involvement 
of various immune related pathways. Several componen ts of the complement cascade along 
with  other  inflammation  mediators  have  been  associated  with  the  development  of 
atherosclerosis and myocardial infarction (MI). Elev ated serum levels of complement C3 
and C5a, and circulating immune complex (CICs) have bee n reported to be independent risk 
factors for MI 
261  
262  
263 . In addition, complement factor H (CFH) is present i n the early 
atherosclerotic lesions and has been implicated in athe rogenesis
264 . 
 
There are many similarities in the pathological chang es between AMD and atherosclerosis. 
In  particular,  the  pathogenesis  of  both  diseases  involves  i nflammation  and  lipid 
accumulation  in  affected  tissues.  In  addition,  genom e  wide  linkage  studies  have  shown 
evidence of linkage of a region on chromosome 2 both  with AMD and with coronary artery 
disease
265;266,267 . Therefore, we hypothesised  and  examined a possible a ssociation of the 
CFH Y402H polymorphism with coronary heart disease and at herosclerosis.     
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6.5.1   SUBJECTS AND METHODS 
 
We studied a group of 1170 Caucasian patients with coronary artery di sease and a group 
of 560 healthy control subjects. The patients all had angiographica lly confirmed coronary 
artery  disease  and  were  recruited  at  the  Wessex  Cardiothoraci c  Unit,  Southampton 
General Hospital as previously described
268  . Characteristics of the patients have been 
described in the same publication 
268 . The study was approved by the South and West 
Local Research Ethics Committee (number 298/99), and all subjects ga ve written consent. 
The controls were healthy Caucasian individuals without  CAD, recruited from ophthalmic 
clinics at Southampton General Hospital. Information o btained for the controls included 
relevant past medical and cardiovascular history, smo king history, ocular history, use of 
medications, vitamin or dietary supplementation; he ight, weight, body mass index (BMI) 
measurements were also recorded. From the above CAD patie nts and control subjects, we 
identified a sub set of 233 pairs of age and gender matched  patients and controls.  
 
CFH GENOTYPING ASSAY 
Genotyping was done using the 5' nuclease assay for all elic discrimination as described in 
chapter 4.   
6.5.2   STATISTICAL METHODS AND ANALYSIS 
Allelic  and  genotype  distributions  were  tested  for  con formity  to  Hardy Weinberg 
equilibrium by χ
2  analysis. One way ANOVA and Chi square tests ( P  values with Yate's 
correction and 1
df ) were carried out to examine differences in quantitative and c ategorical 
variables between groups, and between CFH genotypes. In these analyse s, triglyceride 
values were log transformed to normalize the distribution. Logist ic regression analysis 
was used to evaluate the effects of genotypes on severity of CAD and occurrenc e of MI. In 
these  analyses,  the  number  of  diseased  vessels  or  occurrence  of  MI  was  entered  as  
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dependent variable and the genotypes as independent variable, while ag e, gender, body 
mass  index  (BMI),  smoking  status,  diabetes,  hypertensi on,  cholesterol  and  triglyceride 
levels,  and  family  history  of  CAD  as  covariates  in  the  re gression  model.  The  level  of 
statistical  significance  in  the  study  was  set  at  P   <  0.05.  All  statistical  analyses  were 
performed using the SPSS statistical software package ve rsion 12.0. 
6.5.3   RESULTS 
 
Baseline demographics of the CAD patients (n=1170) and nor mal controls (n=560) are as 
described in table 36. The observed CFH genotype dist ributions in both groups were in 
Hardy Weinberg equilibrium. 
CFH POLYMORPHISM AND CAD  
The CFH genotype distributions were similar between CAD case s and normal controls, both 
in the sample as a whole and in a subset of 233 pair s of age and sex matched cases and 
controls (table 36). Analysis in the entire CAD patien t group (n=1170) showed that there 
was no difference in CFH genotype distribution between  patients with either one, two or 
three diseased coronary arteries (table 37), or between patient s with an MI and those without 
(table 38).  
 
CFH GENOTYPES AND CARDIOVASCULAR RISK FACTORS 
In the CAD patient group, genotype frequencies were simi lar in males and females. There 
was no  significant  difference in mean  age between t he  genotype groups. There was no 
significant difference in plasma levels of cholesterol  and triglyceride, between the CFH 
genotypes, neither was there any association of the CFH  polymorphism with BMI, smoking 
status, diabetes, hypertension or a family history of CAD  (data not shown).  
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Table 36. Basic demographic and clinical characteristic s of the subjects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quantitative data are presented as mean (standard deviation). 
 
 
Table 37.  CFH genotype distribution in the age and sex ma tched cohort. 
 
CFH genotype   CHD cases  
n=220 
Normal controls  
n=228 
P  values  
CC  (%)                    43 (19.5)  48 (21.1)  0.72 
CT (%)   99 (45.0)  94 (41.2)  0.44 
TT (%)  78 (35.5)  86 (37.7)  0.62 
Chi square  P  value using Yate's correction and 1
df 
 
 
Table 38. CFH genotype distribution in patients with 1, 2 or 3 di seased coronary vessels and 
in patients with and without MI. 
 
CFH genotype 
total n=1122 
1 vessel 
n=454 
2 vessels 
n=380 
3 vessels 
n=288 
With MI 
n=615 
 Without MI 
n=507 
CC  (%)                    78 (17.2)  66 (17.4)  48 (16.7)  101 (16.4)  91 (17.9) 
CT (%)   214 (47.1)  168 (44.2)  147 (51.0)  291 (47.3)  238  (46.9) 
TT (%)  162 (35.7)  146 (38.4)  93 (32.3)  223 (36.3)  178 ( 35.1) 
P  = 0.49 and  P  = 0.78 (Chi square values with 1
df ). 
 
 
6.5.4   DISCUSSION 
Complement activation can arise through the classical,  lectin, or alternative pathways
49 . All 
three pathways lead to the generation of a C3 convertase  enzyme and subsequent activation 
  CHD cases 
total n = 1170 
Controls  
total n = 560  
Age      63.29 (9.96)    69.10 (9.76) 
Sex    Female 
          Male 
274 (23.4%) 
896 (76.6%) 
  308 (55.0%) 
  252 (45.0%) 
Smoking status 
Current and ex  smokers         
n=872 
872 (74.5%) 
  n=294 
  294(53.0%) 
Body mass index (kg/m2)  27.49 (4.25)    27.27 (4.70)  
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of the immune response, terminal pathway pore like mem brane attack complex (C5b 9) 
formation  then  leads  to  cell  lysis.  CFH  is  an  essentia l  inhibitor  of  the  alternative 
complement pathway preventing uncontrolled complement ac tivation
49 . The CFH Y402H 
polymorphism is particularly interesting since it lo cates to the SCR7 domain of the CFH 
protein, implicated as a binding site for heparin, c rea ctive protein (CRP), streptococcal M 
proteins and various microbes
49 . CHF through its direct binding to CRP is known to reduce 
the deposition of C5b 9 complexes. It has been proposed that CF H through its direct binding 
to CRP normally reduces complement mediated depositio n and this process may therefore 
be defective due to the variant CFH protein in atherosclero sis. 
 
In this study, we did not find evidence of an associati on of the CFH Y402H variant with 
CAD susceptibility, CAD severity, occurrence of MI,  or cardiovascular risk factors such as 
plasma levels of cholesterol and triglycerides, diabete s, and hypertension. This was despite 
an adequate power in the study (80% power to detect si gnificant differences in genotype 
frequencies  between  cases  and  controls  at  an  alpha  level  of  0.05).  For  example,  for  a 
genotype occurring at a frequency of 10% in the control po pulation, detectable odds ratios 
were  1.84  for  a  predisposing  genotype  and  0.45  for  a  protec tive  genotype  with  95% 
confidence.  Our  study  is  hypothesis  driven  with  the  resu lts  suggesting  no  association 
between  CAD  and  CFH  Y402H  polymorphism.  By  virtue  of   the  study  design,  direct 
evidence for non functionality of this polymorphism ca nnot be provided, and it is important 
to note that a different unidentified CFH gene varia nt might exist which is not in linkage 
disequilibrium with the analysed CFH polymorphism. To  conclude, in this study based on a 
UK Caucasian population, no evidence was found to associa te the complement factor H 
Y402H gene variant with coronary heart disease, severit y of CAD, and cardiovascular risk 
factors.  
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7.  CHAPTER SEVEN: HLA CW*0701 GENOTYPE AND NATURAL  
KILLER CELL RECEPTOR AA HAPLOTYPES ARE ASSOCIATED 
WITH AMD.  
7.1   INTRODUCTION 
There are now multiple lines of evidence suggesting an imp ortant role for inflammatory 
events in the pathogenesis of AMD. Histologically, extra  cellular drusen deposits seen in the 
retina of AMD patients have been shown to contain protei ns which modulate the body's 
response to inflammation. These proteins include vitrone ctin, complement and 
immunoglobulins
269 . Inflammatory cells including macrophages
53;270;271 , multinucleate giant 
cells
271;272,273 , fibroblasts and mast cells have been observed in asso ciation with Bruch’s 
membrane in AMD donor eyes
55 . Some characteristics of AMD have also been described i n 
mice with macrophage defects
59 .  Natural Killer (NK) cells which are lymphocytes of th e 
innate immune system, have been reported to be present in s ub retinal neovascular lesions 
seen in AMD patients 
274 . NK cells may therefore also have a role in AMD. 
 
The Human Leukocyte Antigen (HLA) system is essentia l for the immune regulation of self 
and foreign peptides via presentation of processed ant igenic peptides to both CD4 helper 
and CD8 cytotoxic T lymphocytes. We previously reported  the association of HLA with 
age related macular degeneration (AMD) in a UK cohort
150 . Evidence from that study points 
to an important mechanism which may contribute to su sceptibility for immune mediated 
attacks on RPE or endothelial cells in AMD. Individual s harbouring the HLA Cw*0701 
allele were found to have an increased risk of developing A MD 
150 .   
 
HLA class I molecules are ligands for killer cell immu noglobulin like receptors (KIRs), a 
group of regulatory molecules which are expressed predom inantly by natural killer (NK) 
cells and also T cells. Natural killer cells are invol ved in the early responses against infected  
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or transformed cells by production of cytokines and direct  cytotoxicity.  They also cross talk 
with macrophages and dendritic cells.  Thus, KIR and HLA  in combination are involved in 
both innate and adaptive immune responses.  
 
Healthy cells are protected from spontaneous killing wh en they express an appropriate HLA 
class I ligand for an inhibitory KIR receptor expressed o n NK cells. This observation 
corresponds with the reported phenotypic dominance of KIR m ediated inhibition over 
activation
275 . However, aberrant or reduced levels of HLA class I expr ession can result in 
spontaneous destruction by NK cells. In this context, the expr ession patterns of HLA class I 
and class II antigens in the choroid and sub RPE deposits s een in our previous AMD study 
seem important. Notably, the presence of class II antigen s in drusen and RPE cells
276  and the 
apparent lack of class I antigens.  
 
NK cells interact with HLA class I (A,B,C) ligands thro ugh KIR receptors. Particularly 
relevant to NK recognition by KIRs are polymorphic HLA  C molecules.Through interaction 
with inhibitory KIRs, HLA C molecules are able to modu late NK cell function.Thus, KIR 
genes are likely to play a significant role in the contr ol of the immune response . It follows 
that certain combinations of HLA C and KIR gene variants  may influence susceptibility to 
AMD. To test this hypothesis we have analysed HLA C and  KIR genotypes both 
individually and in combination for association with AMD.  
 
7.2   METHODS 
AMD subjects and normal controls over age 55 were recruited as pe r previous methodology. 
Retinal  photographs  and  angiograms  were  graded  into  geograp hic  atrophy  or  choroidal  
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neovascularization (CNV) sub groups. The CNV AMD group  was further categorised into 
occult, minimally classic and predominantly classic CNV  sub groups.  
 
HLA AND KIR GENOTYPING BY PCR-SSP 
Data from HLA genotyping for principal HLA class I all ele groups including the Cw allele 
was available for the Southampton cohort of 104 AMD ca ses and 93 age matched healthy 
controls. This group of patients and controls were th en also genotyped for KIR genes.  
 
The KIR locus contains polymorphic and homologous genes ma pping to chromosome 
19q13.4. KIR genotyping can be locus or allele specific. Loc us specific genotyping which 
detects the presence or absence of each gene in a given i ndividual was employed in this 
study. The PEL FREEZ KIR genotyping kit (Dynal Biotech
® ) was employed to detect the 
presence or absence of 16 KIR genes (2DL1, 2DL2, 2DL3, 2DL4, 2D L5, 2DS1, 2DS2, 
2DS3, 2DS4, 2DS5, 3DL1, 3DL2, 3DL3, 3DS1, 2DP1, 3DP1). Th is kit utilises PCR 
sequence specific primer amplification methods (PCR SSP ) published previously
277;278 . The 
primer sets amplify 16 KIR alleles described by the int ernational nomenclature committee 
of WHO (http://www.ebi.ac.uk/ipd/kir/).  
 
Gel images of PCR products  were photographed under ultra violet transillumination and 
interpreted by two independent observers (SVG and AJL).  Genotyping was validated by 
random repeat typing in 10% of cases and controls, for ea ch of the HLA and KIR genotypes 
which showed a trend for significance ( P  value <1.0) for association with AMD in the study. 
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7.3   STATISTICAL METHODS AND ANALYSIS 
Power calculations were performed utilizing the Epi Info  statistical package (version 3.4.1, 
2007) provided by the Center for Disease Control and Pr evention (CDC). These calculations 
were based upon the number of cases and controls to be gen otyped and the known 
frequency of specific HLA/KIR alleles. Allelic distrib utions for each locus were tested for 
conformity to Hardy Weinberg equilibrium. Alleles at  each locus were said to be in Hardy 
Weinberg equilibrium if the observed homozygote and het erozygote frequencies did not 
differ significantly (p>0.05) from expected frequencies.   
 
KIR and HLA genotype frequencies were compared in ca ses and controls by two tailed  P  
values calculated using the chi squared test. Adjustment for mu ltiple comparisons was made 
using the Bonferroni method i.e.  P  values for each comparison less than or equal to 0.05 
were multiplied by the number of study comparisons (n = 3 i n the HLA analysis and n = 6 in 
the combined HLA C  KIR genotype analysis). The level o f statistical significance was set 
at  P  < 0.05 and  P c  < 0.05 after application of the Bonferroni correction.  Odds Ratios were 
estimated using the approximation of Woolf to avoid pro blems when critical entries were 
zero. All statistical analyses were performed using t he SAS statistical software package 
version 9.1. 
 
7.4   RESULTS 
Baseline  demographics  of  the  unrelated  caucasian  cohor t  recruited  from  a  single  clinic 
population at Southampton (104 cases with AMD and 93 no rmal controls) are described in 
table  1.  AMD  grading  data  from  fundus  photographs  and  fluorescein  angiograms  were 
available for 58 (55.8%) of the 104 AMD cases (table  1). Genotyped frequencies were 
distributed  in  accordance  with  Hardy Weinberg  equilibri um  for  all  HLA  and  KIR  loci  
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tested. The results from genotyping repeats performed  in 10% of cases and controls were 
found  to  be  100%  concordant  with  those  obtained  during  i nitial  genotyping.  In  total, 
genotyping data for 23 HLA C principal allele groups was  available for analysis after HLA 
class  I  genotyping. The  allele frequencies  for  both the  HLA and KIR genotypes in the 
control  group  were  similar  to  those  previously  repo rted  for  the  respective  Caucasian 
populations
126;127;152 .  
 
Table 39. Basic available demographic characteristics of  the HLA KIR study population.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  AMD CASES 
total n = 104 (%) 
CONTROLS  
total n = 93 (%) 
Age    Mean      76.5    73.1            
          Range    55   91    55   91 
          SD    7.8    10.2 
Sex    Female 
          Male 
  67 (64.4)       
  37 (35.6) 
  58 (62.4) 
  35 (37.6) 
BMI    
          Mean 
          Range 
          SD 
  n = 86 
  26.4 
  17.3 – 40.5   
  4.6 
  n = 84 
  26.1 
  17.7 – 36.9 
  4.5 
Smoking status 
          Ever smoked 
          Never smoked 
  n = 86 
  49 (57.0)     
  37 (43.0) 
  n = 86 
  34 (39.5) 
  52 (60.5) 
AMD subtypes 
         Dry AMD 
         Occult CNV 
         Minimally classic CNV 
         Predominantly classic CNV 
  n = 58 
   29 (50.0) 
   11 (19.0) 
   09 (15.5) 
   09 (15.5) 
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HLA-KIR RESULTS 
The allele frequencies of HLA C alleles seen in our contro ls were similar to those previously 
reported for the UK population.
152  Based on known KIR ligand specificity to a dimorph ism 
on HLA C allotypes
275 , HLA C alleles were initially grouped into C1 and C2  allele groups 
in the Southampton cohort. The frequency of individual s with two copies of HLA C1 alleles 
(C1C1), one copy of C1 (C1C2) and two copies of HLA C2  alleles (C2C2) was similar 
between cases and controls (table 3). HLA C1 and C2 allele dist ributions and the prevalence 
of HLA Cw*07 principal allele groups with the exceptio n of Cw*0701 did not show any 
significant difference between AMD cases and controls.  The HLA Cw*0701 allele was 
found to be strongly associated with the AMD group ( P =0.03, OR=1.92). 
 
Table  40.  HLA  C  allele  groups  (C1,  C2),  Cw*07  and  Cw*0701 allele frequenci es in 
Southampton AMD and control groups. 
HLA C 
allele/s 
AMD 
Group 
n =104 (%)    
Control 
Group 
 n =93 (%) 
P  
value
†  
Odds  
Ratio
‡  
95% CI 
C1C1  43 (41.3)   46 (49.4)   0.25  0.72  0.41 1.27 
C1C2  50 (48.1)   34 (36.6)   0.10  1.60  0.91 2.84 
C2C2  11 (10.6)   13 (14.0)   0.46  0.73  0.31 1.71 
C1 alleles  136 (65.4)  126 (67.7)  0.38  1.16  0.82 1.64 
C2 alleles  72 (34.6)  60 (32.3)  0.14  1.44  0.88 2.39 
Cw*07 allele  63 (60.1)  46 (49.5)  0.11  1.57  0.89   2.76  
Cw*0701 allele  43 (41.3)  25 (26.9)  0.03*  1.92  1.05   3. 50 
† Two sided  P  values using chi squared test (*Significant values). 
‡ Odds Ratio using the 
approximation of Woolf.  
 
Of  the  16  KIR  genes  tested  (table  4),  the  frequency  of  KIR   2DL5  was  found  to  be 
significantly more in the control group as compared to  AMD patients (39.8% vs. 28.8%). 
This gene is a component of the “B” group of KIR haplot ypes.  The significant protective  
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odds ratio for this association was 0.45 ( P =0.006). None of the remaining 15 KIR genes 
showed  any  trend  for  significant  association  with  ei ther  AMD  or  control  groups.    No 
significant  associations  with  AMD  were  observed  for   the  HLA  C1  allele  group  in 
combination with its known KIR ligands, KIR2DL2, KIR2DL3 an d KIR2DS2 (table 5). The 
remaining HLA C1, C*07 and C*0701 allele combinations wi th KIR ligand alleles also did 
not show any significant association with AMD. 
 
Table 41. KIR genotype   and haplotype   frequencies in Southampton AMD and control 
groups.  
KIR 
genotypes 
AMD Group 
 n =104 (%) 
Control Group 
 n =93 (%)  
P  
value
†  
Odds  
Ratio
‡  
95% CI 
2DL1  101 (97.1)  91 (97.8)  0.74  0.74  0.12 4.52 
2DL2  50 (48.1)  48 (51.6)  0.24   0.87  0.50 1.52 
2DL3  98 (94.2)  90 (96.8)  0.39  0.54  0.13 2.24 
2DL4  103 (99.0)  93 (100.0)  0.34  1.90  1.67 2.17 
2DL5  38 (28.8)  52 (39.8)  0.006*  0.45  0.26 0.80 
2DS1  36 (34.6)  43 (46.2)  0.09  0.61  0.35 1.09 
2DS2  50 (48.1)  50 (53.8)  0.42  0.79  0.45 1.39 
2DS3  25 (24.0)  32 (34.4)  0.10  0.60  0.32 1.12 
2DS4  95 (30.8)  89 (50.5)  0.21  0.47  0.14 1.59 
2DS5  27 (26.0)  28 (30.1)  0.51  0.81  0.44 1.52 
3DL1  101 (97.1)  90 (96.8)  0.89  1.12  0.22 5.70 
3DL2  104 (100.0)  93 (100.0)                        
3DL3  104 (100.0)  92 (98.9)  0.29  3.38  0.13 84.3 
3DS1  30 (28.8)  34 (36.6)  0.24  0.70  0.38 1.28 
2DP1  101 (97.1)  91 (97.8)  0.74  0.74  0.12 4.53 
3DP1  104 (100.0)  93 (100.0)                       
AA  35 (33.6)  23 (24.7)  0.17  1.54  0.82 2.87 
AB/BB  69 (71.2)  70 (51.6)  0.17  0.65  0.34 1.20 
† Two sided  P  values using chi squared test (*Significant values). 
‡ Odds Ratio using the 
approximation of Woolf. 
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It has previously been noted that there is association  with specific KIR halpotypes in the 
development of pre eclampsia where this genotype has bee n suggested to influence vascular 
remodelling.
279  As KIR2DL5 is present on the majority of B group haplotype s, we 
determined if a haplotypic association was relevant for A MD or CNV formation in AMD.  
 
The observed KIR genotypes were grouped into AA, AB , and BB haplotypes based on gene 
content.  The KIR A halotype is “inhibitory” and conta ins KIR2DS4 and KIR2DL4 as 
activating KIR and is the most common KIR haplotype being  present in about 30% of the 
Caucasian population. The remaining genotypes were categ orised as B haplotypes.  The 
Southampton cohort with KIR2DS4 and KIR2DL4 as the only  activating receptors were 
thus  designated  “AA”  and  the  remainder  “AB/BB”.(table  4).  There  was  no  significant 
difference in the distribution of the AA and AB/BB  genotypes between the AMD cases and 
controls. 
 
Table 42. HLA C and KIR receptor paired genotype frequencies in AMD and controls.  
HLA  +  KIR 
genotypes 
AMD Group 
 n =104 (%) 
Control Group 
 n =93 (%)  
P  value
†   Odds  
Ratio
‡  
95% CI 
C1 + 2DL2  37 (35.6)  43 (46.2)  0.12  0.64  0.36 1.14 
C1 + 2DL3  87 (83.7)  77 (82.8)  0.87  1.06  0.50 2.25 
C1 + 2DL5  33 (31.7)  47 (50.5)  0.007*  0.45  0.25 0.81  
C1 + 2DS2  37 (35.6)  45 (48.4)  0.07  0.59  0.33 1.04 
C7 + 2DL2  27 (26.0)  27 (29.0)  0.62  0.86  0.46 1.60 
C7 + 2DL3  62 (59.6)  43 (46.2)  0.06  1.71  0.97 3.02 
C7 + 2DL5  22 (21.1)  28 (30.1)  0.15  0.62  0.32 1.19 
C7 + 2DS2  28 (26.9)  29 (31.2)  0.51  0.81  0.44 1.50 
Cw*0701 + 2DL2  19 (18.3)  14 (15.1)  0.54  1.26  0.59 2 .68 
Cw*0701 + 2DL3   18 (17.3)  24 (25.8)  0.14  0.60  0.30  1.20 
Cw*0701 + 2DL5  13 (12.5)  18 (19.3)  0.19  0.59  0.27 1 .29 
Cw*0701 + 2DS2  20 (19.2)  15 (16.1)  0.57  1.23  0.59 2 .59 
† Two sided  P  values using chi squared test. 
‡ Odds Ratio using the approximation of Woolf.  
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To further test the KIR – HLA haplotype model of Hiby et al  
279 , we performed univariate 
analyses. Variables tested in this analysis included co mbined frequencies of the C1 group of 
HLA alleles, the individual HLA alleles,  Cw*07, Cw*0701  and the AA KIR haplotypes 
(table 6). The combination of total HLA Cw*07 alleles a nd KIR AA haplotypes correlated 
significantly with AMD status (odds ratio= 3.36,  P =0.003,  P c =0.018). When looking at the 
individual HLA C*0701 allele and KIR AA haplotypes in co mbination, a strong association 
was seen with AMD. The odds ratio risk for AMD was signifi cant at 4.35 ( P =0.006, 
P c =0.036) for this HLA KIR allele combination.  
In order to distinguish these independent variables, we  performed  multivariate analysis by 
logistic regression using the binary logit model with ba ckward elimination (table 7). The 
significance of the HLA Cw*0701   KIR AA paired associat ion with AMD did not alter 
after this analysis. No significance was found with KIR 2 DL5 and KIR AA genotypes in the 
regression model. Interestingly, the effect of HLA Cw*0701  when KIR AA genotypes were 
removed was found to be non significant.    
 Table 43. HLA C and KIR genotype paired frequencies in S outhampton AMD and controls. 
 
HLA  +  KIR 
genotype 
AMD Group  
 n =104 (%) 
Control Group 
 n =93 (%)  
P  
value
†  
P c  
value
§  
Odds  
Ratio
‡  
95% CI 
C*1 + AA  31 (29.8)  23 (24.7)  0.42  2.52  1.29  0.68 2.43 
Cw*07 + AA  25 (24.0)  8 (8.6)  0.003*  0.018*  3.36  1.43 7 .89 
Cw*0701 + AA  17 (16.3)  4 (4.3)  0.006*  0.036*  4.34  1.40  13.44 
C*1 + AB/BB  67 (64.4)  70 (75.3)  0.09  0.54  0.59  0.32 1 .10 
Cw*07 + AB/BB  38 (36.5)  38 (40.9)  0.54  3.24  0.83  0.47  1.48 
Cw*0701  + AB/BB  26 (25.0)  21 (22.6)  0.69  4.14  1.14  0.5 9 2.21 
† Two sided  P  values using chi squared test (*Significant values); 
§ P c  indicates  P  values after 
application of Bonferroni correction factor (n=6). 
‡ Odds Ratio using the approximation of 
Woolf.  
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Further categorization was possible in 58 subjects i n the Southampton AMD group, who 
were  divided  into  4  sub groups  of  increasing  AMD  severit y;  dry  AMD,  occult  CNV, 
minimally  classic  CNV  and  predominantly  classic  CNV  b ased  on  available  fluorescein 
angiographic data. No significant difference or associa tions could be found in these patient 
sub groups when tested for HLA alleles C1, Cw*07, Cw *0701 or their combinations with 
KIR genes and KIR AB/BB or AA haplotypes (data not shown).  
 
7.5   DISCUSSION  
The importance of defining associations between HLA and K IR genes in AMD lies in 
providing new insights into its basic pathogenesis and  to help define an ‘at risk’ population 
for preventive measures to become applicable. Due to the  critical role of HLA in regulating 
the immune response, the majority of HLA gene polymorphisms  are known to result in 
functional amino acid substitutions in the expressed HLA mo lecules. These variant HLA 
molecules in turn affect the immune response to a vast r ange of antigens, with inter 
individual differences in immune responses to complex o r simple antigens
280 . Many HLA 
gene polymorphisms have been linked to susceptibility in  a large number of 
immunologically mediated diseases affecting the retina  and uvea of the eye, the skin, gut, 
endocrine and joint systems
281 . KIR gene models have now been proposed which 
genetically control levels of activation or inhibition
275 . Many KIR genes and combinations 
of HLA class I  KIR genotypes that predispose to activating rece ptor–ligand interactions 
have now been linked to autoimmune inflammatory diseases  like rheumatoid arthritis
282 , 
psoriatic arthritis
283 , psoriasis vulgaris
284 , etc. 
 
Significant associations have previously been reported be tween HLA DRB1*15 
( P c =0.000001) and DQB1*06 ( P c =0.00001) alleles and the development of CNV in  
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presumed ocular histoplasmosis syndrome
285 . These findings, along with the data from the 
current study, support the notion that certain HLA all eles are associated with CNV in 
various retinal diseases. Hence, further investigation of  these three HLA alleles in a larger 
and/or different cohort would be useful in determining  the amount of risk contributed by 
these alleles towards advanced AMD and CNV formation. 
 
The combined HLA Cw*0701 allele and KIR AA haplotype associ ation with AMD status 
was highly significant in the Southampton cohort when  tested by stepwise logistic 
regression analysis. The risk for disease was greater  than 4 fold when compared to controls 
for this paired HLA allele and KIR haplotype. Prepondera nce of inhibiting KIR 2DL5 in 
controls seems to be protective for AMD while the presence of an appropriate H LA C1 
ligand interaction seems to render an individual  more susceptible to AMD.  This may  be 
because KIR2DL5 is a component of the B group of haplotypes. Therefore its associa tion 
with protection from AMD could be an inverse correlate of the susceptibility ef fect of the 
A group of haplotypes.  Alternatively KIR2DL5 itself or the B group of haplotypes which 
contain the majority of the activating KIR may be protective against this di sorder. 
 
Traditionally, activating KIR genotypes have been reported as being import ant in 
inflammatory conditions. A weak association of the activating receptor–li gand pair 
KIR2DS2:HLA C 1 was observed in diabetes mellitus
286  . A correlation with an 
‘activating’ KIR genotype was also found in the chronic inflammatory idiopathic  
bronchiectasis
287 . This activating receptor association appears to be involved more in co 
stimulation or activation of T cells than of NK cells.
288    
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The underlying mechanisms by which KIR and HLA genes determ ine susceptibility to 
various ocular diseases has not been fully elucidated y et and it should be stressed that a 
KIR HLA association determined by a case control study doe s not necessarily confirm KIR 
HLA causality, but may reflect linkage disequilibrium (L D) with causal polymorphisms in 
other genes. The epistatic interactions of KIR with HLA ma ke this less likely though.  
Although we cannot exclude LD with non KIR HLA polymorphisms  as causal in AMD, our 
data bears similarities to that observed in pre eclamp sia.
279   In this disease the KIR HLA 
genotype of the mother and foetus seems to influence vascul ar remodelling in the placenta 
leading to pre eclampsia. This model could therefore be  relevant in AMD or in particular 
during CNV formation. 
 
It is important to note that the AA haplotype is a minim al KIR haplotype containing the 
inhibitory receptors for groups 1 and group 2 HLA C allotype s (KIR2DL1 and KIR2DL3) 
and the activating KIR2DL4 and KIR2DS4, the latter gene being  non functional in many 
individuals.
289 .As the KIR2DL3: HLA C interaction is considered one  of weak inhibition 
this halplotype is weakly inhibitory. This interaction  may confer susceptibility to AMD via 
either NK cells or via weak inhibition of KIR positive  T cells, which are predominantly of 
the antigen experienced effector memory type.
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Due to the extreme polymorphic nature of the KIR and HLA  gene regions, sampling 
variation between cases and controls can easily lead to  both false positive and false negative 
associations. Accordingly, a Bonferroni correction was appli ed in this study. Applying the 
correction for functionally well characterized KIR alleles p ermitted a realistic Bonferroni 
correction, rather than an over conservative correction for  all possible KIR alleles, which 
may cause even true positive associations to be discarde d.    
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This study had 80% power to detect significant differen ces in HLA allele frequencies 
between cases and controls at an alpha level of 0.05. For exa mple, for an allele occurring at 
a frequency of 10% in the control population, detectable o dds ratios are 2.3 for a 
predisposing allele and 0.5 for a protective allele with 9 5% confidence levels. The 
corresponding detectable odds ratio figures for KIR genes  was 2.9 for a predisposing 
genotype and 0.2 for a protective genotype with 95% confidence  levels. We may therefore 
have not detected smaller HLA and KIR associations with our  sample sizes. 
 
In  summary,  this  study  is  the  first  to  establish  HLA C/KIR  gene  mediat ed  genetic 
susceptibility in AMD . HLA AMD associations were reproducible to a major ext ent in a 
different  population  cohort.  These  could  therefore  be   important  for  AMD  among  most 
western  populations.  The  HLA  C*0701  allele  in  combinati on  with  inhibiting  KIR 
haplotypes  (AA  genotype)  is  strongly  associated  with  A MD.  Following  on  from  this 
hypothesis generating study, further larger studies in dif ferent ethnic populations are further 
needed to confirm these HLA KIR associations with AM D. In addition, where possible 
these studies should be complemented by functional stu dies to determine the contribution of 
these genes to the development of AMD. Dissecting the r ole of HLA and immune pathways 
in  AMD  may  ultimately  lead  to  opportunities  to  modul ate  these  pathways  by  precise 
pharmacological means and thus improve the visual outc ome in this devastating disease. 
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8.  CHAPTER EIGHT: SUMMARY AND FUTURE RESEARCH.  
8.1   SUMMARY 
In summary, evidence from my initial study of the HLA  system which is essential for the 
immune regulation of self and foreign peptides
150  points to an important mechanism which 
may contribute to susceptibility for immune mediated  attacks on RPE or endothelial cells in 
AMD. The HLA study showed that individuals harbouring the  HLA Cw*0701 allele had an 
increased risk of developing AMD
212  and also reported the localization of HLA class I and 
DR antigens in the choriocapillaris and drusen, respec tively
106;212 . These novel HLA AMD 
associations  were  reproducible  in  a  cohort  of  AMD  case s  and  controls  from Michigan. 
Therefore these HLA associations could predictably pl ay an important role in AMD among 
most western populations. This research has provided evidence f or our hypothesis of g enetic 
predisposition to inflammation as being important in a  significant proportion of AMD cases.  
 
Our results confirm previous CRP associations with AM D. Interleukin IL8 251A/T variant 
may have a pro inflammatory role in AMD while the ICAM 1 12959G/A variant appears to 
raise ICAM1 levels especially in cigarette smokers a nd could predict AMD development. 
The effect of smoking seen in AMD may thus be mediate d in part by increased expression 
of ICAM1. Finally, the strong association of the CFH Y402H  coding polymorphism with 
AMD was confirmed in our UK cohort, while no associa tion could be found between CRP 
levels  and  the  CFH  Y402H  polymorphism  in  AMD.  CFH  Y40 2H  association  was 
significantly strongest in the predominantly classic  CNV group both for CC (OR=17.87,  P = 
< 0.0001) and CT (OR=9.06,  P = 0.0002) genotypes. These patients seemed to have po orer 
visual outcomes following PDT, this was significant b oth in the CFH CC and CT genotype  
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groups ( P = 0.038; 50% of CC cases, n=13 and 45% of the CT cases,  n=12) who lost 15 or 
more ETDRS letters. 
Following  this  evidence  for  complement  activation  in  A MD,  I  tested  other 
epidemiologically  similar  diseases  like  coronary  heart  d isease  and  atherosclerosis 
(characterized by lipid like deposits similar to drusen i n AMD) for possible association with 
the CFH Y402H polymorphism.  No evidence was found in  this large UK Caucasian cohort 
to  link  this  CFH  polymorphism  with  CHD,  coronary  arte ry  disease  severity  (CAD), 
recurrence of myocardial infarction or plasma levels of ch olesterol and triglycerides. 
 
In addition to testing various immune linked genetic pathways, I also e valuated critical 
genes encoding structural membrane proteins which may have func tional implications in 
AMD. Although the fibulin group of genes have been strong  associated with AMD and 
novel fibulin5 missense mutations have been found in  our cohort, mutation screening of 
linked candidate genes responsible for basement memb rane integrity and elastinogenesis 
(LOXL1), and testing for promoter region SNP's in PEDF  and CRYAA genes did not yield 
significant results. These null findings need to be confi rmed by studying other population 
cohorts and also perhaps by LD based studies.  
     
Following the HLA results, further analysis of their in teraction with KIR ligands in AMD 
was undertaken. Healthy cells are protected from sponta neous killing when they express an 
appropriate  HLA  class  I  ligand  for  an  inhibitory  KIR   receptor  expressed  on  NK  cells. 
Analysis of KIR genotypes in AMD showed that HLA C*070 1 allele in combination with 
inhibiting KIR haplotypes (AA genotype) is strongly asso ciated with AMD status ( P =0.006, 
P c =0.036, OR= 4.34).  HLA C/KIR gene mediated genetic susceptibility in AMD seems 
important and needs to be explored  in different population studies.  
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8.2   FUTURE RESEARCH 
Following on from this hypothesis generating research,  further larger studies in different 
ethnic populations are needed to confirm these HLA KI R associations with AMD. To this 
end, complete HLA class I genotyping and KIR genotypi ng is planned to be done in the 
Michigan cohort. Functional studies need to be undertak en to determine the contribution of 
these genes to the development of AMD. The effect of thes e genotypes on outcomes to 
AMD treatments need to be assessed prospectively. Dissect ing the role of other immune 
pathways in AMD would ultimately lead to ways to mod ulate these pathways by precise 
pharmacological means and thus improve the visual outc ome in this devastating disease. 
  
145  
PUBLICATIONS  
1.    Age related macular degeneration is associated with t he HLA Cw*0701 genotype and 
Natural Killer cell receptor AA haplotype. SV Goverdhan, S I Khakoo, A Swaroop, J 
Heckenlively, X Chen, AJ Lotery, Accepted for publication i n IOVS (May 2008). 
2.   Interleukin 8 promoter polymorphism  251A/T is a risk facto r for age related macular  
degeneration. SV Goverdhan, S Ennis, SR Hannan, KC Madhus udhana, AJ Cree, AJ 
Luff, AJ Lotery. Br J Ophthalmol. 2008 Apr;92(4):537 40. E pub 2008 Feb 29. 
3.   An analysis of the CFH Y402H genotype in AMD patients and con trols from the UK, 
and response to PDT treatment. SV Goverdhan, S Hannan, RB N ewsom, AJ Luff, H 
Griffiths, AJ Lotery. Eye, 2007 Apr 27; [Epub]. 
4.    Complement Factor H Y402H gene polymorphism in coronary  artery disease and 
atherosclerosis. SV Goverdhan, AJ Lotery, AJ Cree, S Ye , Atherosclerosis, 
2006;188:213 214. 
4. HLA and eye disease: a synopsis. SV Goverdhan, WM Howe ll, AJ Lotery, Review,       
     International Journal of Immunogenetics, 2005;32:333 42.   
5. Association of HLA class I and class II polymorphisms w ith age related macular     
    degeneration. SV Goverdhan, WM Howell, RF Mullins,  C Osmond, PR Hodgkins, J    
     Self, K Avery, AJ Lotery. Invest Ophthalmol Vis Sci  2005;46:1726 34. 
6. Macular degeneration associated with a novel Treache r Collins TCOF1 mutation  
    and evaluation of this mutation in Age related macular  degeneration. SV Goverdhan, IK   
   Temple, J Self, AJ Lotery, MJ Dixon, AR   Evans, Br. J. Ophthalmol, 89, 1063 1064. 
7. Newer insights into the molecular genetics of Age  related macular degeneration. 
     SV Goverdhan, AJ Lotery. Eye News 2005;12(2):9 14.  
8.  Radiotherapy for Age related Macular Degeneration : no more pilot studies please. 
     SV Goverdhan, FA Gibbs, A J Lotery. Editorial. Eye. 2 004 Oct 22; (Epub).  
146  
9.  Age related  macular  degeneration:  Where  are  we  n ow?  SV Goverdhan, AJ  Luff, AJ 
Booth, AJ lotery. Review. Optometry today, 2004;44(24) D ec:39 43. 
PRESENTATIONS   
1.   “HLA Cw*0701 Genotype and Natural Killer Cell Receptor  AA Haplotype are associated 
with Age related macular degeneration”.  ARVO annual m eeting, Florida, April 2008. 
2.    “HLA genotypes and Age related macular degeneration: A re plication study in a North 
American cohort”.  ARVO annual meeting, Florida, May 2007.  
3.   “Does  CFH  Y402H  Polymorphism  Influence  Visual  Outcome s  Following  V PDT 
Therapy for    Age Related Macular Degeneration?”  Pa per at ARVO annual meeting, 
Florida, May 2006.  
4.   “Novel HLA gene polymorphisms in age related macular Dege neration”.  
  Paper at Royal Society of Medicine, London June 2005.   
5.   “HLA polymorphisms in Age related macular degeneration” .  
   Rapid fire presentation at RCO annual congress, Birmingh am, May 2005. 
5.   “CRP and sICAM 1 as biomarkers in Age related macular d egeneration.” 
     Paper at ARVO annual meeting, Florida, May 2005. 
6.   “Association of HLA class I and class II polymorphisms wit h age related macular   
      Degeneration”. Presented at the House of Lords parli amentary meeting for   
      researchers, London, Mar 2005.  
7.   “Association of HLA polymorphisms in Age related macula r degeneration” 
     ARVO meeting, Florida, April 2004. 
8.   “Current status of nutritional supplementation and smok ing in patients with age            
     related macular degeneration (AMD): implication s from AREDS” 
     RCO Annual Congress, May 2004.  
147  
9.   “Macular degeneration associated with a novel Treacher C ollins TCOF1 mutation and 
evaluation of this mutation in Age related macular degen eration” European Pediatric 
Ophthalmological Society meeting, Manchester, Oct 2004. 
 
 
Reference List 
 
  1.   Royal College of Ophthalmologists. A national rese arch strategy for ophthalmology. 
Royal College of Ophthalmologists, London.  5 10. 
  2.   Brody, B. L., Gamst, A. C., Williams, R. A., Smith,  A. R., Lau, P. W., Dolnak, D., 
Rapaport, M. H., Kaplan, R. M., and Brown, S. I. Depression , visual acuity, 
comorbidity, and disability associated with age related  macular degeneration. 
Ophthalmology 108(10), 1893 1900. 
  3.   Bird, A. C., Bressler, N. M., Bressler, S. B., Chisho lm, I. H., Coscas, G., Davis, M. 
D., de Jong, P. T., Klaver, C. C., Klein, B. E., Klein, R ., and . An international 
classification and grading system for age related maculopa thy and age related 
macular degeneration. The International ARM Epidemiologica l Study Group. 
Surv.Ophthalmol. 39(5), 367 374. 
  4.   Bressler, N. M., Bressler, S. B., Seddon, J. M., Gr agoudas, E. S., and Jacobson, L. P. 
Drusen characteristics in patients with exudative versus  non exudative age related 
macular degeneration. Retina 8(2), 109 114. 
  5.   Pauleikhoff, D., Barondes, M. J., Minassian, D., Chi sholm, I. H., and Bird, A. C. 
Drusen as risk factors in age related macular disease. A m.J.Ophthalmol. 109(1), 38 
43.  
148  
  6.   MPS study group. Subfoveal neovascular lesions in age  related macular 
degeneration. Guidelines for evaluation and treatment in the  macular 
photocoagulation study. Macular Photocoagulation Study G roup [see comments]. 
Arch Ophthalmol 109(9), 1242 57. 
  7.   Farkas, T. G., Sylvester, V., and Archer, D. The ul trastructure of drusen. 
Am.J.Ophthalmol. 71(6), 1196 1205. 
  8.   Wolter, J. R and Falls, H. F. Bilateral confluent dr usen. Arch.Ophthalmol. 68, 219 
226. 
  9.   Farkas, T. G., Sylvester, V., Archer, D., and Altona,  M. The histochemistry of 
drusen. Am.J.Ophthalmol. 71(6), 1206 1215. 
  10.   Newsome, D. A., Hewitt, A. T., Huh, W., Robey, P. G.,  and Hassell, J. R. Detection 
of specific extracellular matrix molecules in drusen, Bruch' s membrane, and ciliary 
body. Am.J.Ophthalmol. 104(4), 373 381. 
  11.   Dentchev, T., Milam, A. H., Lee, V. M., Trojanowski , J. Q., and Dunaief, J. L. 
Amyloid beta is found in drusen from some age related m acular degeneration 
retinas, but not in drusen from normal retinas. Mol.Vis.  9, 184 190. 
  12.   Hageman, G. S., Luthert, P. J., Victor Chong, N. H., Jo hnson, L. V., Anderson, D. 
H., and Mullins, R. F. An integrated hypothesis that co nsiders drusen as biomarkers 
of immune mediated processes at the RPE Bruch's membrane  interface in aging and 
age related macular degeneration. Prog.Retin.Eye Res.  20(6), 705 732.  
149  
  13.   Mullins, R. F. and Hageman, G. S. Human ocular dru sen possess novel core 
domains with a distinct carbohydrate composition. J.His tochem.Cytochem. 47(12), 
1533 1540. 
  14.   Seddon, J. M., Willett, W. C., Speizer, F. E., a nd Hankinson, S. E. A prospective 
study of cigarette smoking and age related macular dege neration in women. JAMA 
276(14), 1141 1146. 
  15.   de Jong, P. T., Bergen, A. A., Klaver, C. C., van Dui jn, C. M., and Assink, J. M. 
Age related maculopathy: its genetic basis. Eye 15(Pt 3) , 396 400. 
  16.   Klaver, C. C., Kliffen, M., van Duijn, C. M., Hofma n, A., Cruts, M., Grobbee, D. E., 
van Broeckhoven, C., and de Jong, P. T. Genetic associati on of apolipoprotein E 
with age related macular degeneration. Am J Hum.Genet.  63(1), 200 206. 
  17.   Klaver, C. C., Wolfs, R. C., Assink, J. J., van Du ijn, C. M., Hofman, A., and de 
Jong, P. T. Genetic risk of age related maculopathy. P opulation based familial 
aggregation study. Arch.Ophthalmol. 116(12), 1646 1651. 
  18.   Heiba, I. M., Elston, R. C., Klein, B. E., and Klei n, R. Sibling correlations and 
segregation analysis of age related maculopathy: the Be aver Dam Eye Study. 
Genetic Epidemiology 11(1), 51 67. 
  19.   Schultz, D. W., Klein, M. L., Humpert, A. J., Luzie r, C. W., Persun, V., Schain, M., 
Mahan, A., Runckel, C., Cassera, M., Vittal, V., Doyle, T.  M., Martin, T. M., 
Weleber, R. G., Francis, P. J., and Acott, T. S. Analysi s of the ARMD1 locus: 
evidence that a mutation in HEMICENTIN 1 is associate d with age related macular 
degeneration in a large family. Hum.Mol.Genet. 12(24), 331 5 3323.  
150  
  20.   Allikmets, R., Seddon, J. M., Bernstein, P. S.,  Hutchinson, A., Atkinson, A., 
Sharma, S., Gerrard, B., Li, W., Metzker, M. L., Wadeliu s, C., Caskey, C. T., Dean, 
M., and Petrukhin, K. Evaluation of the Best disease gene  in patients with age 
related macular degeneration and other maculopathies. H um Genet 104(6), 449 53. 
  21.   Marquardt, A., Stohr, H., Passmore, L. A., Kramer, F. , Rivera, A., and Weber, B. H. 
Mutations in a novel gene, VMD2, encoding a protein of unk nown properties cause 
juvenile onset vitelliform macular dystrophy (Best's dis ease). Hum Mol Genet 7(9), 
1517 25. 
  22.   Rivera, A., White, K., Stohr, H., Steiner, K., Hemm rich, N., Grimm, T., Jurklies, B., 
Lorenz, B., Scholl, H. P., Apfelstedt Sylla, E., and Weber , B. H. A comprehensive 
survey of sequence variation in the ABCA4 (ABCR) gene in  Stargardt disease and 
age related macular degeneration. Am J Hum Genet 67(4) , 800 13. 
  23.   Weber, B. H., Vogt, G., Pruett, R. C., Stohr, H., and  Felbor, U. Mutations in the 
tissue inhibitor of metalloproteinases 3 (TIMP3) in patie nts with Sorsby's fundus 
dystrophy. Nat Genet 8(4), 352 6. 
  24.   Lotery, A. J., Munier, F. L., Fishman, G. A., Weleber , R. G., Jacobson, S. G., 
Affatigato, L. M., Nichols, B. E., Schorderet, D. F., Sheff ield, V. C., and Stone, E. 
M. Allelic variation in the VMD2 gene in best disease an d age related macular 
degeneration. Invest Ophthalmol.Vis.Sci. 41(6), 1291 1296. 
  25.   Nichols, B., Sheffield, V., Vadenburgh, K., Drack, A. , Kimura, A., and Stone, E. 
Butterfly shaped pigment dystrophy of fovea caused by a  point mutation in codon 
167 of RDS gene. Nature Genetics 3, 202 207.  
151  
  26.   Zhang, K., Nguyen, T. E., Crandall, A., and Donoso, L. A . Genetic and Molecular 
Studies of Macular Dystrophies: Recent Developments.  Survey of Ophthalmology 
40(1), 51 61. 
  27.   Stone, E. M., Webster, A. R., Vandenburgh, K., S treb, L. M., Hockey, R. R., Lotery, 
A. J., and Sheffield, V. C. Allelic variation in ABCR as sociated with Stargardt 
disease but not age  related macular degeneration [le tter]. Nat Genet 20(4), 328 9. 
  28.   Klein, M. L., Mauldin, W. M., and Stoumbos, V. D . Heredity and age related 
macular degeneration. Observations in monozygotic twins. A rchives of 
Ophthalmology 112(7), 932 937. 
  29.   Meyers, S. M., GREENE, T., and GUTMAN, F. A. A tw in study of age related 
macular degeneration. American Journal of Ophthalmology 120,  757 766. 
  30.   Gottfredsdottir, M. S., Sverrisson, T., Musch, D.  C., and Stefansson, E. Age related 
macular degeneration in monozygotic twins and their spou ses in Iceland. Acta 
Ophthalmol.Scand. 77(4), 422 425. 
  31.   Piguet, B., Haimovici, R., and Bird, A. C. Dominant ly inherited drusen represent 
more than one disorder: a historical review. Eye 9(( Pt 1 )), 34 41. 
  32.   Smith, W., Assink, J., Klein, R., Mitchell, P ., Klaver, C. C., Klein, B. E., Hofman, 
A., Jensen, S., Wang, J. J., and de Jong, P. T. Risk fac tors for age related macular 
degeneration: Pooled findings from three continents. O phthalmology 108(4), 697 
704.  
152  
  33.   Hyman, L. G., Lilienfeld, A. M., Ferris, F. L. 3d, an d Fine, S. L. Senile macular 
degeneration: a case control study. American Journal o f Epidemiology 118(2), 213 
227. 
  34.   Seddon, J. M., Ajani, U. A., and Mitchell, B. D. F amilial aggregation of age related 
maculopathy. Am J Ophthalmol 123(2), 199 206. 
  35.   Silvestri, G., Johnston, P. B., and Hughes, A. E. Is gen etic predisposition an 
important risk factor in age related macular degenerati on? Eye 8 ( Pt 5), 564 568. 
  36.   Dryja, T. P., Hahn, L. B., Kajiwara, K., and Berson,  E. L. Dominant and digenic 
mutations in the peripherin/RDS and ROM1 genes in retin itis pigmentosa. Invest 
Ophthalmol.Vis.Sci. 38(10), 1972 1982. 
  37.   Stone, E. M., Lotery, A. J., Munier, F. L., Heon, E ., Piguet, B., Guymer, R. H., 
Vandenburgh, K., Cousin, P., Nishimura, D., Swiderski, R. E.,  Silvestri, G., Mackey, 
D. A., Hageman, G. S., Bird, A. C., Sheffield, V. C., and  Schorderet, D. F. A single 
EFEMP1 mutation associated with both Malattia Leventines e and Doyne 
honeycomb retinal dystrophy. Nat Genet 22(2), 199 202. 
  38.   Stone, E. M., Braun, T. A., Russell, S. R., Kuehn, M . H., Lotery, A. J., Moore, P. A., 
Eastman, C. G., Casavant, T. L., and Sheffield, V. C. Mis sense variations in the 
fibulin 5 gene and age related macular degeneration. N.Eng l.J.Med. 351(4), 346 
353. 
  39.   Klaver, C. C., Kliffen, M., van Duijn, C. M., Hofma n, A., Cruts, M., Grobbee, D. E., 
van Broeckhoven, C., and de Jong, P. T. Genetic associati on of apolipoprotein E 
with age related macular degeneration. Am J Hum.Genet.  63(1), 200 206.  
153  
  40.   Klein, M. L., Schultz, D. W., Edwards, A., Matise , T. C., Rust, K., Berselli, C. B., 
Trzupek, K., Weleber, R. G., Ott, J., Wirtz, M. K., and A cott, T. S. Age related 
macular degeneration. Clinical features in a large family  and linkage to chromosome 
1q. Arch Ophthalmol 116(8), 1082 8. 
  41.   Zurdel, J., Finckh, U., Menzer, G., Nitsch, R. M., a nd Richard, G. CST3 genotype 
associated with exudative age related macular degenerat ion. Br.J.Ophthalmol. 86(2), 
214 219. 
  42.   Kimura, K., Isashiki, Y., Sonoda, S., Kakiuchi Mat sumoto, T., and Ohba, N. Genetic 
association of manganese superoxide dismutase with exuda tive age related macular 
degeneration. Am.J.Ophthalmol. 130(6), 769 773. 
  43.   Zareparsi, S., Buraczynska, M., Branham, K. E., Shah,  S., Eng, D., Li, M., Pawar, 
H., Yashar, B. M., Moroi, S. E., Lichter, P. R., Petty, H.  R., Richards, J. E., 
Abecasis, G. R., Elner, V. M., and Swaroop, A. Toll like re ceptor 4 variant D299G 
is associated with susceptibility to age related macul ar degeneration. 
Hum.Mol.Genet.  
  44.   Hamdi, H. K., Reznik, J., Castellon, R., Atilano , S. R., Ong, J. M., Udar, N., Tavis, 
J. H., Aoki, A. M., Nesburn, A. B., Boyer, D. S., Small, K . W., Brown, D. J., and 
Kenney, M. C. Alu DNA polymorphism in ACE gene is protec tive for age related 
macular degeneration. Biochem.Biophys.Res.Commun. 295(3 ), 668 672. 
  45.   Seddon, J. M., Gensler, G., Milton, R. C., Klein , M. L., and Rifai, N. Association 
between C reactive protein and age related macular dege neration. JAMA 291(6), 
704 710.  
154  
  46.   Haines, J. L., Hauser, M. A., Schmidt, S., Scott,  W. K., Olson, L. M., Gallins, P., 
Spencer, K. L., Kwan, S. Y., Noureddine, M., Gilbert, J.  R., Schnetz Boutaud, N., 
Agarwal, A., Postel, E. A., and Pericak Vance, M. A. Compl ement factor H variant 
increases the risk of age related macular degeneratio n. Science 308(5720), 419 421. 
  47.   Klein, R. J., Zeiss, C., Chew, E. Y., Tsai, J. Y.,  Sackler, R. S., Haynes, C., Henning, 
A. K., Sangiovanni, J. P., Mane, S. M., Mayne, S. T., Bra cken, M. B., Ferris, F. L., 
Ott, J., Barnstable, C., and Hoh, J. Complement factor  H polymorphism in age 
related macular degeneration. Science 308(5720), 385 389 . 
  48.   Edwards, A. O., Ritter, Iii R., Abel, K. J., Mann ing, A., Panhuysen, C., and Farrer, 
L. A. Complement Factor H Polymorphism and Age Related  Macular Degeneration. 
Science . 
  49.   Rodriguez, de Cordoba, Esparza Gordillo, J., Goic oechea, de Jorge, Lopez Trascasa, 
M., and Sanchez Corral, P. The human complement factor H : functional roles, 
genetic variations and disease associations. Mol.Immuno l. 41(4), 355 367. 
  50.   Mullins, R. F., Aptsiauri, N., and Hageman, G. S.  Structure and composition of 
drusen associated with glomerulonephritis: implications  for the role of complement 
activation in drusen biogenesis. Eye 15(Pt 3), 390 5. 
  51.   Mullins, R. F., Russell, S. R., Anderson, D. H.,  and Hageman, G. S. Drusen 
associated with aging and age related macular degenera tion contain proteins 
common to extracellular deposits associated with atheros clerosis, elastosis, 
amyloidosis, and dense deposit disease. FASEB J. 14(7),  835 846. 
  52.   Hageman, G. S., Luthert, P. J., Victor Chong, N. H., Jo hnson, L. V., Anderson, D. 
H., and Mullins, R. F. An integrated hypothesis that co nsiders drusen as biomarkers  
155  
of immune mediated processes at the RPE Bruch's membrane  interface in aging and 
age related macular degeneration. Prog.Retin.Eye Res.  20(6), 705 732. 
  53.   Streilein, J. W., Wilbanks, G. A., and Cousins,  S. W. Immunoregulatory 
mechanisms of the eye. J Neuroimmunol. 39(3), 185 200. 
  54.   Penfold, P. L., Madigan, M. C., Gillies, M. C., and  Provis, J. M. Immunological and 
aetiological aspects of macular degeneration. Prog.Retin.E ye Res. 20(3), 385 414. 
  55.   Penfold, P. L., Killingsworth, M. C., and Sarks, S . H. Senile macular degeneration: 
the involvement of immunocompetent cells. Graefes Arch. Clin.Exp.Ophthalmol. 
223(2), 69 76. 
  56.   Penfold, P. L., Killingsworth, M. C., and Sarks, S . H. Senile macular degeneration. 
The involvement of giant cells in atrophy of the retinal p igment epithelium. Invest 
Ophthalmol Vis.Sci. 27(3), 364 371. 
  57.   Dastgheib, K. and Green, W. R. Granulomatous reacti on to Bruch's membrane in 
age related macular degeneration. Arch Ophthalmol 112 (6), 813 818. 
  58.   Penfold, P. L., Killingsworth, M. C., and Sarks, S . H. Senile macular degeneration: 
the involvement of immunocompetent cells. Graefes Arch. Clin.Exp.Ophthalmol. 
223(2), 69 76. 
  59.   Ambati, J., Anand, A., Fernandez, S., Sakurai, E.,  Lynn, B. C., Kuziel, W. A., 
Rollins, B. J., and Ambati, B. K. An animal model of age  related macular 
degeneration in senescent Ccl 2  or Ccr 2 deficient m ice. Nat.Med. 9(11), 1390 
1397.  
156  
  60.   Penfold, P. L., Provis, J. M., Furby, J. H., Gate nby, P. A., and Billson, F. A. 
Autoantibodies to retinal astrocytes associated with age  related macular 
degeneration. Graefes Arch.Clin.Exp.Ophthalmol. 228(3),  270 274. 
  61.   Gurne, D. H., Tso, M. O., Edward, D. P., and Ripps,  H. Antiretinal antibodies in 
serum of patients with age related macular degeneration . Ophthalmology 98(5), 602 
607. 
  62.   Kalayoglu, Murat V., Galvan, Carlos, Mahdi, Olaima tu S., Byrne, Gerald I., and 
Mansour, Sam. Serological Association Between Chlamydia  pneumoniae Infection 
and Age Related Macular Degeneration. Archives of Ophtha lmology 121(4), 478. 
  63.   Taubes, G. Cardiovascular disease. Does inflammati on cut to the heart of the matter? 
Science 296(5566), 242 245. 
  64.   Hall, Nigel F., Gale, Catharine R., Syddall, Holly, P hillips, David I. W., and Martyn, 
Christopher N. Risk of macular degeneration in users of st atins: cross sectional 
study. Bmj 323(7309), 375. 
  65.   Seddon, J. M., George, S., Rosner, B., and Rifai, N . Progression of age related 
macular degeneration: prospective assessment of C reacti ve protein, interleukin 6, 
and other cardiovascular biomarkers. Arch.Ophthalmol. 123 (6), 774 782. 
  66.   Goverdhan, S. V., Rose Zerilli, M, Howell, M. W.,  Chong, V., Osmond, C, and 
Lotery, A. J. CRP and sICAM 1 as Biomarkers in Age Related  Macular 
Degeneration. Association for Research in Vision and Oph thalmology(ARVO).  
abstract 1147.  
157  
  67.   Young, R. W. Pathophysiology of age related macul ar degeneration. Surv 
Ophthalmol 31(5), 291 306. 
  68.   Delcourt, C., Michel, F., Colvez, A., Lacroux, A., D elage, M., and Vernet, M. H. 
Associations of cardiovascular disease and its risk factor s with age related macular 
degeneration: the POLA study. Ophthalmic Epidemiol. 8(4) , 237 249. 
  69.   Hyman, L. and Neborsky, R. Risk factors for age relat ed macular degeneration: an 
update. Curr.Opin.Ophthalmol. 13(3), 171 175. 
  70.   Snow, K. K. and Seddon, J. M. Do age related macu lar degeneration and 
cardiovascular disease share common antecedents? Ophtha lmic Epidemiol. 6(2), 
125 143. 
  71.   Bressler, N. M. Photodynamic therapy of subfoveal ch oroidal neovascularization in 
age  related macular degeneration with verteporfin: t wo year results of 2 randomized 
clinical trials tap report 2. Arch Ophthalmol 119(2), 1 98 207. 
  72.   Blumenkranz, M. S., Bressler, N. M., Bressler, S. B ., Donati, G., Fish, G. E., 
Haynes, L. A., Lewis, H., Miller, J. W., Mones, J. M., Pot ter, M. J., Pournaras, C., 
Reaves, A., Rosenfeld, P. J., Schachat, A. P., Schmidt  Erfurth, U., Sickenburg, M., 
Singerman, L. J., Slakter, J. S., Strong, A., and Vannier , S. Verteporfin therapy for 
subfoveal choroidal neovascularization in age related macul ar degeneration: three 
year results of an open label extension of 2 randomized c linical trials  TAP Report 
no. 5. Arch.Ophthalmol. 120(10), 1307 1314. 
  73.   Blinder, K. J., Bradley, S., Bressler, N. M., Bressl er, S. B., Donati, G., Hao, Y., Ma, 
C., Menchini, U., Miller, J., Potter, M. J., Pournaras,  C., Reaves, A., Rosenfeld, P. J., 
Strong, H. A., Stur, M., Su, X. Y., and Virgili, G. Effec t of lesion size, visual acuity,  
158  
and lesion composition on visual acuity change with and wi thout verteporfin therapy 
for choroidal neovascularization secondary to age relat ed macular degeneration: 
TAP and VIP report no. 1. Am.J.Ophthalmol. 136(3), 407 41 8. 
  74.   Grossniklaus, H. E., Ling, J. X., Wallace, T. M., Di thmar, S., Lawson, D. H., Cohen, 
C., Elner, V. M., Elner, S. G., and Sternberg, P., Jr. M acrophage and retinal pigment 
epithelium expression of angiogenic cytokines in choroidal  neovascularization. 
Mol.Vis. 8, 119 126. 
  75.   Kijlstra, A., La, Heij E., and Hendrikse, F. Immun ological factors in the 
pathogenesis and treatment of age related macular degen eration. 
Ocul.Immunol.Inflamm. 13(1), 3 11. 
  76.   Vinores, S. A. Technology evaluation: pegaptanib, Ey etech/Pfizer. 
Curr.Opin.Mol.Ther. 5(6), 673 679. 
  77.   Rich, R. M., Rosenfeld, P. J., Puliafito, C. A. , Dubovy, S. R., Davis, J. L., Flynn, H. 
W., Jr., Gonzalez, S., Feuer, W. J., Lin, R. C., Lalwani , G. A., Nguyen, J. K., and 
Kumar, G. Short term safety and efficacy of intravitr eal bevacizumab (Avastin) for 
neovascular age related macular degeneration. Retina 26( 5), 495 511. 
  78.   Avery, R. L., Pieramici, D. J., Rabena, M. D., C astellarin, A. A., Nasir, M. A., and 
Giust, M. J. Intravitreal bevacizumab (Avastin) for neovas cular age related macular 
degeneration. Ophthalmology 113(3), 363 372. 
  79.   Bashshur, Z. F., Bazarbachi, A., Schakal, A., Haddad, Z.  A., El Haibi, C. P., and 
Noureddin, B. N. Intravitreal bevacizumab for the managem ent of choroidal 
neovascularization in age related macular degeneration . Am.J.Ophthalmol. 142(1), 
1 9.  
159  
  80.   Pieramici, D. J. and Avery, R. L. Ranibizumab: t reatment in patients with 
neovascular age related macular degeneration. Expert.Opi n.Biol.Ther. 6(11), 1237 
1245. 
  81.   Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boy er, D. S., Kaiser, P. K., Chung, C. 
Y., and Kim, R. Y. Ranibizumab for neovascular age relate d macular degeneration. 
N.Engl.J.Med. 355(14), 1419 1431. 
  82.   Lotery, A. J., Yang, G. S., Mullins, R. F., Russell, S . R., Schmidt, M., Stone, E. M., 
Lindbloom, J. D., Chiorini, J. A., Kotin, R. M., and Davi dson, B. L. Adeno 
associated virus type 5: transduction efficiency and cell  type specificity in the 
primate retina. Hum.Gene Ther. 14(17), 1663 1671. 
  83.   Rasmussen, H., Chu, K. W., Campochiaro, P., Gehlb ach, P. L., Haller, J. A., Handa, 
J. T., Nguyen, Q. D., and Sung, J. U. Clinical protocol. A n open label, phase I, 
single administration, dose escalation study of ADGVPEDF .11D (ADPEDF) in 
neovascular age related macular degeneration (AMD). Hum. Gene Ther. 12(16), 
2029 2032. 
  84.   Klein, M. L. and Francis, P. J. Genetics of age rel ated macular degeneration. 
Ophthalmol.Clin.North Am. 16(4), 567 574. 
  85.   Hageman, G. S., Luthert, P. J., Victor Chong, N. H., Jo hnson, L. V., Anderson, D. 
H., and Mullins, R. F. An integrated hypothesis that co nsiders drusen as biomarkers 
of immune mediated processes at the RPE Bruch's membrane  interface in aging and 
age related macular degeneration. Prog.Retin.Eye Res.  20(6), 705 732. 
  86.   Anderson, D. H., Talaga, K. C., Rivest, A. J., Ba rron, E., Hageman, G. S., and 
Johnson, L. V. Characterization of beta amyloid assemb lies in drusen: the deposits  
160  
associated with aging and age related macular degenera tion. Exp.Eye Res. 78(2), 
243 256. 
  87.   Penfold, P. L., Madigan, M. C., Gillies, M. C., and  Provis, J. M. Immunological and 
aetiological aspects of macular degeneration. Prog.Retin.E ye Res. 20(3), 385 414. 
  88.   Zarbin, M. A. Current concepts in the pathogenesis  of age related macular 
degeneration. Arch.Ophthalmol. 122(4), 598 614. 
  89.   Cooper, D. N., Smith, B. A., Cooke, H. J., Niemann,  S., and Schmidtke, J. An 
estimate of unique dna sequence heterozygosity in the hum an genome. Human 
Genetics 69, 201 205. 
  90.   Forrest, S., Cotton, R., Landegren, U., and Southe rn, E. M. How to find all those 
mutations. Nature Genetics 10, 375 376. 
  91.   Orita, M., Iwahana, H., Kanazawa, H., Hayashi, K.,  and Sekiya, T. Detection of 
polymorphisms of human DNA by gel electrophoresis as si ngle strand conformation 
polymorphisms. Proc Natl Acad Sci U S A 86(8), 2766 70. 
  92.   Sheffield, V. C., Beck, J. S., Kwitek, A. E., Sa ndstrom, D. W., and Stone, E. M. The 
sensitivity of single strand conformation polymorphism ana lysis for the detection of 
single base substitutions. Genomics 16(2), 325 32. 
  93.   Till, B. J., Burtner, C., Comai, L., and Henikoff, S . Mismatch cleavage by single 
strand specific nucleases. Nucleic Acids Res. 32(8), 2632  2641. 
  94.   Miller, S. A., Dykes, D. D., and Polesky, H. F. A si mple salting out procedure for 
extracting DNA from human nucleated cells. Nucleic Acids R es. 16(3), 1215.  
161  
  95.   Saiki, R. K., Scharf, S., Faloona, F., Mullis, K.  B., Horn, G. T., Erlich, H. A., and 
Arnheim, N. Enzymatic amplification of beta globin geno mic sequences and 
restriction site analysis for diagnosis of sickle cell a nemia. Science 230, 1350 1354. 
  96.   Rozen, S. and Skaletsky, H. Primer3 on the WWW fo r general users and for 
biologist programmers. Methods Mol.Biol. 132, 365 386. 
  97.   Risk factors associated with age related macul ar degeneration. A case control study 
in the age related eye disease study: age related eye d isease study report number 3. 
Age Related Eye Disease Study Research Group. Ophthalmo logy 107(12), 2224 
2232. 
  98.   Miller, S. A., Dykes, D. D., and Polesky, H. F. A si mple salting out procedure for 
extracting DNA from human nucleated cells. Nucleic Acids R es. 16(3), 1215. 
  99.   IMGT/HLA Sequence Database. European Bioinformati cs Institute. 
http://www.ebi.ac.uk/imgt/hla .  
  100.   Little, A. M. and Parham, P. Polymorphism and evolu tion of HLA class I and II 
genes and molecules. Rev.Immunogenet. 1(1), 105 123. 
  101.   Streilein, J. W. Ocular immune privilege: the e ye takes a dim but practical view of 
immunity and inflammation. J.Leukoc.Biol. 74(2), 179 185. 
  102.   Niederkorn, J. Y. Mechanisms of immune privilege i n the eye and hair follicle. 
J.Investig.Dermatol.Symp.Proc. 8(2), 168 172. 
  103.   Abi Hanna, D., Wakefield, D., and Watkins, S. HLA  antigens in ocular tissues. I. In 
vivo expression in human eyes. Transplantation 45(3), 6 10 613.  
162  
  104.   Penfold, P. L., Provis, J. M., and Liew, S. C. Hum an retinal microglia express 
phenotypic characteristics in common with dendritic ant igen presenting cells. J 
Neuroimmunol. 45(1 2), 183 191. 
  105.   Bakker, M., Grumet, F. C., Feltkamp, T. E., and Ki jlstra, A. HLA antigens in the 
human uvea. Doc.Ophthalmol. 61(3 4), 271 279. 
  106.   Penfold, P. L., Liew, S. C., Madigan, M. C., and  Provis, J. M. Modulation of major 
histocompatibility complex class II expression in retina s with age related macular 
degeneration. Invest Ophthalmol.Vis.Sci. 38(10), 2125 2133.  
  107.   Penfold, P. L., Wong, J. G., Gyory, J., and Billso n, F. A. Effects of triamcinolone 
acetonide on microglial morphology and quantitative expressi on of MHC II in 
exudative age related macular degeneration. Clin.Experiment .Ophthalmol. 29(3), 
188 192. 
  108.   Gillies, M. C., Simpson, J. M., Luo, W., Penfold,  P., Hunyor, A. B., Chua, W., 
Mitchell, P., and Billson, F. A randomized clinical trial  of a single dose of 
intravitreal triamcinolone acetonide for neovascular age  related macular 
degeneration: one year results. Arch.Ophthalmol. 121(5 ), 667 673. 
  109.   Jonas, J. B., Kreissig, I., Hugger, P., Sauder, G. , Panda Jonas, S., and Degenring, R. 
Intravitreal triamcinolone acetonide for exudative age r elated macular degeneration. 
Br.J.Ophthalmol. 87(4), 462 468. 
  110.   Spaide, Richard F., Sorenson, John, and Maranan, Le andro. Combined 
photodynamic therapy with verteporfin and intravitreal tr iamcinolone acetonide for 
choroidal neovascularization. Ophthalmology 110(8), 1517 152 5.  
163  
  111.   Goverdhan, S. V., Lotery, A. J., and Howell, W. M.  HLA and eye disease: a 
synopsis. Int.J.Immunogenet. 32(6), 333 342. 
  112.   Enzmann, V., Hollborn, M., Wiedemann, P., and Koh en, L. Molecular and cellular 
evidence for T cell stimulation by allogeneic retinal pig ment epithelium cells in 
vitro. Graefes Arch.Clin.Exp.Ophthalmol. 239(6), 445 451. 
  113.   Risk factors associated with age related macu lar degeneration. A case control study 
in the age related eye disease study: age related eye d isease study report number 3. 
Age Related Eye Disease Study Research Group. Ophthalmol ogy 107(12), 2224 
2232. 
  114.   Miller, S. A., Dykes, D. D., and Polesky, H. F. A s imple salting out procedure for 
extracting DNA from human nucleated cells. Nucleic Acids R es. 16(3), 1215. 
  115.   Bunce, M., O'Neill, C. M., Barnardo, M. C., Krausa,  P., Browning, M. J., Morris, P. 
J., and Welsh, K. I. Phototyping: comprehensive DNA typing  for HLA A, B, C, 
DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes  utilizing 
sequence specific primers (PCR SSP). Tissue Antigens  46(5), 355 367. 
  116.   Bateman, A. C., Sage, D. A., al Talib, R. K., The aker, J. M., Jones, D. B., and 
Howell, W. M. Investigation of specimen mislabelling  in paraffin embedded tissue 
using a rapid, allele specific, PCR based HLA class II typi ng method. 
Histopathology 28(2), 169 174. 
  117.   Olerup, O. and Zetterquist, H. HLA DR typing by  PCR amplification with 
sequence specific primers (PCR SSP) in 2 hours: an alt ernative to serological DR 
typing in clinical practice including donor recipient matc hing in cadaveric 
transplantation. Tissue Antigens 39(5), 225 235.  
164  
  118.   Schaffer, M. and Olerup, O. HLA AB typing by poly merase chain reaction with 
sequence specific primers: more accurate, less errors,  and increased resolution 
compared to serological typing. Tissue Antigens 58(5), 29 9 307. 
  119.   Bunce, M., Taylor, C. J., and Welsh, K. I. Rapid H LA DQB typing by eight 
polymerase chain reaction amplifications with sequence  specific primers (PCR 
SSP). Hum.Immunol. 37(4), 201 206. 
  120.   Olerup, O. and Zetterguist, H. DR "low resoluti on" PCR SSP typing  a correction 
and an up date. Tissue Antigens 41(1), 55 56. 
  121.   Hageman, G. S., Mullins, R. F., Russell, S. R., J ohnson, L. V., and Anderson, D. H. 
Vitronectin is a constituent of ocular drusen and the vit ronectin gene is expressed in 
human retinal pigmented epithelial cells. FASEB J 13(3 ), 477 484. 
  122.   Alex Lancaster, Mark P Nelson, Richard M Single, Diog o Meyer, and Glenys 
Thomson. PyPop: a software framework for population geno mics: analyzing large 
scale multi locus genotype data. Pacific Symposium on Bi ocomputing . 
  123.   Guo, S. W. and Thompson, E. A. Performing the exact  test of Hardy Weinberg 
proportion for multiple alleles. Biometrics 48(2), 361 37 2. 
  124.   Svejgaard, A. and Ryder, L. P. HLA and disease ass ociations: detecting the strongest 
association. Tissue Antigens 43(1), 18 27. 
  125.   Allele frequencies in worldwide populations.  http://www.datatechniques.biz/allele/  . 
  126.   Darke, C., Guttridge, M. G., Thompson, J., McN amara, S., Street, J., and Thomas, 
M. HLA class I (A, B) and II (DR, DQ) gene and haplotype freque ncies in blood 
donors from Wales. Exp.Clin.Immunogenet. 15(2), 69 83.  
165  
  127.   Finch, T., Lawlor, E., Borton, M., Barnes, C. A., M cNamara, S., O'Riordan, J., 
McCann, S. R., and Darke, C. Distribution of HLA A, B and DR  genes and 
haplotypes in the Irish population. Exp.Clin.Immunogenet. 14( 4), 250 263. 
  128.   Mullins, R. F., Russell, S. R., Anderson, D. H. , and Hageman, G. S. Drusen 
associated with aging and age related macular degenera tion contain proteins 
common to extracellular deposits associated with atheros clerosis, elastosis, 
amyloidosis, and dense deposit disease. FASEB J 14(7),  835 846. 
  129.   Howell, W. M., Calder, P. C., and Grimble, R. F . Gene polymorphisms, 
inflammatory diseases and cancer. Proc.Nutr.Soc. 61(4), 4 47 456. 
  130.   Thorsby, E. Invited anniversary review: HLA asso ciated diseases. Hum.Immunol. 
53(1), 1 11. 
  131.   Follmann, D. A. Comparing HLA antigen frequenci es between two groups of 
patients. Stat.Med. 22(12), 1999 2013. 
  132.   Svejgaard, A. and Ryder, L. P. HLA and disease ass ociations: detecting the strongest 
association. Tissue Antigens 43(1), 18 27. 
  133.   Thomson, W., Barrett, J. H., Donn, R., Pepper, L.,  Kennedy, L. J., Ollier, W. E., 
Silman, A. J., Woo, P., and Southwood, T. Juvenile idi opathic arthritis classified by 
the ILAR criteria: HLA associations in UK patients. Rheu matology.(Oxford) 41(10), 
1183 1189. 
  134.   Donaldson, P. T. and Norris, S. Evaluation of the  role of MHC class II alleles, 
haplotypes and selected amino acid sequences in primar y sclerosing cholangitis. 
Autoimmunity 35(8), 555 564.  
166  
  135.   Derhaag, P. J., Linssen, A., Broekema, N., de Waa l, L. P., and Feltkamp, T. E. A 
familial study of the inheritance of HLA B27 positive a cute anterior uveitis. Am J 
Ophthalmol. 105(6), 603 606. 
  136.   Derhaag, P. J., de Waal, L. P., Linssen, A., and Fe ltkamp, T. E. Acute anterior 
uveitis and HLA B27 subtypes. Invest Ophthalmol.Vis.Sci.  29(7), 1137 1140. 
  137.   Baarsma, G. S., Priem, H. A., and Kijlstra, A. As sociation of birdshot 
retinochoroidopathy and HLA A29 antigen. Curr.Eye Res. 9 Su ppl, 63 68. 
  138.   Bloch Michel, E. and Frau, E. Birdshot retinochoroido pathy and HLA A29+ and 
HLA A29  idiopathic retinal vasculitis: comparative stud y of 56 cases. 
Can.J.Ophthalmol. 26(7), 361 366. 
  139.   Kilmartin, D. J., Wilson, D., Liversidge, J., Dick , A. D., Bruce, J., Acheson, R. W., 
Urbaniak, S. J., and Forrester, J. V. Immunogenetics and cli nical phenotype of 
sympathetic ophthalmia in British and Irish patients. Br. J.Ophthalmol. 85(3), 281 
286. 
  140.   Oruc, S., Duffy, B. F., Mohanakumar, T., and Kaplan,  H. J. The association of HLA 
class II with pars planitis. Am.J.Ophthalmol. 131(5), 65 7 659. 
  141.   Lopez Vazquez, A., Rodrigo, L., Fuentes, D., Riestr a, S., Bousono, C., Garcia 
Fernandez, S., Martinez Borra, J., Gonzalez, S., and Lope z Larrea, C. MHC class I 
chain related gene A (MICA) modulates the development of  coeliac disease in 
patients with the high risk heterodimer DQA1*0501/DQB1*0 201. Gut 50(3), 336 
340.  
167  
  142.   Cavan, D. A., Jacobs, K. H., Penny, M. A., Kelly, M.  A., Mijovic, C., Jenkins, D., 
Fletcher, J. A., and Barnett, A. H. Both DQA1 and DQB1 genes  are implicated in 
HLA associated protection from type 1 (insulin dependent ) diabetes mellitus in a 
British Caucasian population. Diabetologia 36(3), 252 257.  
  143.   Dabil, H., Kaplan, H. J., Duffy, B. F., Phelan, D. L. , Mohanakumar, T., and 
Jaramillo, A. Association of the HLA DR15/HLA DQ6 hapl otype with development 
of choroidal neovascular lesions in presumed ocular hi stoplasmosis syndrome. 
Hum.Immunol. 64(10), 960 964. 
  144.   Bakker, M., Grumet, F. C., Feltkamp, T. E., and Ki jlstra, A. HLA antigens in the 
human uvea. Doc.Ophthalmol. 61(3 4), 271 279. 
  145.   Bakker, M., Grumet, F. C., Feltkamp, T. E., and K ijlstra, A. HLA antigens in the 
human uvea. Doc.Ophthalmol. 61(3 4), 271 279. 
  146.   Gandon, G., Jouanolle, A. M., Chauvel, B., Mauv ieux, V., le Treut, A., Feingold, J., 
Le Gall, J. Y., David, V., and Yaouanq, J. Linkage disequi librium and extended 
haplotypes in the HLA A to D6S105 region: implications  for mapping the 
hemochromatosis gene (HFE). Hum.Genet. 97(1), 103 113. 
  147.   Szpak, Y., Vieville, J. C., Tabary, T., Naud, M. C ., Chopin, M., Edelson, C., Cohen, 
J. H., Dausset, J., de Kozak, Y., and Pla, M. Spontaneou s retinopathy in HLA A29 
transgenic mice. Proc.Natl.Acad.Sci.U.S.A 98(5), 2572 25 76. 
  148.   Enzmann, V., Hollborn, M., Wiedemann, P., and Koh en, L. Molecular and cellular 
evidence for T cell stimulation by allogeneic retinal pig ment epithelium cells in 
vitro. Graefes Arch.Clin.Exp.Ophthalmol. 239(6), 445 451.  
168  
  149.   Chang, J. H., McCluskey, P., and Wakefield, D. Expre ssion of Toll like Receptor 4 
and Its Associated Lipopolysaccharide Receptor Complex by  Resident Antigen 
Presenting Cells in the Human Uvea. Invest Ophthalmol.Vi s.Sci. 45(6), 1871 1878. 
  150.   Goverdhan, S. V., Howell, M. W., Mullins, R. F.,  Osmond, C., Hodgkins, P. R., 
Self, J., Avery, K., and Lotery, A. J. Association of HLA  class I and class II 
polymorphisms with age related macular degeneration. I nvest Ophthalmol.Vis.Sci. 
46(5), 1726 1734. 
  151.   Allele frequencies in worldwide populations.  http://www.datatechniques.biz/allele/  . 
  152.   Allele frequencies in worldwide populations.  http://www.allelefrequencies.net  . 
  153.   Ioannidis, J. P., Ntzani, E. E., Trikalinos, T. A. , and Contopoulos Ioannidis, D. G. 
Replication validity of genetic association studies. Nat G enet 29(3), 306 309. 
  154.   Christen, W. G., Glynn, R. J., Manson, J. E., Aja ni, U. A., and Buring, J. E. A 
prospective study of cigarette smoking and risk of age relat ed macular degeneration 
in men. JAMA 276(14), 1147 1151. 
  155.   Seddon, J. M., Willett, W. C., Speizer, F. E.,  and Hankinson, S. E. A prospective 
study of cigarette smoking and age related macular dege neration in women. JAMA 
276(14), 1141 1146. 
  156.   Zareparsi, S., Buraczynska, M., Branham, K. E., Shah , S., Eng, D., Li, M., Pawar, 
H., Yashar, B. M., Moroi, S. E., Lichter, P. R., Petty, H.  R., Richards, J. E., 
Abecasis, G. R., Elner, V. M., and Swaroop, A. Toll like re ceptor 4 variant D299G 
is associated with susceptibility to age related macul ar degeneration. 
Hum.Mol.Genet.   
169  
  157.   Hageman, Gregory S., Anderson, Don H., Johnson, Li ncoln V., Hancox, Lisa S., 
Taiber, Andrew J., Hardisty, Lisa I., Hageman, Jill L ., Stockman, Heather A., 
Borchardt, James D., Gehrs, Karen M., Smith, Richard J. H ., Silvestri, Giuliana, 
Russell, Stephen R., Klaver, Caroline C. W., Barbazetto,  Irene, Chang, Stanley, 
Yannuzzi, Lawrence A., Barile, Gaetano R., Merriam, Joh n C., Smith, R. Theodore, 
Olsh, Adam K., Bergeron, Julie, Zernant, Jana, Merriam, J oanna E., Gold, Bert, 
Dean, Michael, and Allikmets, Rando. From The Cover: A comm on haplotype in the 
complement regulatory gene factor H (HF1/CFH) predisposes  individuals to age 
related macular degeneration. PNAS 102(20), 7227 7232. 
  158.   Haines, J. L., Hauser, M. A., Schmidt, S., Scott , W. K., Olson, L. M., Gallins, P., 
Spencer, K. L., Kwan, S. Y., Noureddine, M., Gilbert, J.  R., Schnetz Boutaud, N., 
Agarwal, A., Postel, E. A., and Pericak Vance, M. A. Compl ement factor H variant 
increases the risk of age related macular degeneratio n. Science 308(5720), 419 421. 
  159.   Edwards, A. O., Ritter, R., III, Abel, K. J., Mann ing, A., Panhuysen, C., and Farrer, 
L. A. Complement factor H polymorphism and age related ma cular degeneration. 
Science 308(5720), 421 424. 
  160.   Klein, R. J., Zeiss, C., Chew, E. Y., Tsai, J. Y. , Sackler, R. S., Haynes, C., Henning, 
A. K., Sangiovanni, J. P., Mane, S. M., Mayne, S. T., Bra cken, M. B., Ferris, F. L., 
Ott, J., Barnstable, C., and Hoh, J. Complement factor  H polymorphism in age 
related macular degeneration. Science 308(5720), 385 389 . 
  161.   Stone, Edwin M., Braun, Terry A., Russell, Stephe n R., Kuehn, Markus H., Lotery, 
Andrew J., Moore, Paula A., Eastman, Christopher G., Cas avant, Thomas L., and 
Sheffield, Val C. Missense Variations in the Fibulin  5 Gene and Age Related 
Macular Degeneration. The New England Journal of Medicine  351(4), 346 353.  
170  
  162.   Klaver, C. C., Kliffen, M., van Duijn, C. M., Hofm an, A., Cruts, M., Grobbee, D. E., 
van Broeckhoven, C., and de Jong, P. T. Genetic associati on of apolipoprotein E 
with age related macular degeneration [published errat um appears in Am J Hum 
Genet 1998 Oct;63(4):1252]. Am J Hum Genet 63(1), 200 6. 
  163.   Seddon, J. M., Willett, W. C., Speizer, F. E.,  and Hankinson, S. E. A prospective 
study of cigarette smoking and age related macular dege neration in women. JAMA 
276(14), 1141 1146. 
  164.   Hageman, G. S., Luthert, P. J., Victor Chong, N. H., J ohnson, L. V., Anderson, D. 
H., and Mullins, R. F. An integrated hypothesis that co nsiders drusen as biomarkers 
of immune mediated processes at the RPE Bruch's membrane  interface in aging and 
age related macular degeneration. Prog.Retin.Eye Res.  20(6), 705 732. 
  165.   Gurne, D. H., Tso, M. O., Edward, D. P., and Ripps,  H. Antiretinal antibodies in 
serum of patients with age related macular degeneration . Ophthalmology 98(5), 602 
607. 
  166.   Gabay, C. and Kushner, I. Acute phase proteins and oth er systemic responses to 
inflammation. N.Engl.J.Med. 340(6), 448 454. 
  167.   Macy, E. M., Hayes, T. E., and Tracy, R. P. Varia bility in the measurement of C 
reactive protein in healthy subjects: implications for re ference intervals and 
epidemiological applications. Clin.Chem. 43(1), 52 58.  
  168.   Mendall, M. A., Patel, P., Ballam, L., Strachan , D., and Northfield, T. C. C reactive 
protein and its relation to cardiovascular risk factors: a  population based cross 
sectional study. Bmj 312(7038), 1061 1065.  
171  
  169.   Pankow, J. S., Folsom, A. R., Cushman, M., Borec ki, I. B., Hopkins, P. N., Eckfeldt, 
J. H., and Tracy, R. P. Familial and genetic determinants  of systemic markers of 
inflammation: the NHLBI family heart study. Atheroscler osis 154(3), 681 689. 
  170.   Danesh, J., Muir, J., Wong, Y. K., Ward, M., Gal limore, J. R., and Pepys, M. B. 
Risk factors for coronary heart disease and acute phase  proteins. A population based 
study. Eur.Heart J. 20(13), 954 959. 
  171.   Koenig, W., Sund, M., Frohlich, M., Fischer, H. G ., Lowel, H., Doring, A., 
Hutchinson, W. L., and Pepys, M. B. C Reactive protein, a  sensitive marker of 
inflammation, predicts future risk of coronary heart diseas e in initially healthy 
middle aged men: results from the MONICA (Monitoring Tr ends and Determinants 
in Cardiovascular Disease) Augsburg Cohort Study, 1984  to 1992. Circulation 99(2), 
237 242. 
  172.   Retterstol, L., Eikvar, L., and Berg, K. A twin study of  C Reactive Protein compared 
to other risk factors for coronary heart disease. Atherosc lerosis 169(2), 279 282. 
  173.   MacGregor, A. J., Gallimore, J. R., Spector, T . D., and Pepys, M. B. Genetic effects 
on baseline values of C reactive protein and serum amyloi d a protein: a comparison 
of monozygotic and dizygotic twins. Clin.Chem. 50(1), 13 0 134. 
  174.   Brull, D. J., Serrano, N., Zito, F., Jones, L.,  Montgomery, H. E., Rumley, A., 
Sharma, P., Lowe, G. D., World, M. J., Humphries, S. E., a nd Hingorani, A. D. 
Human CRP gene polymorphism influences CRP levels: imp lications for the 
prediction and pathogenesis of coronary heart disease. 
Arterioscler.Thromb.Vasc.Biol. 23(11), 2063 2069.  
172  
  175.   Szalai, A. J., Wu, J., Lange, E. M., McCrory, M.  A., Langefeld, C. D., Williams, A., 
Zakharkin, S. O., George, V., Allison, D. B., Cooper, G.  S., Xie, F., Fan, Z., Edberg, 
J. C., and Kimberly, R. P. Single nucleotide polymorphi sms in the C reactive protein 
(CRP) gene promoter that affect transcription factor bin ding, alter transcriptional 
activity, and associate with differences in baseline ser um CRP level. J.Mol.Med. 
83(6), 440 447. 
  176.   Hageman, G. S., Anderson, D. H., Johnson, L. V., H ancox, L. S., Taiber, A. J., 
Hardisty, L. I., Hageman, J. L., Stockman, H. A., Borchardt,  J. D., Gehrs, K. M., 
Smith, R. J., Silvestri, G., Russell, S. R., Klaver, C . C., Barbazetto, I., Chang, S., 
Yannuzzi, L. A., Barile, G. R., Merriam, J. C., Smith,  R. T., Olsh, A. K., Bergeron, 
J., Zernant, J., Merriam, J. E., Gold, B., Dean, M., and  Allikmets, R. A common 
haplotype in the complement regulatory gene factor H (HF 1/CFH) predisposes 
individuals to age related macular degeneration. Proc. Natl.Acad.Sci.U.S.A 102(20), 
7227 7232. 
  177.   Pasceri, V., Willerson, J. T., and Yeh, E. T. Dir ect proinflammatory effect of C 
reactive protein on human endothelial cells. Circulati on 102(18), 2165 2168. 
  178.   Duguid, I. G., Boyd, A. W., and Mandel, T. E. Adhesio n molecules are expressed in 
the human retina and choroid. Curr.Eye Res. 11 Suppl,  153 159. 
  179.   Sakurai, E., Taguchi, H., Anand, A., Ambati, B. K., G ragoudas, E. S., Miller, J. W., 
Adamis, A. P., and Ambati, J. Targeted disruption of the C D18 or ICAM 1 gene 
inhibits choroidal neovascularization. Invest Ophthalmol.V is.Sci. 44(6), 2743 2749. 
  180.   Yeh, D. C., Bula, D. V., Miller, J. W., Gragoudas , E. S., and Arroyo, J. G. 
Expression of leukocyte adhesion molecules in human subfo veal choroidal  
173  
neovascular membranes treated with and without photodynami c therapy. Invest 
Ophthalmol.Vis.Sci. 45(7), 2368 2373. 
  181.   Challa, J. K., Gillies, M. C., Penfold, P. L.,  Gyory, J. F., Hunyor, A. B., and Billson, 
F. A. Exudative macular degeneration and intravitreal tri amcinolone: 18 month 
follow up. Aust.N.Z.J.Ophthalmol. 26(4), 277 281. 
  182.   Penfold, P. L., Wen, L., Madigan, M. C., Gillies, M . C., King, N. J., and Provis, J. 
M. Triamcinolone acetonide modulates permeability and  intercellular adhesion 
molecule 1 (ICAM 1) expression of the ECV304 cell line: i mplications for macular 
degeneration. Clin.Exp.Immunol. 121(3), 458 465. 
  183.   Labarrere, C. A., Lee, J. B., Nelson, D. R., Al H assani, M., Miller, S. J., and Pitts, D. 
E. C reactive protein, arterial endothelial activation, a nd development of transplant 
coronary artery disease: a prospective study. Lancet 360(9 344), 1462 1467. 
  184.   Hashimoto, H., Kitagawa, K., Hougaku, H., Shimizu , Y., Sakaguchi, M., Nagai, Y., 
Iyama, S., Yamanishi, H., Matsumoto, M., and Hori, M. C r eactive protein is an 
independent predictor of the rate of increase in earl y carotid atherosclerosis. 
Circulation 104(1), 63 67. 
  185.   Kondo, K., Kitagawa, K., Nagai, Y., Yamagami, H.,  Hashimoto, H., Hougaku, H., 
and Hori, M. Associations of soluble intercellular ad hesion molecule 1 with carotid 
atherosclerosis progression. Atherosclerosis 179(1), 155 1 60. 
  186.   Macchioni, P., Boiardi, L., Casali, B., Nicoli, D. , Farnetti, E., and Salvarani, C. 
Intercellular adhesion molecule 1 (ICAM 1) gene polymorphis ms in Italian patients 
with rheumatoid arthritis. Clin.Exp.Rheumatol. 18(5), 55 3 558.  
174  
  187.   Braun, C., Zahn, R., Martin, K., Albert, E., and  Folwaczny, C. Polymorphisms of the 
ICAM 1 gene are associated with inflammatory bowel diseas e, regardless of the p 
ANCA status. Clin.Immunol. 101(3), 357 360. 
  188.   Salvarani, C., Casali, B., Boiardi, L., Ranzi,  A., Macchioni, P., Nicoli, D., Farnetti, 
E., Brini, M., and Portioli, I. Intercellular adhesion mole cule 1 gene polymorphisms 
in polymyalgia rheumatica/giant cell arteritis: assoc iation with disease risk and 
severity. J.Rheumatol. 27(5), 1215 1221. 
  189.   Verity, D. H., Vaughan, R. W., Kondeatis, E., Madan at, W., Zureikat, H., Fayyad, 
F., Marr, J. E., Kanawati, C. A., Wallace, G. R., and St anford, M. R. Intercellular 
adhesion molecule 1 gene polymorphisms in Behcet's disease . Eur.J.Immunogenet. 
27(2), 73 76. 
  190.   Boiardi, L., Salvarani, C., Casali, B., Olivie ri, I., Ciancio, G., Cantini, F., Salvi, F., 
Malatesta, R., Govoni, M., Trotta, F., Filippini, D., Pa olazzi, G., Nicoli, D., Farnetti, 
E., and Macchioni, L. Intercellular adhesion molecule 1  gene polymorphisms in 
Behcet's Disease. J.Rheumatol. 28(6), 1283 1287. 
  191.   Kim, E. H., Mok, J. W., Bang, D., Lee, E. S., Lee,  S., and Park, K. S. The 
ICAM1469*E is associated with susceptibility to ocular le sions and vasculitis in 
Korean patients with Behcet's disease. Adv.Exp.Med.Biol. 528 , 235 236. 
  192.   Infante, J., Llorca, J., Berciano, J., and Comba rros, O. Interleukin 8, intercellular 
adhesion molecule 1 and tumour necrosis factor alpha gene  polymorphisms and the 
risk for multiple system atrophy. J.Neurol.Sci. 228(1 ), 11 13. 
  193.   Higgins, G. T., Wang, J. H., Dockery, P., Cleary, P.  E., and Redmond, H. P. 
Induction of angiogenic cytokine expression in cultured RPE b y ingestion of  
175  
oxidized photoreceptor outer segments. Invest Ophthalmo l.Vis.Sci. 44(4), 1775 
1782. 
  194.   Radisavljevic, Z., Avraham, H., and Avraham, S. Vasc ular endothelial growth factor 
up regulates ICAM 1 expression via the phosphatidylinosit ol 3 OH 
kinase/AKT/Nitric oxide pathway and modulates migration o f brain microvascular 
endothelial cells. J.Biol.Chem. 275(27), 20770 20774. 
  195.   Frank, R. N., Amin, R. H., Eliott, D., Puklin, J . E., and Abrams, G. W. Basic 
fibroblast growth factor and vascular endothelial growth  factor are present in 
epiretinal and choroidal neovascular membranes. Am.J.Ophtha lmol. 122(3), 393 
403. 
  196.   Lopez, P. F., Sippy, B. D., Lambert, H. M., Thach, A. B. , and Hinton, D. R. 
Transdifferentiated retinal pigment epithelial cells are  immunoreactive for vascular 
endothelial growth factor in surgically excised age relate d macular degeneration 
related choroidal neovascular membranes. Invest Ophthal mol.Vis.Sci. 37(5), 855 
868. 
  197.   Smith, D. R., Polverini, P. J., Kunkel, S. L., O rringer, M. B., Whyte, R. I., Burdick, 
M. D., Wilke, C. A., and Strieter, R. M. Inhibition of  interleukin 8 attenuates 
angiogenesis in bronchogenic carcinoma. The Journal of Exper imental Medicine 
179(5), 1409 1415. 
  198.   Vairaktaris, E., Yapijakis, C., Serefoglou, Z., D erka, S., Vassiliou, S., Nkenke, E., 
Vylliotis, A., Wiltfang, J., Avgoustidis, D., Critselis , E., Neukam, F. W., and 
Patsouris, E. The interleukin 8 ( 251A/T) polymorphism i s associated with increased 
risk for oral squamous cell carcinoma. Eur.J.Surg.Oncol.   
176  
  199.   Enzmann, V., Hollborn, M., Kuhnhoff, S., Wiedema nn, P., and Kohen, L. Influence 
of interleukin 10 and transforming growth factor beta on T ce ll stimulation through 
allogeneic retinal pigment epithelium cells in vitro.  Ophthalmic Res. 34(4), 232 240. 
  200.   Enzmann, V., Hollborn, M., Poschinger, K., Wiedem ann, P., and Kohen, L. 
Immunosuppression by IL 10 transfected human retinal pi gment epithelial cells in 
vitro. Curr.Eye Res. 23(2), 98 105. 
  201.   Matsuda, M., Salazar, F., Petersson, M., Masucci,  G., Hansson, J., Pisa, P., Zhang, 
Q. J., Masucci, M. G., and Kiessling, R. Interleukin 10  pretreatment protects target 
cells from tumor  and allo specific cytotoxic T cells a nd downregulates HLA class I 
expression. The Journal of Experimental Medicine 180(6), 23 71 2376. 
  202.   de Waal, Malefyt R., Haanen, J., Spits, H., R oncarolo, M. G., te, Velde A., Figdor, 
C., Johnson, K., Kastelein, R., Yssel, H., and de Vries , J. E. Interleukin 10 (IL 10) 
and viral IL 10 strongly reduce antigen specific human T  cell proliferation by 
diminishing the antigen presenting capacity of monocytes v ia downregulation of 
class II major histocompatibility complex expression. The  Journal of Experimental 
Medicine 174(4), 915 924. 
  203.   Enk, A. H., Angeloni, V. L., Udey, M. C., and Katz, S . I. Inhibition of Langerhans 
cell antigen presenting function by IL 10. A role for IL 10  in induction of tolerance. 
J.Immunol. 151(5), 2390 2398. 
  204.   Kohno, T., Mizukami, H., Suzuki, M., Saga, Y., Ta kei, Y., Shimpo, M., Matsushita, 
T., Okada, T., Hanazono, Y., Kume, A., Sato, I., and Ozawa, K . Interleukin 10 
mediated inhibition of angiogenesis and tumor growth in mic e bearing VEGF 
producing ovarian cancer. Cancer Res. 63(16), 5091 5094.  
177  
  205.   Howell, W. M., Turner, S. J., Bateman, A. C., an d Theaker, J. M. IL 10 promoter 
polymorphisms influence tumour development in cutaneous  malignant melanoma. 
Genes Immun. 2(1), 25 31. 
  206.   AREDS Research Group. A Randomized, Placebo Co ntrolled, Clinical Trial of 
High Dose Supplementation with Vitamins C and E,  Beta  Carotene, and Zinc for 
Age Related Macular Degeneration and Vision Loss. Arch  Ophthalmal 119, 1417 
1435. 
  207.   Ridker, Paul M. Clinical Application of C Reacti ve Protein for Cardiovascular 
Disease Detection and Prevention. Circulation 107(3), 36 3 369. 
  208.   Suk, H. Jacqueline, Ridker, Paul M., Cook, Nancy  R., and Zee, Robert Y. L. 
Relation of polymorphism within the C reactive protein ge ne and plasma CRP 
levels. Atherosclerosis 178(1), 139 145. 
  209.   Baird, P. N., Islam, F. M., Richardson, A. J.,  Cain, M., Hunt, N., and Guymer, R. 
Analysis of the Y402H variant of the complement factor H g ene in age related 
macular degeneration. Invest Ophthalmol.Vis.Sci. 47(10),  4194 4198. 
  210.   Chen, L. J., Liu, D. T., Tam, P. O., Chan, W. M.,  Liu, K., Chong, K. K., Lam, D. S., 
and Pang, C. P. Association of complement factor H polymorp hisms with exudative 
age related macular degeneration. Mol.Vis. 12, 1536 15 42. 
  211.   Sanchez, E., Sabio, J. M., Callejas, J. L., de,  Ramon E., Garcia Portales, R., Garcia 
Hernandez, F. J., Jimenez Alonso, J., Gonzalez Escriba no, M. F., Martin, J., and 
Koeleman, B. P. Association study of genetic variants of  pro inflammatory 
chemokine and cytokine genes in systemic lupus erythemat osus. BMC.Med.Genet. 
7, 48.  
178  
  212.   Goverdhan, Srini V., Howell, Martin W., Mullins,  Robert F., Osmond, Clive, 
Hodgkins, Peter R., Self, James, Avery, Kim, and Lotery, Andr ew J. Association of 
HLA Class I and Class II Polymorphisms with Age Related M acular Degeneration. 
Investigative Ophthalmology Visual Science 46(5), 1726 1734. 
  213.   Rifai, N. and Ridker, P. M. High sensitivity C re active protein: a novel and 
promising marker of coronary heart disease. Clin.Chem. 47(3 ), 403 411. 
  214.   Nidorf, M. and Thompson, P. L. Effect of colchici ne (0.5 mg twice daily) on high 
sensitivity C reactive protein independent of aspirin a nd atorvastatin in patients with 
stable coronary artery disease. Am.J Cardiol. 99(6), 805 80 7. 
  215.   Yang, X., Cullen, S. N., Li, J. H., Chapman, R. W.,  and Jewell, D. P. Susceptibility 
to primary sclerosing cholangitis is associated with poly morphisms of intercellular 
adhesion molecule 1. J.Hepatol. 40(3), 375 379. 
  216.   Vine, A. K., Stader, J., Branham, K., Musch, D.  C., and Swaroop, A. Biomarkers of 
Cardiovascular Disease as Risk Factors for Age Related  Macular Degeneration. 
Ophthalmology . 
  217.   McGwin, G., Hall, T. A., Xie, A., and Owsley, C. Th e relation between C reactive 
protein and age related macular degeneration in the Cardi ovascular Health Study. 
Br.J.Ophthalmol. 89(9), 1166 1170. 
  218.   Miller, D. T., Zee, R. Y., Suk, Danik J., Kozlows ki, P., Chasman, D. I., Lazarus, R., 
Cook, N. R., Ridker, P. M., and Kwiatkowski, D. J. Associa tion of common CRP 
gene variants with CRP levels and cardiovascular events . Ann.Hum.Genet. 69(Pt 6), 
623 638.  
179  
  219.   Brull, D. J., Serrano, N., Zito, F., Jones, L.,  Montgomery, H. E., Rumley, A., 
Sharma, P., Lowe, G. D., World, M. J., Humphries, S. E., a nd Hingorani, A. D. 
Human CRP gene polymorphism influences CRP levels: imp lications for the 
prediction and pathogenesis of coronary heart disease. 
Arterioscler.Thromb.Vasc.Biol. 23(11), 2063 2069. 
  220.   Joussen, A. M., Poulaki, V., Qin, W., Kirchhof,  B., Mitsiades, N., Wiegand, S. J., 
Rudge, J., Yancopoulos, G. D., and Adamis, A. P. Retinal va scular endothelial 
growth factor induces intercellular adhesion molecule 1 a nd endothelial nitric oxide 
synthase expression and initiates early diabetic retinal  leukocyte adhesion in vivo. 
Am.J.Pathol. 160(2), 501 509. 
  221.   Beatty, S., Koh, H., Phil, M., Henson, D., and Boult on, M. The role of oxidative 
stress in the pathogenesis of age related macular degene ration. Surv.Ophthalmol. 
45(2), 115 134. 
  222.   Ponthieux, A., Lambert, D., Herbeth, B., Droesch, S. , Pfister, M., and Visvikis, S. 
Association between Gly241Arg ICAM 1 gene polymorphism an d serum sICAM 1 
concentration in the Stanislas cohort. Eur.J.Hum.Genet.  11(9), 679 686. 
  223.   Lee, E. B., Kim, J. Y., Kim, E. H., Nam, J. H.,  Park, K. S., and Song, Y. W. 
Intercellular adhesion molecule 1 polymorphisms in Kore an patients with 
rheumatoid arthritis. Tissue Antigens 64(4), 473 477. 
  224.   Matsuzawa, J., Sugimura, K., Matsuda, Y., Takaz oe, M., Ishizuka, K., Mochizuki, 
T., Seki, S. S., Yoneyama, O., Bannnai, H., Suzuki, K.,  Honma, T., and Asakura, H. 
Association between K469E allele of intercellular adhes ion molecule 1 gene and 
inflammatory bowel disease in a Japanese population. G ut 52(1), 75 78.  
180  
  225.   Oshima, Y., Ishibashi, T., Murata, T., Tahara, Y., K iyohara, Y., and Kubota, T. 
Prevalence of age related maculopathy in a representative  Japanese population: the 
Hisayama study. Br.J.Ophthalmol. 85(10), 1153 1157. 
  226.   Hull, J., Thomson, A., and Kwiatkowski, D. Associ ation of respiratory syncytial 
virus bronchiolitis with the interleukin 8 gene region in U K families. Thorax 55(12), 
1023 1027. 
  227.   Lee, W. P., Tai, D. I., Lan, K. H., Li, A. F., Hsu, H . C., Lin, E. J., Lin, Y. P., Sheu, 
M. L., Li, C. P., Chang, F. Y., Chao, Y., Yen, S. H., and Lee , S. D. The  251T allele 
of the interleukin 8 promoter is associated with increas ed risk of gastric carcinoma 
featuring diffuse type histopathology in Chinese populatio n. Clin.Cancer Res. 
11(18), 6431 6441. 
  228.   Ito, H., Matsuo, K., Hamajima, N., Okuma, K., Sai to, T., and Tajima, K. Significant 
association of interleukin 8  251T/A polymorphism with  smoking behavior in a 
Japanese population. J.Hum.Genet.  
  229.   Koch, A. E., Polverini, P. J., Kunkel, S. L., Harlow , L. A., DiPietro, L. A., Elner, V. 
M., Elner, S. G., and Strieter, R. M. Interleukin 8 as a m acrophage derived mediator 
of angiogenesis. Science 258(5089), 1798 1801. 
  230.   Klaver, Caroline C. W., Assink, Jacqueline J. M. , van Leeuwen, Redmer, Wolfs, 
Roger C. W., Vingerling, Johannes R., Stijnen, Theo, Hofma n, Albert, and de Jong, 
Paulus T. V. M. Incidence and Progression Rates of Age Rel ated Maculopathy: The 
Rotterdam Study. Investigative Ophthalmology Visual Scien ce 42(10), 2237 2241. 
  231.   Berendschot, Tos T. J. M., Willemse Assink, Jac queline J. M., Bastiaanse, Mieke, 
de Jong, Paulus T. V. M., and van Norren, Dirk. Macular  Pigment and Melanin in  
181  
Age Related Maculopathy in a General Population. Investigati ve Ophthalmology 
Visual Science 43(6), 1928 1932. 
  232.   Stone, Edwin M., Sheffield, Val C., and Hagema n, Gregory S. Molecular genetics of 
age related macular degeneration. Human Molecular Genet ics 10(20), 2285 2292. 
  233.   Haines, J. L., Schnetz Boutaud, N., Schmidt, S.,  Scott, W. K., Agarwal, A., Postel, 
E. A., Olson, L., Kenealy, S. J., Hauser, M., Gilbert, J. R ., and Pericak Vance, M. A. 
Functional candidate genes in age related macular degener ation: significant 
association with VEGF, VLDLR, and LRP6. Invest Ophthalmol.V is.Sci. 47(1), 329 
335. 
  234.   Pauleikhoff, D., Harper, C. A., Marshall, J., and B ird, A. C. Aging changes in 
Bruch's membrane. A histochemical and morphologic study. Op hthalmology 97(2), 
171 178. 
  235.   Spraul, C. W., Lang, G. E., Grossniklaus, H. E.,  and Lang, G. K. Histologic and 
morphometric analysis of the choroid, Bruch's membrane, an d retinal pigment 
epithelium in postmortem eyes with age related macula r degeneration and histologic 
examination of surgically excised choroidal neovascular me mbranes. 
Surv.Ophthalmol. 44 Suppl 1, S10 S32. 
  236.   Cai, H. and Del Priore, L. V. Bruch membrane aging a lters the gene expression 
profile of human retinal pigment epithelium. Curr.Eye Re s. 31(2), 181 189. 
  237.   Tombran Tink, J., Shivaram, S. M., Chader, G.  J., Johnson, L. V., and Bok, D. 
Expression, secretion, and age related downregulation of  pigment epithelium 
derived factor, a serpin with neurotrophic activity. J.Neu rosci. 15(7 Pt 1), 4992 
5003.  
182  
  238.   Bhutto, I. A., McLeod, D. S., Hasegawa, T., Kim, S . Y., Merges, C., Tong, P., and 
Lutty, G. A. Pigment epithelium derived factor (PEDF) and  vascular endothelial 
growth factor (VEGF) in aged human choroid and eyes with ag e related macular 
degeneration. Exp.Eye Res. 82(1), 99 110. 
  239.   Mori, K., Duh, E., Gehlbach, P., Ando, A., Takahash i, K., Pearlman, J., Mori, K., 
Yang, H. S., Zack, D. J., Ettyreddy, D., Brough, D. E., Wei, L . L., and Campochiaro, 
P. A. Pigment epithelium derived factor inhibits reti nal and choroidal 
neovascularization. J.Cell Physiol 188(2), 253 263. 
  240.   Campochiaro, P. A., Nguyen, Q. D., Shah, S. M. , Klein, M. L., Holz, E., Frank, R. 
N., Saperstein, D. A., Gupta, A., Stout, J. T., Macko, J. , DiBartolomeo, R., and Wei, 
L. L. Adenoviral vector delivered pigment epithelium derived  factor for neovascular 
age related macular degeneration: results of a phase I cl inical trial. Hum.Gene Ther. 
17(2), 167 176. 
  241.   Marshall, G. E., Konstas, A. G., Reid, G. G., Edwar ds, J. G., and Lee, W. R. Type 
IV collagen and laminin in Bruch's membrane and basal li near deposit in the human 
macula. Br.J.Ophthalmol. 76(10), 607 614. 
  242.   Dixon, M. J., Read, A. P., Donnai, D., Colley, A., Di xon, J., and Williamson, R. The 
gene for Treacher Collins syndrome maps to the long arm  of chromosome 5. 
Am.J.Hum.Genet. 49(1), 17 22. 
  243.   Underhill, Peter A., Jin, Li, Lin, Alice A., Me hdi, S. Qasim, Jenkins, Trefor, 
Vollrath, Douglas, Davis, Ronald W., Cavalli Sforza, L. L uca, and Oefner, Peter J. 
Detection of Numerous Y Chromosome Biallelic Polymorphis ms by Denaturing 
High Performance LiquidáChromatography. Genome Research 7( 10), 996 1005.  
183  
  244.   Risk factors associated with age related macu lar degeneration. A case control study 
in the age related eye disease study: age related eye d isease study report number 3. 
Age Related Eye Disease Study Research Group. Ophthalmol ogy 107(12), 2224 
2232. 
  245.   Marsh, K. L. and Dixon, M. J. Treacher Collins sy ndrome. Adv.Otorhinolaryngol. 
56, 53 59. 
  246.   Hansen, M., Lucarelli, M. J., Whiteman, D. A., an d Mulliken, J. B. Treacher Collins 
syndrome: phenotypic variability in a family including an  infant with arhinia and 
uveal colobomas. Am.J.Med.Genet. 61(1), 71 74. 
  247.   Prenner, J. L., Binenbaum, G., Carpentieri, D. F., Gold stein, S. M., Douglas, R. S., 
Ruchelli, E., Katowitz, J. A., and Hertle, R. W. Treache r Collins syndrome with 
novel ophthalmic findings and visceral anomalies. Br.J. Ophthalmol. 86(4), 472 473. 
  248.   Prenner, J. L., Binenbaum, G., Carpentieri, D. F., Gold stein, S. M., Douglas, R. S., 
Ruchelli, E., Katowitz, J. A., and Hertle, R. W. Treache r Collins syndrome with 
novel ophthalmic findings and visceral anomalies. Br.J. Ophthalmol. 86(4), 472 473. 
  249.   Positional cloning of a gene involved in the pathogen esis of Treacher Collins 
syndrome. The Treacher Collins Syndrome Collaborative Gr oup. Nat.Genet. 12(2), 
130 136. 
  250.   Splendore, A., Silva, E. O., Alonso, L. G., Richie ri Costa, A., Alonso, N., Rosa, A., 
Carakushanky, G., Cavalcanti, D. P., Brunoni, D., and Pass os Bueno, M. R. High 
mutation detection rate in TCOF1 among Treacher Collins s yndrome patients 
reveals clustering of mutations and 16 novel pathogenic cha nges. Hum.Mutat. 16(4), 
315 322.  
184  
  251.   Dixon, Jill, Brakebusch, Cord, Fassler, Reinhard,  and Dixon, Michael J. Increased 
levels of apoptosis in the prefusion neural folds underlie th e craniofacial disorder, 
Treacher Collins syndrome. Hum.Mol.Genet. 9(10), 1473 148 0. 
  252.   Xu, P. X., Adams, J., Peters, H., Brown, M. C., H eaney, S., and Maas, R. Eya1 
deficient mice lack ears and kidneys and show abnormal ap optosis of organ 
primordia. Nat.Genet. 23(1), 113 117. 
  253.   Donoso, L. A., Kim, D., Frost, A., Callahan, A., a nd Hageman, G. The role of 
inflammation in the pathogenesis of age related macular  degeneration. 
Surv.Ophthalmol. 51(2), 137 152. 
  254.   Schmidt Erfurth, U. and Hasan, T. Mechanisms of ac tion of photodynamic therapy 
with verteporfin for the treatment of age related mac ular degeneration. 
Surv.Ophthalmol. 45(3), 195 214. 
  255.   Alexander, J. J., Pickering, M. C., Haas, M., Osaw e, I., and Quigg, R. J. 
Complement factor h limits immune complex deposition and p revents inflammation 
and scarring in glomeruli of mice with chronic serum sick ness. J.Am.Soc.Nephrol. 
16(1), 52 57. 
  256.   Wachtlin, J., Behme, T., Heimann, H., Kellner, U ., and Foerster, M. H. Concentric 
retinal pigment epithelium atrophy after a single photody namic therapy. Graefes 
Arch.Clin.Exp.Ophthalmol. 241(6), 518 521. 
  257.   Risk factors associated with age related macu lar degeneration. A case control study 
in the age related eye disease study: age related eye d isease study report number 3. 
Age Related Eye Disease Study Research Group. Ophthalmol ogy 107(12), 2224 
2232.  
185  
  258.   Sepp, T., Khan, J. C., Thurlby, D. A., Shahid, H ., Clayton, D. G., Moore, A. T., 
Bird, A. C., and Yates, J. R. Complement factor H varia nt Y402H is a major risk 
determinant for geographic atrophy and choroidal neovascula rization in smokers and 
nonsmokers. Invest Ophthalmol.Vis.Sci. 47(2), 536 540. 
  259.   Magnusson, K. P., Duan, S., Sigurdsson, H., Peturss on, H., Yang, Z., Zhao, Y., 
Bernstein, P. S., Ge, J., Jonasson, F., Stefansson, E ., Helgadottir, G., Zabriskie, N. 
A., Jonsson, T., Bjornsson, A., Thorlacius, T., Jonsson , P. V., Thorleifsson, G., 
Kong, A., Stefansson, H., Zhang, K., Stefansson, K., and G ulcher, J. R. CFH Y402H 
confers similar risk of soft drusen and both forms of a dvanced AMD. PLoS.Med. 
3(1), e5. 
  260.   Zareparsi, S., Branham, K. E., Li, M., Shah, S., K lein, R. J., Ott, J., Hoh, J., 
Abecasis, G. R., and Swaroop, A. Strong association of the  Y402H variant in 
complement factor H at 1q32 with susceptibility to age r elated macular 
degeneration. Am.J.Hum.Genet. 77(1), 149 153. 
  261.   Muscari, A., Bozzoli, C., Puddu, G. M., Sangiorgi , Z., Dormi, A., Rovinetti, C., 
Descovich, G. C., and Puddu, P. Association of serum C3  levels with the risk of 
myocardial infarction. Am.J.Med. 98(4), 357 364. 
  262.   Speidl, W. S., Exner, M., Amighi, J., Kastl, S.  P., Zorn, G., Maurer, G., Wagner, O., 
Huber, K., Minar, E., Wojta, J., and Schillinger, M. Comp lement component C5a 
predicts future cardiovascular events in patients with ad vanced atherosclerosis. 
Eur.Heart J. 26(21), 2294 2299.  
186  
  263.   Mustafa, A., Nityanand, S., Berglund, L., Lithell, H.,  and Lefvert, A. K. Circulating 
immune complexes in 50 year old men as a strong and indepen dent risk factor for 
myocardial infarction. Circulation 102(21), 2576 2581. 
  264.   Oksjoki, R., Jarva, H., Kovanen, P. T., Laine, P.,  Meri, S., and Pentikainen, M. O. 
Association between complement factor H and proteoglycans  in early human 
coronary atherosclerotic lesions: implications for loca l regulation of complement 
activation. Arterioscler.Thromb.Vasc.Biol. 23(4), 630 636.  
  265.   Harrap, S. B., Zammit, K. S., Wong, Z. Y., Williams , F. M., Bahlo, M., Tonkin, A. 
M., and Anderson, S. T. Genome wide linkage analysis of th e acute coronary 
syndrome suggests a locus on chromosome 2. Arterioscler.Thr omb.Vasc.Biol. 22(5), 
874 878. 
  266.   Samani, N. J., Burton, P., Mangino, M., Ball, S. G ., Balmforth, A. J., Barrett, J., 
Bishop, T., and Hall, A. A genomewide linkage study of 1,93 3 families affected by 
premature coronary artery disease: The British Heart F oundation (BHF) Family 
Heart Study. Am.J.Hum.Genet. 77(6), 1011 1020. 
  267.   Seddon, J. M., Santangelo, S. L., Book, K., Chong,  S., and Cote, J. A genomewide 
scan for age related macular degeneration provides eviden ce for linkage to several 
chromosomal regions. Am.J.Hum.Genet. 73(4), 780 790. 
  268.   Ye, S., Dunleavey, L., Bannister, W., Day, L. B., T apper, W., Collins, A. R., Day, I. 
N., and Simpson, I. Independent effects of the  219 G>T a nd epsilon 2/ epsilon 3/ 
epsilon 4 polymorphisms in the apolipoprotein E gene on cor onary artery disease: 
the Southampton Atherosclerosis Study. Eur.J.Hum.Genet.  11(6), 437 443.  
187  
  269.   Hageman, G. S., Luthert, P. J., Victor Chong, N. H., J ohnson, L. V., Anderson, D. 
H., and Mullins, R. F. An integrated hypothesis that co nsiders drusen as biomarkers 
of immune mediated processes at the RPE Bruch's membrane  interface in aging and 
age related macular degeneration. Prog.Retin.Eye Res.  20(6), 705 732. 
  270.   Duvall, J. and Tso, M. O. Cellular mechanisms o f resolution of drusen after laser 
coagulation. An experimental study. Arch.Ophthalmol. 103( 5), 694 703. 
  271.   Killingsworth, M. C., Sarks, J. P., and Sarks,  S. H. Macrophages related to Bruch's 
membrane in age related macular degeneration. Eye 4 ( P t 4), 613 621. 
  272.   Penfold, P. L., Madigan, M. C., Gillies, M. C., a nd Provis, J. M. Immunological and 
aetiological aspects of macular degeneration. Prog.Retin.E ye Res. 20(3), 385 414. 
  273.   Dastgheib, K. and Green, W. R. Granulomatous react ion to Bruch's membrane in 
age related macular degeneration. Arch.Ophthalmol. 11 2(6), 813 818. 
  274.   Baudouin, C., Peyman, G. A., Fredj Reygrobellet,  D., Gordon, W. C., Lapalus, P., 
Gastaud, P., and Bazan, N. G. Immunohistological study of  subretinal membranes in 
age related macular degeneration. Jpn.J.Ophthalmol. 3 6(4), 443 451. 
  275.   Carrington, M. and Martin, M. P. The impact of var iation at the KIR gene cluster on 
human disease. Curr.Top.Microbiol.Immunol. 298, 225 257. 
  276.   Mullins, R. F., Russell, S. R., Anderson, D. H. , and Hageman, G. S. Drusen 
associated with aging and age related macular degenera tion contain proteins 
common to extracellular deposits associated with atheros clerosis, elastosis, 
amyloidosis, and dense deposit disease. FASEB J 14(7),  835 846.  
188  
  277.   Marsh, S. G., Parham, P., Dupont, B., Geraghty, D. E ., Trowsdale, J., Middleton, D., 
Vilches, C., Carrington, M., Witt, C., Guethlein, L. A.,  Shilling, H., Garcia, C. A., 
Hsu, K. C., and Wain, H. Killer cell immunoglobulin lik e receptor (KIR) 
nomenclature report, 2002. Hum.Immunol. 64(6), 648 654. 
  278.   Gomez Lozano, N. and Vilches, C. Genotyping of hu man killer cell 
immunoglobulin like receptor genes by polymerase chain  reaction with sequence 
specific primers: an update. Tissue Antigens 59(3), 184 193.  
  279.   Hiby, S. E., Walker, J. J., O'shaughnessy, K. M. , Redman, C. W., Carrington, M., 
Trowsdale, J., and Moffett, A. Combinations of maternal  KIR and fetal HLA C 
genes influence the risk of preeclampsia and reproductive  success. J Exp.Med. 
200(8), 957 965. 
  280.   Howell, W. M., Calder, P. C., and Grimble, R. F . Gene polymorphisms, 
inflammatory diseases and cancer. Proc.Nutr.Soc. 61(4), 4 47 456. 
  281.   Thorsby, E. Invited anniversary review: HLA asso ciated diseases. Hum.Immunol. 
53(1), 1 11. 
  282.   Namekawa, T., Snyder, M. R., Yen, J. H., Goehring , B. E., Leibson, P. J., Weyand, 
C. M., and Goronzy, J. J. Killer cell activating recep tors function as costimulatory 
molecules on CD4+CD28null T cells clonally expanded in rheu matoid arthritis. 
J.Immunol. 165(2), 1138 1145. 
  283.   Nelson, G. W., Martin, M. P., Gladman, D., Wade,  J., Trowsdale, J., and Carrington, 
M. Cutting edge: heterozygote advantage in autoimmune dis ease: hierarchy of 
protection/susceptibility conferred by HLA and kille r Ig like receptor combinations 
in psoriatic arthritis. J.Immunol. 173(7), 4273 4276.  
189  
  284.   Luszczek, W., Manczak, M., Cislo, M., Nockowski, P ., Wisniewski, A., Jasek, M., 
and Kusnierczyk, P. Gene for the activating natural killer  cell receptor, KIR2DS1, is 
associated with susceptibility to psoriasis vulgaris. H um.Immunol. 65(7), 758 766. 
  285.   Dabil, H., Kaplan, H. J., Duffy, B. F., Phelan, D. L. , Mohanakumar, T., and 
Jaramillo, A. Association of the HLA DR15/HLA DQ6 hapl otype with development 
of choroidal neovascular lesions in presumed ocular his toplasmosis syndrome. 
Hum.Immunol. 64(10), 960 964. 
  286.   van der Slik, A. R., Koeleman, B. P., Verduijn, W.,  Bruining, G. J., Roep, B. O., and 
Giphart, M. J. KIR in type 1 diabetes: disparate dis tribution of activating and 
inhibitory natural killer cell receptors in patients vers us HLA matched control 
subjects. Diabetes 52(10), 2639 2642. 
  287.   Boyton, R. J., Smith, J., Ward, R., Jones, M. , Ozerovitch, L., Wilson, R., Rose, M., 
Trowsdale, J., and Altmann, D. M. HLA C and killer cell  immunoglobulin like 
receptor genes in idiopathic bronchiectasis. Am.J.Respir.C rit Care Med. 173(3), 327 
333. 
  288.   Snyder, M. R., Lucas, M., Vivier, E., Weyand, C. M ., and Goronzy, J. J. Selective 
activation of the c Jun NH2 terminal protein kinase signa ling pathway by 
stimulatory KIR in the absence of KARAP/DAP12 in CD4+ T c ells. J Exp.Med. 
197(4), 437 449. 
  289.   Denis, L., Sivula, J., Gourraud, P. A., Kerdudou , N., Chout, R., Ricard, C., Moisan, 
J. P., Gagne, K., Partanen, J., and Bignon, J. D. Genetic  diversity of KIR natural 
killer cell markers in populations from France, Guadeloupe,  Finland, Senegal and 
Reunion. Tissue Antigens 66(4), 267 276.  
190  
  290.   Vely, F., Peyrat, M., Couedel, C., Morcet, J., Hal ary, F., Davodeau, F., Romagne, F., 
Scotet, E., Saulquin, X., Houssaint, E., Schleinitz, N.,  Moretta, A., Vivier, E., and 
Bonneville, M. Regulation of inhibitory and activating k iller cell Ig like receptor 
expression occurs in T cells after termination of TCR re arrangements. J Immunol. 
166(4), 2487 2494. 
 
 